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Abstract 
The ability to engineer microvasculature would be of great utility for the tissue 
engineering of highly metabolic tissues such as myocardium. In addition, the 
alignment of such a network is critical to the success of using it to deliver oxygen 
to tissue cells because it provides natural inlet and outlet sides for perfusion. In 
this work, the ability of engineered microvessels to align with their fibrin gel 
matrix has been examined and a bioreactor has been designed to harness this 
ability and perfuse the engineered tissue. The results indicate that engineered 
microvasculature can be aligned via cell-induced gel compaction and that this 
compaction improves lumen density. Interstitial flow provided an additional 
increase in lumen density. A mathematical model of fluid flow through engineered 
microvessels and a variety of image analysis methods were also developed. 
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Chapter 1. Introduction 
1.1. Anatomy 
1.1.1. Gross Cardiac Anatomy 
The heart is a volume displacement pump with two halves, which drive 
two circulations: the pulmonary and the systemic.1 Systemic circulation returns to 
the heart via the inferior and superior vena cava and enter the right atrium. 
During atrial systole, the blood is pumped through the tricuspid valve into the 
right ventricle. From there the contraction of the ventricle pumps the blood 
through the pulmonary valve into the pulmonary artery. This artery then 
branches, directing blood to each lung for oxygenation.2 The blood returns to the 
heart via four pulmonary veins, each of which anastomoses with the left atrium.3 
From there, the blood traverses the mitral valve and enters the left ventricle (LV), 
which pumps the blood through the aortic valve into the aorta for systemic 
delivery. Due to the higher resistance of the systemic circulation than the 
pulmonary circulation, the LV is thicker than the right ventricle (8-10 mm vs. 2-3 
mm).4 The atria are box-shaped, whereas the ventricles are conically-shaped, 
and the left and right halves separated by the atrial and ventricular septa, 
respectively.2 The atria and ventricles are separated by the cardiac skeleton, a 
region of dense fibrous tissue, which serves to connect the atria and ventricles, 
strengthen the valve annuli, which all exist within the skeleton, and provide an 
electrical barrier between the atria and ventricles, facilitating their asynchronous 
contraction.3 The heart is shaped similarly to an inverted pyramid, with the atria 
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and great arteries as the base of the pyramid and the ventricles narrowing to 
become the apex of the pyramid.2 
1.1.2. Anatomy of the Myocardium 
The ventricular wall can be divided into three layers: the epicardium, which 
is on the outer surface of the wall and is covered by a layer of epithelial cells, the 
myocardium, which consists of cardiomyocytes, and the endocardium, which is 
on the inner surface of the wall and is lined with endothelial cells.3 In the 
myocardium, the cardiomyocytes are arranged into long interconnected muscle 
fibers. Each cell is short with several branches, and is connected at its ends to 
other cardiomyocytes via intercalated discs.3 These discs contain gap junctions 
which enable the direct passage of ions from one cell to another, facilitating 
coordinated contraction. The entire ventricle is connected electrically through 
these junctions.3 The muscle fibers are arranged parallel to one another, 
although the orientation gradually changes throughout the wall thickness so that 
the difference in alignment angle between the subepicardium and the 
subendocardium is 90. This arrangement results in a spiral-like contraction, 
similar to that of wringing out a rag.5 
1.1.3. Coronary Arteries and Veins 
The myocardium is nourished through the coronary circulation, which 
stems from the right and left coronary arteries. These two arteries emerge from 
the aorta at the sinuses of Valsalva, which are located just on the distal side of 
the aortic valve. The ostia of the coronary arteries are covered by the aortic valve 
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leaflets when the valve is open, and so flow through the coronary circulation only 
occurs during ventricular diastole, offset with the remainder of the systemic 
circulation.3 The course of the large coronary arteries is typically atop the 
myocardium, following interventricular or atrioventricular sulci. Main coronary 
branches are also typically found outside rather than within the myocardium.3 
 The left main coronary artery bisects within 5-10 mm of the aorta into the 
left anterior descending (LAD) artery and the circumflex artery. The LAD follows 
the anterior interventricular groove and provides diagonal branches, which supply 
the right and left ventricles, and septal branches, which supply the ventricular 
septum. The LAD is variable in length, and can occasionally continue across the 
apex to the posterior side of the heart.2 The circumflex artery follows the 
atrioventricular sulcus laterally and around to the posterior side of the heart, 
providing branches that supply the left ventricle and atrium. In addition, in about 
40% of hearts, the circumflex artery forms the sinoatrial node artery. In more than 
85% of hearts the circumflex artery terminates near the cardiac crux; however, in 
humans with left arterial dominance, the circumflex artery turns and follows the 
posterior interventricular groove, becoming the posterior descending artery.6 The 
posterior descending artery supplies the right ventricle, ventricular septum and 
the atrioventricular node.3  
 The right coronary artery generates two large branches near the aorta, the 
conus artery, which supplies the right ventricle, and the atrial branch, which 
supplies the right atrium. The atrial branch also supplies the sinoatrial node in 
about 60% of hearts.2 From there the right coronary artery follows the 
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atrioventricular groove in a pattern mirroring the circumflex artery. A variable 
number of branches supplying the right ventricle and atrium are produced. In 
most hearts, the right coronary artery turns at the cardiac crux to form the 
posterior descending artery.3 
 The coronary veins typically run parallel to the coronary arteries. 
Approximately 85% of the veins converge into the coronary sinus, which follows 
the posterior atrioventricular sulcus and enters the right atrium. The remaining 
15% of the coronary circulation is divided between 2-4 anterior cardiac veins, 
which drain the anterior right ventricle, and the myriad Thebesian veins, which 
drain directly from capillaries and venules within the myocardium into the right 
atrium. 
1.1.4. Coronary Microvasculature 
The coronary microvasculature consists of vessels less than 200 µm in 
diameter and consists of arterioles (10-200 µm), capillaries (<10 µm) and venules 
(10-200 µm). These vessels are typically arranged in networks parallel to 
myofibrils, although the distance between an arteriole and venule in the same 
circuit is 10 fold larger than the average length of a capillary (50 µm), so some 
non-parallel capillaries exist.7 Due to the high metabolic demand of the 
myocardium, capillaries are extremely dense; on average adult human 
myocardium contains 2000 capillaries per square millimeter, making the distance 
between capillaries around 20 µm.8,9 At birth, capillary density is closer to 
3000/mm2 and decreases over the first few years of life to the adult level, 
suggesting that the coronary microcirculation grows in coordination with the 
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heart.8 In addition, the capillary density varies with depth in the myocardium; the 
subendocardial muscle has a 10% higher microvascular density than the 
subepicardial muscle.10 This increased density counteracts the effects of cardiac 
contraction on the coronary blood flow. In the subendocardial muscle, 
microvessels are compressed 10-20% in diameter during systole, which induces 
retrograde flow in the arterioles. In comparison, microvessel diameter change is 
negligible in the subepicardial muscle, as is retrograde flow.7 
At rest, the myocardium extracts 70-80% of the oxygen delivered by the 
microcirculation (compared to 30-40% for skeletal muscle), so increased 
demands due to exercise are met primarily by increased blood flow. This requires 
tight regulation of coronary blood flow, which is accomplished by endocrine and 
paracrine control of vascular resistance.10 The majority of vascular resistance is 
due to the precapillary sphincters of arterioles, which dilate in response to 
endothelium-produced nitric oxide (NO), among other substances.7,10 
1.2. Disease 
1.2.1. Coronary Artery Disease 
All arteries, including coronaries, consist of three layers. The intima 
consists of a single layer of endothelial cells on the inner surface of the artery 
and a thin layer of connective tissue, the basal lamina. The media contains 
structural (collagen) and elastic (elastin) proteins as well as smooth muscle cells, 
which maintain the proteins. The final layer is the adventitia, which contains 
connective tissue.11 Atherosclerosis involves the buildup of fatty plaques within 
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the intima of an artery and can lead to myocardial ischemia and death. The 
mechanisms by which these plaques build up are largely unknown; however, the 
plaques do typically follow a pattern of growth. During the initiation phase, lipids 
begin to accumulate in the intima and are oxidized, making them recognizable by 
monocytes. Monocytes then enter the intima and engulf lipids, becoming foam 
cells.6 Extracellular lipids begin to accumulate in the intima during the evolution 
phase, and coalesce to form the lipid core of the plaque. Smooth muscle cells 
migrate into the intima and begin to both proliferate and secrete collagens. When 
a plaque is in the advanced phase, some lipids have crystalized, the core is 
distinct, and a fibrous cap has been deposited by the smooth muscle cells. At this 
point, the fate of the plaque is variable. Some remain as is, some calcify, and 
others become complicated by thrombus.6 
Thrombi occur in two ways. The first is through denudation of the vessel, 
which exposes the underlying fibrous cap. A thrombus forms on top of the cap, 
and is usually small unless a very large area has been denuded. These small 
thrombi can separate from the plaque, becoming emboli, and serve to occlude 
smaller distal arteries. The second way is through plaque rupture, in which the 
stress experienced by the fibrous cap in systole (which can be up to 10 times 
greater than normal wall stresses) causes the cap to fissure, spilling the lipid 
contents of the plaque into the arterial lumen. These lipids are highly 
thrombogenic, and the artery is often completely occluded.6 
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1.2.2. Acute Myocardial Infarction 
For unknown reasons, the coronary arteries are highly susceptible to 
atherosclerosis.6 When atherosclerotic lesions cause coronary arteries become 
critical (more than 50% occluded by diameter), flow disruptions occur, and very 
small changes in vessel diameter cause large changes in flow rates.11 Vessel 
narrowing caused by these plaques often induces myocardial ischemia. 
Occlusions, typically due to thrombi or emboli, result in ischemia and, if 
reperfusion is not established quickly, infarction of the area distal to the 
occlusion.11 The size of the affected area (and thus the symptoms of the 
infarction) varies widely. Small areas in general go unnoticed, but the 
accumulated damage of many small infarcts can be detrimental. When a large 
area is affected, immediate treatment is required, with the goal of reperfusion as 
quickly as possible, thereby rescuing as much myocardium as possible. The time 
before reperfusion is highly correlated with outcome (longer times leading to 
poorer outcomes), as cardiomyocytes have a very high demand for oxygen and 
therefore respond quickly to ischemia. Although the heart is only 0.5% of total 
body mass, it requires 7% of the body’s oxygen.12 When a cardiomyocyte is 
exposed to an occlusion of blood flow, it will stop beating after about 60 seconds, 
and reversible injury occurs after about 20 minutes. By 40 minutes, only 60-70% 
of the affected area will survive upon reperfusion, and by 3 hours, this 
percentage has dropped to 10%. After about 6 hours, the entire area is 
irreversibly damaged.13 Therefore, perfusion must be re-established very quickly 
after infarction to prevent myocardial death. 
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1.2.3. Congestive Heart Failure 
Congestive heart failure (CHF) affects more than 500,000 Americans each 
year, killing over 50,000 annually, and in the majority of cases, CHF is a sequela 
to one or more myocardial infarctions.14 The reduction of function of the infarcted 
area leads to decreased ejection fraction, triggering compensatory 
mechanisms.15 Adrenergic stimulation increases heart rate and contractile force 
of living myocardium,14 and increased blood volume in the left ventricle improves 
contractility via the Frank-Starling mechanism.15 Over time, these result in 
cardiomyocyte hypertrophy, which necessitates changes in the cells’ electrical 
biochemical properties.14 When the infarcted area is small (<20% of the left 
ventricular circumference), these mechanisms keep cardiac output normal. 
However, when an infarct is large, or many small infarcts accumulate, the 
compensatory mechanisms cannot fully offset the damage.15 Because of this, 
these initially beneficial modifications progressively become detrimental and 
ultimately result in CHF.16 
1.3. Current Treatments for Heart Disease 
1.3.1. Pharmacological 
Many pharmaceuticals are used to treat heart disease patients on the 
spectrum from atherosclerosis to CHF, but the majority work to improve cardiac 
output by increasing cardiomyocyte contractility, decreasing heart rate, or 
decreasing systemic vascular resistance.14 Ionotropes affect intracellular calcium 
levels, increasing the strength myocyte contraction. Beta blockers are 
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sympathetic pathway antagonists that reduce heart rate. Combined with 
improved myocyte contractility, a lower heart rate increases stroke volume, 
leading to improved overall cardiac output.14 Vascular resistance can be reduced 
by vasodilators, such as nitrates, or by agents that reduce blood volume, such as 
ACE inhibitors and diuretics.14 Despite the numerous pharmaceuticals that have 
been developed, none are effective at preventing CHF, and many have extensive 
side effects. 
1.3.2. Transcatheter 
Once atherosclerosis is discovered, several transcatheter techniques are 
often employed to widen diseased vessel in an attempt to prevent MI and CHF. 
Balloon angioplasty involves the insertion of a balloon over a catheter through a 
vein to the point of the atherosclerotic lesion. The balloon is then inflated, 
pushing the vessel wall outward, widening the vessel.17 Another technique 
implants a stent, which is crimped over the angioplasty balloon and expands 
upon the balloon’s inflation, providing additional support to keep the vessel open. 
Now popular are drug-eluting stents, which provide localized delivery of anti-
proliferative drug to prevent restenosis, a common problem with angioplasty and 
standard stents.17 Although these therapies do provide relief of symptoms, they 
do little to prevent MI or CHF, because only a small number of vessels are 
treated. MI is often caused by occlusions in smaller vessels that would not be 
treated with stents or angioplasty.17  
10 
 
1.3.3. Surgical 
Surgical options for the treatment of heart disease depend on the stage of 
disease. When atherosclerosis is detected or an MI occurs, coronary artery 
bypass grafting (CABG) is an option, in which another vessel is used to divert 
blood around a severe atherosclerotic lesion. Similar to the transcatheter options, 
CABG treats only major vessels, and so is limited in its ability to prevent future MI 
or CHF. In addition, only a few vessels can be used for such grafting, leaving 
some patients without this option.18 When heart disease is at a more advanced 
stage, mechanical support of the heart is often used. Typically this is in the form 
of a ventricular assist device (VAD), although in recent years several total 
artificial hearts have also been made available. VADs can be either uni- or 
biventricular, and can have a variety of different pumping mechanisms, including 
volume displacement, which is similar to the heart, and axial flow, which creates 
non-pulsatile flow.1,19 Although the use of these devices is occasionally 
associated with cardiac recovery (about 5% of cases), in general patients 
continue to decline, albeit more slowly, after the initial improvement. In addition, 
long term use of mechanical support is linked to unfavorable outcomes, and 
therefore it is most often used as a bridge to heart transplantation.1,19 
1.3.4. Transplantation 
Cardiac transplantation is the gold standard for the treatment of patients 
with end-stage CHF.20 The lifespan of a transplanted heart ranges from 10 to 20 
years, much longer than mechanical support, and patients tend to improve more 
after heart transplantation than after the implantation of a mechanical support 
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device.21 However, the major limitation of this technique is the lack of donor 
hearts; 20-25% of patients on the waiting list die before receiving an organ.21,22 
1.4. Tissue Engineering Strategies 
1.4.1. Design Criteria 
It is evident that the currently available treatments for MI and CHF are 
insufficient, and new strategies are needed. Tissue engineering, in which the 
goal is to create living tissue in vitro, provides an opportunity to improve upon 
available therapies. One such improvement would be to create a “patch” of 
engineered myocardium, which would then be implanted to replace the function 
of native myocardium damaged by MI. If implanted soon after MI, this repair 
would negate the need for compensatory mechanisms, and prevent the 
progression to heart failure. Clearly this myocardial patch would need to 
electrically couple with the native myocardium and produce enough contraction 
force to replace the function of the damaged tissue. This will likely require the 
production of a large and thick tissue, as the infarcts that eventually cause heart 
failure tend to be quite large (40% of LV or more) and generally span the entire 
LV wall thickness (8-10 mm).4 The patch would also need match the mechanical 
properties of myocardium, stiff enough to prevent ventricular dilation, which often 
occurs after MI, yet flexible enough to reduce its volume upon contraction. In 
addition to these functional requirements, the ideal patch would be constructed 
from autologous cells to avoid immunosuppressive drugs. The above design 
criteria provide a framework from which develop such a myocardial patch 
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1.4.2. Scaffolds 
A variety of scaffolds have been used in the design of engineered 
myocardium, including synthetic and natural polymers. Synthetic polymers such 
as polyglycolic acid (PGA) and poly(lactic-co-glycolic acid) (PLGA) are typically 
biodegradable, and are often modified, coated, or mixed with other polymers to 
include cell binding domains.23–27 Natural polymers include type I collagen, fibrin, 
alginate, and Matrigel, a mix of extracellular matrix (ECM) polymers and growth 
factors derived from tumor cells.28–38 In addition to the above approaches, 
several groups have developed tissues by culturing monolayers of 
cardiomyocytes and other native heart cells, which produce ECM; however, 
these are typically quite thin.39–41 As the scaffold provides the bulk of a tissue’s 
mechanical properties, it is critical that the scaffold eventually have the 
appropriate stiffness for myocardium, to meet the design criterion mentioned 
above. In general, scaffolds from synthetic polymers are initially too stiff, and 
those from natural polymers are too soft. Natural polymers have an advantage 
over synthetic in that they avoid unnatural and possibly toxic (if in high 
concentrations such as at the tissue site) degradation products. Among natural 
polymers, fibrin stimulates tissue growth because it is involved in the tissue 
formation process known as wound healing. Thus, although collagen I may 
appear to be a more obvious choice because collagen fibrils provide much of the 
mechanical strength found in native tissues, fibrin gels induce more collagen 
production by cells than collagen gels, leading to stronger tissues at the end of 
the culture period.42 However, this strength is not only due to the collagen 
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produce by the cells, but also to the compaction of the gel by the cells, which 
increases the tissue density. Fibrin, compacted during culture by the entrapped 
cells, therefore, has been the scaffold of choice used in these studies.  
1.4.3. Cell Sources 
Cell source is a challenge in myocardial tissue engineering due to the non-
proliferative state of adult cardiomyocytes. The majority of work done on 
engineered myocardium has utilized animal cells, primarily the neonatal rat 
cardiac population, due to the relative ease of obtaining cells. However, a source 
of human cardiomyocytes is required, and autologous cells preferred, as noted 
above. Adult cardiac stem cells have been identified as a possible cell source, 
but are difficult to isolate. Cardiomyocytes derived from human embryonic stem 
cells have also been suggested, but they are ethically problematic. Promising cell 
populations include cardiomyocytes derived from induced pluripotent (iPS) cells 
or other non-embryonic stem cells, which avoid the problems associated with the 
above cell types. It remains to be seen if any of these cell types will be 
appropriate, or if a different cell population will be needed. 
1.4.4. Current Technologies 
Much progress has been made by numerous groups in the creation of 
myocardial patches. As noted above, one important design criterion is that the 
patch generate enough force to be physiologically relevant. Current results for 
tissues containing rat cardiomyocytes exhibit contraction forces ranging from 
0.01-1.3 mN/mm2.29,32,35,38 This remains quite low in comparison to human 
14 
 
cardiac muscle, which produces a twitch force of 44 mN/mm2,43 although it is 
unclear whether a contraction force equal to that of native myocardium will be 
required for the patch to be effective. Recently results of tissues containing 
human iPS-derived cardiomyocytes were reported; the maximum twitch force 
achieved was 0.08 mN/mm2.37 Alignment of cardiomyocytes, as occurs in native 
myocardium, has been shown to improve contraction force, via improved gap 
junction formation, and accounts for the highest forces recorded in engineered 
myocardium.31,38 In addition, the presence of non-cardiomyocytes improves 
contraction force.31 
Another important criterion is that the patch be able to electrically integrate 
with the heart. This has not been demonstrated directly to date, although several 
groups have shown an improvements in LV function when a patch is implanted in 
an infarct model.30,44 However, it is unclear whether the cells provide additional 
benefit over just the bare scaffold.45 
1.5. Engineered Microvasculature 
1.5.1. Design Criteria 
The high metabolic demands of cardiomyocytes, especially when densely 
cultured, as would be needed to achieve high contraction forces, eliminates 
diffusion as a viable means for nutrient delivery to engineered myocardium. One 
alternative method for delivering nutrients is to engineer a microvascular network 
within the patch. However, the mere presence of a microvascular network is not 
enough to provide nutrients; culture medium must flow through the network, 
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mimicking blood flow in capillaries. Therefore, an engineered microvasculature 
must be capable of supporting flow and a perfusion circuit must be designed to 
drive the flow of culture medium through the network. To have directional flow, 
the network must also have inlet and outlet sides, with aligned vessels in 
between. In addition, the network must not regress over time, must be permeable 
to nutrients and waste products, and must be of sufficient capillary density to 
maintain the cardiomyocytes. Finally, the microvascular network would need to 
be compatible with the requirements listed above for the heart patch, including 
aligned and compacted fibrin gel as a scaffold, and the use of autologous cells. 
1.5.2. Role of Support Cells 
In vivo, capillaries are surrounded by a sparse layer of supporting cells 
termed pericytes (PCs). PCs are highly mobile and their processes extend to 
reach many ECs; primary processes extend along the capillary axis while 
secondary processes extend circumferentially.46,47 They are often located within 
the vascular basement membrane, and are directly connected to ECs via tight 
junctions.46 During development these PCs are recruited to the forming 
capillaries, and this recruitment signals the end of the microvascular “plasticity 
window,” in which the microvessels freely grow and regress.47,48 ECs recruit PCs 
by releasing PDGF-B,49 and PC recruitment can be blocked by knocking out 
PDGF or its receptor.49,50 The knockout phenotype includes lethality at birth due 
to microvascular hemhorrage and increased vessel diameter due to unchecked 
EC proliferation. Interestingly, however, there is no difference in vessel length or 
branching between knockout and wild type animals.50 This suggests that PCs are 
16 
 
responsible for regulating microvascular stability, permeability and diameter, but 
not microvessel patterning. The mechanism by which PCs have these effects is 
not fully known, but is thought to involve paracrine signaling from both soluble 
and insoluble factors. PCs release Ang-1, a vessel stabilizing protein, and in the 
absence of PCs, Ang-1 can improve microvessel stability, suggesting that the 
PC-derived Ang-1 is partially responsible for the stabilizing effects.51 Insoluble 
factors include type IV collagen and laminin, among other components of the 
vascular basement membrane. PCs both produce and trigger ECs to produce 
basement membrane proteins, which are thought to be critical in the 
maintenance of capillary beds.47,52 
In vitro, it has consistently been reported that without the use of support 
cells microvessels will eventually regress. The support cell types used in the 
literature vary, including fibroblasts, smooth muscle cells, mesenchymal 
progenitor cells (MSCs), and PCs.53–56 The use of these cell types has been met 
with varying degrees of success, but in general they tend to improve microvessel 
formation and/or stability. Fibroblasts and MSCs have been shown to behave 
similarly to PCs in that some of them become recruited to the microvascular 
niche and promote stability.53,54 
Perhaps not unexpectedly, PCs excel at the role of stabilizing engineered 
microvessels, as shown in numerous publications from the laboratory of George 
Davis at the University of Missouri. PCs co-entrapped with human umbilical vein 
ECs (HUVECs) in type I collagen gel recruited to the forming vessels, promoted 
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the assembly of basement membrane, maintained microvessel diameter within 
the physiological range, and stabilized the networks for at least several weeks.56 
1.5.3. Scaffolds 
Although a variety of scaffolds have been used for the engineering of 
microvasculature, the majority of the in vitro work has used hydrogels, primarily 
collagen I or fibrin.53,54,56 Both hydrogel types and combinations of them have 
proved successful; however, fibrin is more advantageous than collagen I due to 
its natural pro-angiogenic role in wound healing. This, combined with the tissue-
formation reasons mentioned above, explains the choice to use fibrin gels as 
scaffolds in these studies. 
1.5.4. Cell Sources 
HUVECs are the most widely studied human EC, and are easily isolated 
and cultured, which explains their popularity. However, HUVECs have limited 
potential to be autologous for heart disease patients. Other possible EC sources 
include circulating populations or ECs derived from embryonic stem cells, iPS 
cells or other stem cells. Aside from embryonic stem cells which evoke ethical 
issues, all of these are possible autologous sources of ECs. Through 
collaboration with Robert Hebbel at the University of Minnesota, these studies 
have used blood outgrowth ECs (BOECs), a type of circulating EC. This cell type 
is positive for many EC markers and well as negative for the monocyte markers 
CD14 and CD45. It also has a very high proliferative potential (1019 cells in 60 
days), making it an ideal candidate for expansion in vitro.57 
18 
 
1.5.5. Current Technologies 
Two basic strategies exist for the engineering of microvasculature. The 
first is to create channels within the scaffold and line them with ECs.58,59 Although 
this strategy is simple conceptually and results in a network of EC-lined tubes 
that can be easily connected to a flow circuit, it is difficult to make complex and 
small (capillary-sized) geometries, and the microvascular patterning must be 
designed. The other basic strategy involves the self-assembly of ECs into 
networks. This method is easy technically, and the network morphology is 
defined by the cells. Within this second method, angiogenic or vasculogenic 
models can be used. Angiogenic models induce sprouting from existing 
monolayers of ECs, which are either monolayers on a surface of the scaffold or 
groups of ECs within the scaffold. Surface monolayers often sprout in response 
to a VEGF gradient.60,61 The mechanism by which sprouts grow from ECs in 
spheroids or adherent to microcarrier beads is less clear, and may require factors 
released by support cells.62,63 Vasculogenic models begin with ECs dispersed 
throughout the scaffold, which then spread and connect to form a network; this is 
the simplest method for forming microvascular networks, and is the method 
adopted in these studies. Several groups have also explored this method with 
promising results; three of the most promising are discussed here. 
Andrew Putnam’s group at the University of Michigan has explored the 
role of MSCs as support cells. HUVECs and MSCs were entrapped in fibrin gel 
and cultured in serum- and cytokine-containing medium. HUVECs formed 
microvascular networks containing lumens and MSCs co-localized with the 
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microvessels.54 After 5 days of culture, the microvessels demonstrated the ability 
to regulate their permeability.64 
At the University of California at Irvine, Steve George’s group entrapped 
human endothelial progenitor cells and human lung fibroblasts in fibrin gel, and 
cultured them in serum- and cytokine-containing medium. Co-localization of the 
fibroblasts to the forming EC networks was observed, and upon implantation in a 
nude mouse model, these vessels anastamosed with the host vessels.53 More 
recent work has shown that interstitial flow in a microfluidic chamber induces EC 
network formation, and that at least some of the vessels are capable of carrying 
flow (unpublished work; personal communication). 
Finally, George Davis’ group at the University of Missouri has 
demonstrated the formation of highly stable microvascular networks by HUVECs 
and PCs in collagen I gel under defined conditions. The culture medium 
contained few cytokines; however three hemopoetic stem cell factors were 
included in the gel formulation to drive capillary morphogenesis: stem cell factor 
(SCF), interleukin-3 (IL-3), and stromal derived factor (SDF)-1α. As noted 
previously, PCs recruit to the HUVEC tubes and induce basement membrane 
deposition.56 
Although the above systems are state-of-the-art, they have several 
limitations. All of them used small volumes of very porous gel to achieve their 
results, limiting their use as engineered tissues due to the size and stiffness of 
the constructs. Clearly a larger initial gel volume and cell-induced gel compaction 
are required to achieve a functional tissue. Cell-induced gel compaction would 
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not only strengthen the tissue mechanically, it would also likely increase the 
capillary density, which is quite low in the above studies. In addition, only one 
group attempted to perfuse their engineered vessels, and that group did so within 
a microfluidic system, which is not compatible with the previous requirements of 
increased size and compaction. More work is certainly required to create a 
system that would perfuse microvessels in a large compacted tissue. Finally, only 
one group used potentially autologous ECs, and only one group (a different one) 
used potentially autologous support cells. The use of autologous cell types, 
although not entirely required, would improve the heart patch. The work 
presented here took steps to address these three areas of needed improvement 
in developing engineered microvasculature for use in a heart patch. 
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Chapter 2. Alignment of Matrix and Endothelial Sprouts 
2.1. Introduction 
One of the design criteria for engineered microvasculature is that the 
microvessels and the matrix be aligned. Alignment of the microvessels not only 
mimics the native architecture of myocardium,65 but also creates natural inlet and 
outlet sides of the network for directional perfusion. The matrix of such a tissue 
construct must also be aligned so that the engineered microvasculature is 
compatible with the myocardial patch, in which alignment has been shown to 
greatly improve contraction force.38 
Studies of cells cultured in 3D environments in vitro suggest that cells are 
able to sense the alignment of nearby extracellular matrix fibers and align with 
the fibers, a phenomenon known as contact guidance.66 For example, when 
magnetic fields were used to align the fibrils of collagen I gel to different extents, 
the alignment of entrapped fibroblasts coincided with that of the collagen fibrils.67 
Similarly, fibroblasts68 and cardiomyocytes38 aligned parallel to matrix fibers in 
fibrin-based tissue-engineered constructs, where the fibril alignment was created 
from mechanically-constrained cell-induced gel compaction. However, few 
studies have investigated the contact guidance response of endothelial cells 
(ECs) or microvessels. ECs elongated in the direction of fiber alignment when 
plated on aligned collagen I fibers69 or aligned electrospun polymer fibers.70 
Other studies have found that stretching induces the alignment of both fibrin or 
collagen fibers and EC tubule structures within the gel, although cause and effect 
were not determined between the fiber and cell alignment.71,72 Endothelial 
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sprouts were also observed to be aligned with local elastin fibers in the rat 
mesentery, although again cause and effect were not established73. Therefore, 
detailed study is required to determine whether or not fibril alignment is sufficient 
to align microvessels. 
The entrapment of EC spheroids, or aggregates, in fibrin gels is an 
attractive method for studying the alignment of microvessels with matrix. EC 
sprouting from spheroids mimics in vivo sprouting angiogenesis, and the fibrin 
gel can be aligned in several ways to investigate different components of 
alignment. In addition, when spheroids are entrapped at a relatively low density, 
they are separated from each other, so alignment phenomena can be observed 
for a several small isolated systems within a single construct. 
Korff and Augustin74 first demonstrated that the outer layer of EC 
spheroids behaved similarly to the endothelium of a vessel with the center of the 
spheroid as the lumen of the vessel. The surface ECs became quiescent and 
expressed CD31 at cell-cell contacts, and I-CAM and V-CAM expression was 
inducible by TNF-α activation. They also showed improved survival of ECs when 
cultured in suspension as spheroids rather than as single cells. In vitro network 
formation by human umbilical vein EC (HUVEC)  spheroids entrapped in collagen 
I gels has been shown,75 and the ability of nearby sprouts to anastomose within 
fibrin gel has been demonstrated.76 In addition, vessel formation was shown in 
vivo using HUVEC spheroids in a Matrigel/fibrin matrix.77 The co-entrapment of 
support cells such as fibroblasts or smooth muscle cells has been shown to aid 
vessel growth from EC spheroids.77 
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Very limited data is available on the alignment of sprouts from EC 
spheroids, but Korff et al. showed that EC spheroids entrapped in collagen I gels 
can exert traction forces and align the collagen fibrils between nearby 
spheroids.76 The sprouts from these spheroids grew towards each other, but 
cause and effect between sprout growth and collagen fibril alignment and the 
level of tension in the collagen fibril network was not determined. Interestingly, 
this local rearrangement of fibrils was not seen when EC spheroids were 
entrapped in fibrin gel.76 
In the studies presented below, human blood outgrowth EC (hBOEC) 
spheroids and neonatal human dermal fibroblasts (nhDFs; both potentially 
autologous cell types) were co-entrapped in fibrin gel aligned via magnetic force 
or cell-induced compaction. Because the magnetic forces enabled the fibril 
alignment to vary independent of other factors, these experiments enabled the 
determination of causal relationships between fibril and sprout alignment. Sprout 
length, sprout cellularity, and nhDF alignment were also measured in order to 
investigate the mechanism of aligned sprouting.  
2.2. Methods 
2.2.1. Cell Culture 
hBOECs were provided by Dr. Robert Hebbel at the University of 
Minnesota. They were cultured in “hBOEC medium” (EGM-2 (Lonza) with an 
additional 8% FBS and 1% penicillin-streptomycin) in type I rat tail collagen-
coated flasks. Passages 8-12 were used for these experiments. 
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nhDFs were purchased from Lonza and maintained in 50/50 DMEM/F-12 
with 10% FBS, and 1% antibiotic-antimycotic. Passages 8-12 were used for 
these experiments. 
2.2.2. Endothelial Cell Spheroid Formation 
hBOEC spheroids were made via the method of Laib et al.78 by 
suspending 500 cells stained with CellTracker Green (Invitrogen) in a 25 µl drop 
of “spheroid medium” and placing the drops on a petri dish. Spheroid medium 
contained 80% hBOEC medium and 20% methylcellulose medium (1.2% w/v 
methyl cellulose in EBM-2 (Lonza)). The dishes were inverted, and cultured 
overnight. The spheroids were harvested by covering the bottom of the dish with 
HBSS, and pipetting the volume into a conical tube. The spheroids had settled to 
the bottom of the tube within 15 minutes, from where they were removed and 
entrapped in fibrin gel. 
2.2.3. Fibrin Constructs with Magnetic Alignment 
Due to the diamagnetic anisotropy of the fibrinogen molecule, fibrin gels 
can be aligned if they are polymerized in the presence of a strong magnetic 
field.79,80 Teflon rings were attached to rectangular glass coverslips using sterile 
vacuum grease to create wells 1.5 cm in diameter. Fibrin gels (500 µl each) were 
formed within these wells by combining hBOEC spheroids, nhDFs, bovine 
fibrinogen (Sigma) in 20 mM HEPES-buffered saline, bovine thrombin (Sigma) in 
saline, and EGM-2 (Lonza) without FBS. Final gel concentrations were 3.3 mg/ml 
fibrin, 0.08 U/ml thrombin, 68% (v/v) EGM-2 without FBS, 80 spheroids/ml, and 
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250,000 nhDFs/ml. Gels were allowed to polymerize in the presence of a 9.4 T 
magnetic field, a 7 T magnetic field, or no magnetic field (isotropic control) for 15 
minutes. 1 ml of hBOEC medium was added to each well and was replaced 
every 2 days. Fibroblasts were included in these constructs because limited 
sprout growth was observed in constructs without co-entrapped nhDFs.  
Because others have found effects of magnetic field exposure on 
fibroblast and endothelial cell behavior,81–85 additional constructs were made with 
or without spheroids to test the effect of magnetic field exposure on sprout 
growth and proliferation, and on angiogenic factor production by nhDFs. Isotropic 
gels were formed as above and half were exposed to a 9.4T magnetic field after 
gelation for 15 minutes. RNA was harvested from constructs containing only 
nhDFs using an RNeasy extraction kit (Qiagen) after 1 and 3 days of culture, and 
quantitative RT-PCR was performed to investigate VEGF-A, bFGF2, and Ang-1 
production. The forward (f) and reverse (r) primers used were obtained via 
Primer-BLAST (NIH) and are as follows: fVEGF-A 
TTGAATCGGGCCGACGGCTT, rVEGF-1 TTGCCCCTGTCGCTTTCGCT, 
fbFGF2 GCAAGATGCAGGAGAGAGGAAGCC, rbFGF2 
TGCCACGTGAGAGCAGAGCA, fAng-1 TGCCTGCTTCCAGCTTGGCT, and 
rAng-1 TGCCTGAGTCAGCTGCGTGT. Constructs containing only nhDFs were 
harvested after 3 days of culture for DNA quantification using a modified Hoescht 
assay, assuming 7 pg of DNA per cell.86 Spheroids were imaged at day 3 of 
culture and sprout lengths and anisotropy indices were quantified as described 
below. 
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2.2.4. Fibrin Constructs with Cell-Induced Alignment 
Fibrin constructs were made in slab geometries by mixing hBOEC 
spheroids, nhDFs, bovine fibrinogen (Sigma) in 20 mM HEPES-buffered saline, 
bovine thrombin (Sigma) in saline, and EGM-2 (Lonza) without FBS. Final gel 
concentrations were 3.3 mg/ml fibrin, 1.25 U/ml thrombin, 68% (v/v) EGM-2 
without FBS, 36 spheroids/ml, and 250,000 nhDFs/ml. Three geometries were 
used to create slabs with aspect ratios of 1, 2, and 3. The aspect ratio was 
defined as the ratio of the length of the construct to its width. Rectangular score 
marks were made on the bottom of a 150 mm petri dish in sizes 1 cm x 2 cm, 1 
cm x 3 cm, and 1 cm x 4 cm. A 0.5 cm wide porous polyethylene space was fixed 
inside the score mark at each end using sterile vacuum grease. Gel-forming 
solution was mixed for 20 seconds and pipetted into the rectangle between the 
spacers, giving initial construct sizes of 1 cm x 1 cm (250 µl gel), 1 cm x 2 cm 
(500 µl gel), and 1 cm x 3 cm (750 µl gel), corresponding to aspect ratios 1, 2 
and 3 respectively. Constructs were allowed to polymerize for 5 minutes at room 
temperature, after which 35 ml of hBOEC medium was added. hBOEC medium 
was replaced on the day after casting and every 2 days subsequently. 
The following day, slabs were lifted from the dish via the spacers and the 
spacers were reattached to a new dish, with the distance between the spacers 
remaining constant. This action detached the construct from the dish, allowing 
the cells to compact and align the fibrin fibrils between the two spacers. 
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2.2.5. Image Acquisition and Analysis 
Constructs were cultured for 7 days, after which spheroids from each 
condition were imaged using confocal microscopy with a 10x objective. Z-stacks 
were used when required to ensure that all sprout lengths were included. The 
length and angle of each sprout was measured in the XY-projections of the 
spheroids using ImageJ (NIH). Sprouts were predominately linear structures.  
Therefore, a straight line was drawn over each sprout representing the average 
length and angle, and the length and angle of this line was recorded (Figure 2-1). 
The X and Y components of each length were calculated and summed for all 
sprouts within a given construct. The sums were then used to calculate the 
average sprout anisotropy index, defined as the ratio of total X length to total Y 
length (where X is the direction of fibrin fibril alignment). With this definition, a 
high anisotropy index indicates strong sprout alignment, and an anisotropy index 
of 1 is perfectly isotropic. 
For magnetically-aligned constructs, spheroids were also imaged on day 
0. The X and Y diameters were measured and their ratio taken to determine 
whether any elongation of the spheroid in the direction of alignment had 
occurred. 
For nuclear labeling and nhDF alignment measurements, constructs were 
fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton-X, and stained 
with rhodamine phalloidin and Hoescht 33342. Sprouts were then imaged with 
confocal microscopy using a 10x objective and 3x optical zoom. Nuclei fully 
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within the boundaries of CellTracker Green staining were considered within the 
sprout and were manually counted. 
F-actin expressing cells that did not contain the CellTracker Green were 
considered nhDFs. The nhDFs displayed elongated morphology, with nuclei also 
elongated in the same direction as the f-actin fibers. The angle of nuclear 
elongation was measured with ImageJ for nhDFs with nuclei at varying distances 
from the sprout. In the case where the sprout grew at an angle 15-90° from the 
overall fibril alignment direction, the difference between the angle of each 
nucleus and that of the sprout and the difference between the angle of that 
nucleus and that of the overall fibril alignment direction were computed. If the 
difference between the nucleus and sprout angles was smaller than the 
difference between the nucleus and overall fibril angles, the nhDF was 
considered to be more aligned with the sprout than the overall fibril alignment 
direction. For cases where the sprout grew at an angle less than 15° from the 
overall fibril alignment direction, the anisotropy index was calculated as above 
using a standard length for every cell. 
2.2.6. Alignment Mapping 
The fibril alignment of each construct was measured via polarized light 
imaging.87 Briefly, each sample was placed between two linear polarizers, and 
images were taken as one of the polarizers rotated. A custom Matlab script was 
used to calculate the average retardation and alignment direction at each pixel. 
The retardation normalized to tissue thickness is the tissue birefringence, a 
measure of fibril alignment strength. Although the quantitative relationship 
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between fibril alignment distribution and birefringence is unknown, it is 
monotonic.88 For magnetically-aligned samples, the average birefringence of the 
largest square fitting within the well was reported. For constructs with cell-
induced alignment, the average birefringence (across the construct width) in the 
middle of the slab, where birefringence is the highest, was reported, and only 
spheroids in areas where the average birefringence (across the construct width) 
was within 10% of the middle value were analyzed. The Matlab script also 
generated alignment maps, in which line segments representing the local 
strength and direction of alignment overlay a grayscale image indicating the 
retardation of the construct at each pixel. Alignment mapping was performed on 
days 0 and 7 for magnetically-aligned constructs and only on day 7 for cell-
aligned constructs. 
2.2.7. Histology 
Constructs were fixed in 4% paraformaldehyde and frozen in OCT 
embedding medium. 9 µm sections were taken both parallel and perpendicular to 
the direction of alignment using a cryostat. Sections were stained with 
hematoxylin and eosin. 
2.2.8. Statistics 
Data were analyzed in Minitab. Comparisons were made using ANOVA 
with Tukey post-hoc tests, and correlations using linear regression. Both 
comparisons and correlations were considered significant at p < 0.05. At least 30 
sprouts were analyzed in each condition, with 4 magnetically-aligned constructs 
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and 3-4 cell-aligned constructs per condition. PCR data were analyzed by the 
comparative C(T) method followed by ANOVA.89 
2.3. Results 
2.3.1. Increasing fibril alignment via increased magnetic field strength during 
fibrin gel formation increased EC sprout alignment. 
Alignment mapping of magnetically-aligned and isotropic control 
constructs formed within wells made from Teflon rings verified that fibrin fibril 
alignment increased with magnetic field strength (Figure 2-2A-C,G). The 
alignment was uniform across each construct. The spheroids were round 
immediately after gel formation regardless of the application of a magnetic field 
(data not shown). Decreases in fibril alignment occurred between days 0 and 7 
for the 9.4 T and 7 T conditions; however, all measurements of the alignment 
strength of 9.4 T constructs were higher than those of 7 T constructs regardless 
of day, and likewise between 7 T and isotropic control constructs (data not 
shown). In all conditions, the constructs were thinner after 7 days of culture than 
immediately after gelation (data not shown), and thickness varied little across the 
construct. Representative images of spheroids in each condition after 7 days of 
culture are shown in Figure 2-2D-F. Sprout anisotropy index positively correlated 
with increasing birefringence (R2 = 0.84; Figure 2-2H), indicating that the sprouts 
aligned with the fibrin fibrils. 
Alignment mapping of constructs exposed to a 9.4T magnetic field after 
gelation confirmed that the application of a magnetic field after gelation did not 
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induce fibril alignment (data not shown). PCR analysis indicated that the 15 min 
magnetic field exposure itself did not have an effect on the production of VEGF-
A, bFGF2, or Ang-1 (Figure 2-3A). The magnetic field exposure also did not have 
an effect on nhDF proliferation (Figure 2-3B). No difference in sprout length was 
observed between spheroids exposed to the magnetic field and those not 
exposed (Figure 2-3C). 
2.3.2. Increasing fibril alignment via increased aspect ratio of cell-compacted 
fibrin gel increased EC sprout alignment. 
As shown with alignment mapping, fibrin fibril alignment was increased 
within slab constructs aligned via cell-induced gel compaction by increasing the 
construct aspect ratio (Figure 2-4A-C,G). Alignment was stronger in the center of 
the slab constructs and weaker nearer the porous spacers, and quantification 
was thus restricted to the central region where alignment was homogeneous. 
Figure 2-4D-F displays representative images of spheroids in constructs of each 
aspect ratio. Again the sprouts aligned with the fibrin fibrils, as evidenced by the 
positive correlation of sprout anisotropy index with construct birefringence (R2 = 
0.75; Figure 2-4H). 
2.3.3. EC sprouts were lengthened by increasing fiber alignment. 
Longer sprouts were observed when the sprouts and fibrin fibrils were 
more aligned, regardless of the method used to align the fibrils. Sprout length 
was positively correlated with sprout anisotropy index for both magnetically-
aligned constructs (R2 = 0.71) and cell-aligned constructs (R2 = 0.51; Figure 2-5). 
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A positive correlation also existed between sprout length and construct 
birefringence for both magnetically-aligned (R2 = 0.62) and cell-aligned 
constructs (R2 = 0.62; data not shown). In addition, the number of cells per sprout 
increased with sprout length (R2 = 0.38), but the average length per cell (i.e. 
sprout length divided by number of cells; a measure of cell elongation) did not. 
2.3.4. Sprout orientation influenced nhDF alignment. 
nhDF orientation near sprouts in magnetically-aligned constructs was 
observed via rhodamine phalloidin and Hoescht staining (Figure 2-6A-B).  Within 
10 µm of sprouts that grew in directions 15-90° from the overall fibril alignment 
direction, approximately 50% of nhDFs were oriented more closely with the 
sprout than with the overall fibril alignment direction. This percentage is greater 
than that of nhDFs located at distances 10-50 µm and 50-100 µm of a sprout 
(Figure 2-6D). Near sprouts that grew in directions less than 15° from the overall 
fibril alignment direction, a trend was observed that the anisotropy index of the 
nhDFs within 10 µm of the sprout was higher than that of nhDFs at distances 10-
50 µm and 50-100 µm from the sprout, and that of nhDFs in regions with no 
sprouts (Figure 2-6F). 
2.3.5. Sprouts contained patent lumens and connected when in close proximity. 
Sprouts from spheroids in close proximity were able to connect (Figure 2-
7A,B). It is unclear whether the lumens connected as well so as to form an 
anastomosis. H&E staining and vWF immunostaining of histological sections of 
these tissues revealed the presence of lumens within the spheroids (lumen 
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diameter was 50+/-5.5 (s.d.) µm) and sprouts (lumen diameter was 8.5+/-0.64 
(s.d.) µm; Figure 2-7C,D). 
2.4. Discussion 
Previous studies of the alignment of endothelial sprouts with extracellular 
matrix proteins have shown correlations between fibril alignment and sprout 
alignment, but cause and effect relationships were not established. The method 
of using magnetic forces to systematically vary the alignment strength of fibrin 
fibrils leads to the conclusion that fibril alignment is sufficient to induce sprout 
alignment. 
The reduction in thickness of the magnetically-aligned constructs over the 
culture period indicates that cell-mediated tension present within the constructs 
caused compaction in the Z direction. However, construct thickness near the 
edge of the gel was not different from that in the middle of the construct, 
indicating that the construct was not adherent to the Teflon wall. This observation 
reduces the possibility of the formation of an anisotropic tension field, which 
further justifies the conclusion that fibril alignment is sufficient to cause sprout 
alignment. In addition, the sprout alignment effect was still seen to the same 
extent (slope = 0.51 in the plot equivalent to Figure 2-4K) in gels that had been 
deliberately detached from the Teflon wall. The cells producing the compaction-
causing tension and alignment are likely the more numerous nhDFs, although the 
ECs could contribute as well. However, aside from inducing compaction in the Z-
direction, the nhDFs had only a minor effect, if any, on fibril alignment. This is 
evident from the fact that all measurements of alignment strength, even those 
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taken on different days, were different between conditions. Differences did exist 
between days in magnetically-aligned samples, but this may have been due to 
any number of factors other than nhDFs. 
Sprouts from EC spheroids also aligned with fibrin fibrils in the constructs 
that were aligned via cell-induced fibrin gel compaction. However, this method of 
fibril alignment has confounding factors that preclude the same conclusion that 
fiber alignment induces sprout alignment. For example, an anisotropic tension 
exists, with tension in the alignment direction, due to the anchorage of the gel to 
the spacers. Also, the matrix and fibroblast densities may vary with aspect ratio 
because of the different degrees of gel compaction, and associated gradients of 
fiber density could also affect sprout alignment. Additionally, the physical necking 
of the gel could play a role in aligning sprouts, as necking will cause the Y 
component of a sprout’s length to decrease. However, previous results suggest 
that the time scale of necking is slow enough for this effect to be neglected.90 
Rather, the results of this experiment indicate that cell-induced compaction is an 
effective way to align EC sprouts, a conclusion which is pertinent due to the ease 
of using this method for tissue engineering purposes. As mentioned previously, 
cell-induced compaction and alignment of fibrin gel is a critical component to 
creating engineered myocardium,38 where a functional microvasculature is critical 
for maintaining viability in a tissue with physiologically-relevant thickness. This 
work has shown that EC will align compacted fibrin fibrils, suggesting that the 
inclusion of ECs within a compacting fibrin gel is a feasible method for achieving 
an aligned microvascular network. 
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The mechanism by which fibril alignment leads to sprout alignment is 
unknown, but several mechanisms are possible:66,91 1) an aligned fibril matrix 
has pores that are elongated in the direction of fibril alignment, so there  is a 
smaller physical barrier to sprout growth in the direction of alignment; 2) sprouts 
growing along fibrils encounter more adhesion sites, promoting growth in the 
alignment direction; and 3) the anisotropic stiffness of the matrix promotes 
growth in the alignment direction by reducing a sprout’s ability to contract the 
fibril network if it is growing in the alignment direction (high stiffness). Clearly 
these potential mechanisms are not mutually exclusive. 
The finding that sprout length increased with alignment suggests that 
mimicking the native vascular structure may not be the only benefit of aligning 
endothelial sprouts. Longer microvessels more easily encounter a neighboring 
microvessel, which would possibly lower the EC density required to achieve a 
microvascular network. The analysis of isotropic gels either exposed to magnetic 
fields or not suggests that the increased sprout length was due to the fibril 
alignment, not to the exposure of the cells to a magnetic field. This result is not 
unexpected, as many groups have shown that the length of neurite outgrowth is 
increased when the substrate fibers are aligned.79,92–95 The number of cells per 
sprout was positively correlated with sprout length and the mean length per cell 
was not, suggesting that either cell proliferation or recruitment of cells to the 
sprout was responsible for the increased sprout length. The mechanism of this 
increased sprout length is also unknown, but the above hypotheses may explain 
this effect as well.66,91 
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A major difference of interest between the two methods of inducing fibrin 
fibril alignment is that the cell-aligned constructs aligned gradually, whereas the 
magnetically-aligned constructs were fully aligned at gelation. This might cause 
one to hypothesize that because sprouts in magnetically-aligned constructs grew 
in an aligned environment for the full seven days but sprouts in the cell-aligned 
constructs initially grew in an isotropic environment, sprouts in magnetically-
aligned constructs would have a higher anisotropy index for a given day 7 
birefringence level. In support of this idea, it was found that the anisotropy index 
of rat BOEC sprouts in cell-aligned constructs did increase gradually, mirroring 
the gradual increase in fibril alignment (Morin and Tranquillo, unpublished data). 
However, this result was not observed when comparing the relationship between 
birefringence and anisotropy index for different alignment methods. The linear 
regression equation was the same for both magnetically-aligned and cell-aligned 
constructs. The above logic neglects all of the confounding effects occurring in 
the cell-aligned constructs. Anisotropic tension could easily contribute to sprout 
alignment, as could gradients of fibril density. Therefore, it appears that the 
anisotropy index of sprouts in cell-aligned constructs reflects alignment due to 
both contact guidance and other factors, and the sum of all of these effects is 
equivalent to that of contact guidance alone when the sprouts are entrapped in a 
relatively unchanging aligned matrix. 
Comparing the relationship between anisotropy index and sprout length 
for various alignment methods yields another interesting result. The values for 
both linear regression intercept and slope were higher for magnetically-aligned 
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constructs than cell-aligned constructs. Here the first result is likely explained by 
the gradual fibril alignment in cell-aligned constructs. Initially the sprouts grew 
into an isotropic matrix, in which they did not have the cue for longer growth, but 
as the fibrils aligned, the sprouts were able to grow longer. This contact guidance 
response led to longer sprouts overall in more aligned constructs, but they are 
shorter for a given level of sprout alignment due to the gradual fiber alignment.  
The difference in slope indicates that other factors besides contact guidance 
played a role in sprout length. Perhaps the increase in fiber or fibroblast density 
inhibited sprout growth in the cell-aligned constructs. 
Numerous studies have detailed the ability of fibroblasts to align with 
extracellular matrix fibers.67,96 However, the presence of hBOEC sprouts 
introduced an additional factor into the contact guidance response of the nhDFs. 
Instances where sprouts were not aligned with the overall fibril alignment 
direction were particularly interesting because there were potentially two 
conflicting contact guidance signals. Analysis of these cases demonstrated that 
the fraction of nhDFs aligned more closely with the sprout than the overall fibril 
alignment direction was higher for nhDFs within 10 µm of the sprout than those 
outside of 10 µm. These data suggest that the sprout did produce an alignment 
cue, but its range was limited. Evidence for this alignment cue from sprouts was 
also apparent when sprouts grew within 15° of the overall fibril alignment 
direction. Analysis of the nhDF anisotropy index indicated that nhDFs within 10 
µm of a sprout tended to be more aligned than those outside of 10 µm, including 
those in regions where no sprouts were present. Whereas conflicting alignment 
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cues existed when sprouts were not parallel to the overall fibril alignment 
direction, the two alignment cues in this case induced stronger nhDF alignment. 
Since entrapped nhDF were required to obtain sprouts, the interesting question 
of whether the contact guidance response of the nhDF to the aligned fibrils 
amplified the contact guidance response of the sprouts could not be directly 
answered by comparing the outcomes of magnetically-aligned gels with and 
without entrapped nhDF. 
The fact that nhDFs are necessary to induce sprouting in this system 
raises the question of whether the mechanical or chemical signals provided by 
the nhDFs (or both) are required. These two effects are difficult to separate, as 
they are highly interconnected. For example, using an actin inhibitor would inhibit 
gel contraction (and consequent alignment) that occurs mainly due to the nhDFs, 
but this would also likely inhibit sprout growth and affect angiogenic factor 
production. Use of a tissue cell type with a different angiogenic factor production 
profile in lieu of nhDFs (e.g. pericytes) would likely result in a different gel 
compaction rate as well. The only technique available to separate the mechanical 
and chemical effects of nhDFs is siRNA or a similar technology to block the 
expression of specific angiogenic molecules. Because a large number of 
angiogenic factors would need to be blocked individually and in combination to 
draw conclusions, future studies will be needed to determine the answer to this 
interesting question. 
The results presented herein that sprouts from EC spheroids align in 
response to fibril alignment and the evidence for connections between sprouts 
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and lumens within sprouts indicate that contact guidance may be an effective 
way to generate aligned microvascular networks within engineered tissues.  Such 
networks are vital to the culture of thick or highly metabolic engineered tissues as 
they provide inlet and outlet sides for network perfusion. Further research is 
necessary into the exact parameters required to form an aligned microvascular 
network in vitro. 
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2.5. Figures 
 
Figure 2-1.  
Length and angle measurement for a curved sprout. A line was drawn over the 
sprout estimating the length and angle of the sprout in ImageJ.  
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Figure 2-2.  
(A-C) Alignment maps of magnetically-aligned constructs. The lines represent the 
local direction and strength of alignment. Scalebars = 1 mm. (D-E) 
Representative spheroids from magnetically-aligned gels. Scalebars = 100 µm. 
(A,D) Isotropic, (B,E) 7T, (C,F) 9.4T. (G) Birefringence of magnetically-aligned 
gels (mean +/- s.e.m.). *p < 0.05 in comparison to both other groups. (H) 
Correlation between mean construct birefringence and mean sprout anisotropy 
index (R2 = 0.84; slope = 0.45). #p < 0.05 for linear regression. 
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Figure 2-3.  
Effects of magnetic field exposure. Constructs containing nhDFs only or nhDFs 
and hBOEC spheroids were either exposed to a magnetic field for 15 minutes 
after gelation or not. (A) Fold change in abundance of RNA transcripts for VEGF-
A, bFGF2, and Ang-1 due to magnetic field exposure in nhDF-only constructs 
after 1 and 3 days of culture (mean +/- s.e.m.). (B) Cell numbers at day 3 of 
culture in nhDF-only constructs (mean +/- s.e.m.). (C) Sprout length at day 3 of 
culture (mean +/- s.e.m.). 
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Figure 2-4.  
(A-C) Alignment maps of cell-aligned constructs. The lines represent the local 
direction and strength of alignment. Scalebars = 1 mm. (D-F) Representative 
spheroids from cell-aligned gels. Scalebars = 100 µm. Aspect ratios are (A,D) 1, 
(B,E) 2, and (C,F) 3. (G) Birefringence of cell-aligned gels (mean +/- s.e.m.). *p < 
0.05 in comparison to both other groups. (H) Correlation between mean construct 
birefringence and mean sprout anisotropy index (R2 = 0.75; slope = 0.58). #p < 
0.05 for linear regression. 
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Figure 2-5.  
Correlation between mean sprout anisotropy index and mean sprout length for 
magnetically-aligned (R2 = 0.71; slope = 33) and cell-aligned constructs (R2 = 
0.51; slope = 7.9). #p < 0.05 for linear regression. 
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Figure 2-6.  
 (A-B) Rhodamine-phalloidin stain of magnetically-aligned constructs. Red = f-
actin, Green = hBOEC, Blue = nuclei. Angles of sprouts indicated with arrows are 
(A) 35.34° and (B) 3.48°. Scalebars = 50 µm. (C) Fractions of nhDFs more 
strongly aligned with the sprout than the overall fibril alignment direction for 
nhDFs at varying distances from the sprout. Includes only sprouts at angles of 
15-90° from the overall fibril alignment direction. *p < 0.05 in comparison to 0-10. 
(D) Anisotropy index for nhDFs at varying distances from the sprout. This plot 
only includes data from nhDFs near sprouts at an angle of less than 15° from the 
overall fibril alignment direction. *p < 0.05 in comparison to 0-10. 
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Figure 2-7.   
(A-B) Connections of sprouts in cell-aligned gels. Scalebars = 100 µm (C-D) H&E 
stain of cell-aligned gel sections taken (C) parallel and (D) perpendicular to the 
alignment direction. In (C-D), arrowheads indicate spheroids and arrows indicate 
sprouts. Scalebars = 20 µm. 
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Chapter 3. Image Analysis Techniques for the Quantification of 
Microvascular Network Characteristics 
3.1. Introduction 
 Before additional work was done on developing engineered microvascular 
networks, image analysis methods were developed in order to have an objective 
means of quantifying microvascular network characteristics and comparing 
between experimental conditions. Although these methods were developed for 
analyzing the constructs discussed in later chapters, the methods would likely be 
widely applicable. 
The quantification of microvascular network characteristics is of interest to 
a wide variety of researchers. Changes in the microvasculature have been 
implicated in a variety of disease processes, from neurological disorders to 
cancer.97,98 In addition, the development of microvascular networks in vitro has 
been pursued by many for either tissue engineering purposes or as a model for 
the study of endothelial cell (EC) biology. In all of these areas the quantification 
of microvessel characteristics is of critical importance in order to statistically 
differentiate between different treatments or experimental conditions.  
 One of the most commonly used metric is capillary density, which actually 
comprises several different metrics. One is quantified from tissue cross sections 
and reported as capillaries/mm2.99–101 A second, also reported as 
capillaries/mm2, is quantified via nailfold capillaroscopy, in which a finger is 
viewed under light microscopy and the skin capillaries counted.102,103 Although 
these quantification methods are reported with the same units, they are quite 
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different and should not be compared directly. Both methods typically rely heavily 
on manual counting, which is tedious and can introduce bias. 
 Another parameter commonly quantified is the network length per image 
area.53,54 This parameter is typically used when the entire microvascular network 
can be viewed such as in a whole mount tissue preparation or a dorsal window 
chamber. However, this method also relies on manual measurement of the 
lengths of the capillaries, which is time consuming. A high degree of subjectivity 
is also introduced, as the image often contains capillaries that are varying 
distances from the focal plane, and the observer must determine which 
capillaries should be included in the measurement. 
 The introduction of subjectivity into measurements is extremely important 
in the analysis of engineered microvascular networks, as the observer must first 
define what qualifies as a capillary. In cross section, not all EC structures contain 
lumens, and some structures contain multiple lumens either because it was 
sectioned near a bifurcation point or because the several small lumens have not 
yet matured into a single lumen. In whole mount preparations, the microvessels 
often have abnormal morphology that must be measured accurately or 
endothelial cell debris that must be eliminated from measurements. These 
conditions increase the variability in both inter- and intra-observer 
measurements.  
Some work has been done to automate the detection and counting of 
capillaries. Both Ranefall et al. and Kim et al. reported methods for automated 
capillary counting in immunostained sections imaged under light 
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microscopy.104,105 Although these methods were shown to be relatively accurate, 
they counted capillaries by counting positive EC staining rather than the lumens 
themselves. This poses a problem for use with engineered microvasculature, in 
which a positively stained object may correspond to zero or several lumens. 
Additionally, characteristics such as lumen size or shape, which are also of 
importance in microvascular networks both in vitro and in vivo, could not be 
quantified. The alignment of capillaries was also not quantified, which would be 
present in longitudinal sections of anisotropic native or engineered tissues such 
as muscle. Finally, the use of immunohistochemistry rather than 
immunofluorescence limits the possibility of identifying additional cell types, such 
as mural cells, in the same section, because it would be difficult to separate the 
different colors from the light microscopy image. Without identifying both cell 
types in the same section, it would be impossible to accurately quantify 
parameters such as the recruitment level of the mural cells, which is an important 
indicator of microvessel maturity. 
Much more work has examined automated methods for quantifying 
microvessel length. Methods have been developed for analyzing both brightfield 
and fluorescent images, both in vitro and in vivo networks, and both single 
images and z-stacks for 3D reconstruction.71,106–112 Each method has its 
advantages and disadvantages; some require the input of a binary image, which 
is at times non-trivial to obtain,110 some require perfusion of the network for 
imaging,106,109 which cannot always be done for engineered microvasculature, 
and some require extensive serial sections to create a 3D image of the 
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network.107 None of these methods, however, address the quantification of mural 
cell recruitment or network anisotropy, which are important parameters to assess 
both in vitro and in vivo, as they provide information about the maturity and 
alignment of the network, respectively. 
The methods outlined here for analysis of cross sections and whole mount 
preparations of engineered microvasculature address the limitations noted 
above. The cross section program detects lumens within fluorescent images 
based on dark areas surrounded by EC staining, and once they are identified, 
they can be counted and measured as desired. The whole mount program 
quantifies microvessel length as well as bifurcation points. Both programs also 
share two major improvements over others: the inclusion of methods to measure 
mural cell recruitment to the network and network anisotropy. These inclusions 
provide additional quantitative information regarding microvascular maturity and 
alignment, which are useful in many types of microvascular studies. 
3.2. Methods 
3.2.1. Cross Section Algorithm Description 
 An image analysis program for use with cross sections of engineered 
tissues containing microvascular networks was developed in Matlab v. 2012b 
(The Mathworks). The algorithm first thresholded the CD31+ image using several 
threshold values, which were automatically generated using the graythresh 
function. The resulting binary images were then dilated slightly to improve 
connectivity of CD31+ regions. The most dilated image was then presented to 
51 
 
the user for input. A custom function was developed that enabled the user to click 
two points on the image, after which the values of the pixels in a straight line 
between the points were changed to 1. The user was able to connect CD31+ 
regions using this function and thereby enclose lumens that would have 
otherwise gone undetected (Figure 3-1a-c). This method of user input maximized 
accuracy in lumen detection while minimizing the user impact on the size and 
shape of the detected lumens. A while loop enabled the user to make as many 
edits to the thresholded image as necessary. 
After the user input was complete, all of the binary images generated thus 
far (including images that were dilated, not dilated and incorporating user input) 
were assessed for lumens, which were defined as a region of zeros completely 
surrounded by ones. The imfill function was used to fill in such regions, and 
subtracting the original binary image resulted in a lumen image, one of which 
was created for each binary image. The union of all of the lumen images was 
taken as the first lumen image. Due to the thresholding and dilation, the first 
lumen image contained much noise, and therefore further processing to remove 
non-lumens was necessary. 
The hallmark of a lumen is a bright ring of CD31+ staining surrounding a 
dark region. Therefore, the ratio of staining intensity between each region in the 
first lumen image and its immediate surroundings was used to detect true 
lumens. Individually, each potential lumen was dilated by two pixels, and the 
lumen was subtracted to leave the region adjacent to the lumen (Figure 3-1d-f). 
The intensity of the adjacent region in the original image was then compared to 
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the intensity of the lumen in the original image. Those lumens with intensity ratios 
below a given threshold were deleted from the lumen image, forming the second 
lumen image. The threshold value can be modified for each image set to 
minimize user input, although the variation in optimal thresholds is small in 
general. This step is the most computationally expensive, but is critical to 
minimize user input. 
Once the second lumen image was finalized, it was presented to the user 
for input. A custom function enabled the user to draw a polygon and delete all 
lumens within that polygon. Non-lumens present in the second lumen image 
often result from CD31+ structures located near each other; these regions may 
become completely surrounded by CD31+ staining when the binary image is 
dilated (Figure 3-1g-i). A while loop enabled the user to remove as many lumens 
as necessary; after this step was complete, the lumen image was final (Figure 3-
1j-k). The lumen density was expressed as the number of lumens per area. 
At this point the function regionprops was used to calculated properties of 
the lumens such as their size (area) and length (major axis length). The original 
thresholded images were also used to calculate the total level of CD31 staining. 
Additional processing using the imfill command filled in the original binary images 
to produce information about the number of endothelial structures present in the 
image. This filled image was also used to calculate an anisotropy index for the 
image, which describes the alignment of the structures. The length of each 
structure was divided into components parallel and perpendicular to the 
alignment direction, which was defined as the average angle of all structures. 
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The anisotropy index was then defined as the ratio of the sum of structure 
lengths in the direction parallel to alignment to the sum of structure lengths in the 
direction perpendicular to alignment (Figure 3-1l). The length and angle of each 
structure was calculated using regionprops (major axis length and orientation). 
The program was also able to detect the recruitment of support cells 
labeled with a different fluorophore. The support cell image was thresholded and 
small objects (noise) removed using bwareaopen. The intersection of the support 
cell image and the CD31 image was taken, and support cells that contained an 
area of overlap with the CD31 image were considered recruited (Figure 3-2). The 
support cell recruitment level was expressed as the fraction of total support cells 
that were recruited. The total number of support cells per area was also 
recorded. 
Finally, the total cell number per area was also recorded from nuclear 
staining. The image was thresholded and noise removed as above, and the total 
number of nuclei was counted. 
3.2.2. Whole Mount Algorithm Description 
 A second program was developed in Matlab for the analysis of images of 
whole mount CD31 stains of engineered microvasculature in collaboration with 
Paul Carlson, an undergraduate chemical engineer. Although lumens are difficult 
to detect in whole mount staining, other important network characteristics such 
as total vessel length and interconnectivity are much more easily evaluated from 
these images than images of cross sections. 
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 Prior to thresholding the CD31 image, the grayscale image was dilated 
and eroded. This manipulation blurred the staining within the EC structures but 
maintained a relatively strong difference between the structures and the 
background. The blurring made the level of staining within the structure more 
even, enabling easier identification via thresholding. The function graythresh was 
used to automatically detect a threshold level, and a binary image was created 
using a threshold level obtained by multiplying that determined by graythresh by 
0.9. Using a threshold level slightly lower than that determined by graythresh 
produced a binary image in which the identified endothelial structures had a 
similar interconnectivity to the original image (Figure 3-3a-b). Any rounded cells 
were removed using bwareaopen, which removes objects smaller than a certain 
size. The total number of objects (structures) was then counted. 
 Next the function bwmorph (“thin, Inf” command) was used to skeletonize 
the image (Figure 3-3c). Although quite accurate, the skeletonization process 
created small segments that were not part of the original EC geometry, often due 
to variations in microvessel diameter. To obtain accurate information about the 
network characteristics, it was necessary to remove these artifacts. A custom 
function was used to find network bifurcation points using a look up table (LUT), 
which specified that a pixel was a bifurcation point if 3 or more of the 8 pixels 
immediately surrounding it also had a value of 1. These bifurcation points were 
then removed from the skeletonized image, and bwareaopen was used to delete 
small segments, which were the artifacts of the skeletonization process. The 
remaining segments were considered true segments of the EC network, and their 
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properties were quantified (Figure 3-3d). The number of segments was counted, 
and their areas (equaling their lengths; from regionprops) were both averaged 
and summed to obtain the average segment length and the total vessel length, 
respectively. All of these parameters were normalized to the area of the image. 
The orientation of each segment was also quantified using region props and 
used in conjunction with each segment’s length to calculate an anisotropy index, 
indicating the strength of alignment of the segments. Each segment length was 
divided into components parallel and perpendicular to the direction of alignment 
(determined to be the average angle of all segments). The anisotropy index was 
then defined as the ratio of the sum of segment lengths in the direction parallel to 
alignment to the sum of segment lengths in the direction perpendicular to 
alignment. 
The bifurcation points were then added back into the skeletonized image 
and the custom LUT function used again to determine true bifurcation points, as 
points leading to artifact segments, which were not true bifurcation points, were 
counted originally. The true bifurcation points were counted and normalized to 
the image area. 
Additional parameters of interest were then calculated including the 
average length per continuous structure (total length/number of structures), the 
average length per segment (total length/number of segments) and the average 
diameter (total structure area/total length). 
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Finally the number of total cells, the number of support cells, and the level 
of support cell recruitment were quantified using the same algorithm as described 
above for the cross section program. 
3.2.3. Program Validation 
 Both of the programs were validated via comparison to manual 
measurements. For the cross section program, lumens were manually counted 
using ImageJ in 6 cross sections of engineered microvasculature and compared 
to the lumen counts generated by the program. For the whole mount program, 
the total microvessel length, network anisotropy index, and mural cell recruitment 
were measured for 9 images in ImageJ and compared to values output by the 
program. Mural cell recruitment and anisotropy index were not quantified for the 
cross section program because the analysis methods were very similar. Paired t-
tests were used to examine differences between manual and automatic counts; p 
values less than 0.05 were considered significant. 
3.3. Results 
 For the cross section program, no difference was observed between 
manual and semi-automated lumen density measurements (Figure 3-5a). The 
percent errors between the counts for individual images were at or under 10%, 
and the variability in lumen counts appeared to be similar between manual and 
automated measurements. 
 For the whole mount program, there were no differences in the measured 
total network length, mural cell recruitment fraction, and network anisotropy index 
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between manual measurement and automated quantification (Figure 3-5b-d). 
The percent errors between measurements of individual images were slightly 
larger that of the cross section comparison, but still relatively small. All errors 
were under 25%, and most were under 10%. The variability was similar across 
both quantification methods for all measurements. 
3.4. Discussion 
 Despite the previous development of automated image analysis programs 
for both cross section and whole mount preparations, the majority of recent 
publications quantifying microvascular networks relied upon manual 
measurements.53,54,61,62,99–103,113 This may be due to the complex nature of image 
processing algorithms, although some have created graphical user interfaces 
that obviate the need for understanding the algorithms. Another reason may be 
that existing programs may not be robust enough to quantify another user’s 
images or a parameter of interest to particular user may not be quantified by the 
existing program. The Image Processing Toolbox of Matlab, used to create the 
programs described here, provides a balance in terms of complexity: the built-in 
functions reduce the level of knowledge of image processing techniques required 
to use the programs, yet enables users to modify the programs to fit their needs. 
Once the program was optimized for a user’s images and quantification needs, 
the time required to analyze images would be reduced dramatically, and the 
objectivity of the analysis would improve dramatically. 
 Both programs developed here were designed to measure multiple 
microvascular network characteristics. Previous automated image analysis 
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programs have measured some of these characteristics, but two are completely 
novel. The first is the measurement of the level of mural cell recruitment. Higher 
levels of recruitment are indicative of microvascular maturity, and the measured 
value could be compared to native levels of recruitment in the tissue of interest. 
The second is the measurement of microvascular anisotropy. Native capillary 
networks of cardiac and skeletal muscle are highly aligned with the muscle fibers, 
and the degree of alignment of the experimental networks could be compared to 
that of native muscle capillaries. Additionally, alignment of engineered 
microvascular networks may be necessary to facilitate perfusion in vitro. 
 A high level of agreement was observed between manual and automated 
measurements of lumen density (cross section program) and total vessel length, 
mural cell recruitment and network anisotropy (whole mount program). These 
data suggest that the programs produce highly accurate results. Some 
subjectivity is introduced into the cross section program via user input; however 
this input is minimized in terms of both impact on the resulting measurements 
and the time required for input. For example, in the first user input step, the user 
connects areas of positive CD31 staining by clicking on the two endpoints of a 
line between the two areas to be connected. This not only creates a more 
accurate shape of the lumen as compared to tracing the entire lumen manually, 
but also drastically reduces the time required to add the lumen. Future work 
should certainly attempt to fully automate the cross section program to remove all 
observer subjectivity and further reduce the time of analysis. 
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 These programs were optimized for use with engineered microvascular 
networks, and no modifications were necessary to use the programs to analyze 
different image sets. However, it is unclear how many adjustments would be 
required to use the programs to quantify images of other engineered 
microvascular networks (e.g. those formed from a different cell type or within a 
different scaffold) or native networks. Additional work would be necessary to 
adapt these programs to accurately measure the characteristics of all engineered 
or native capillary networks. 
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3.5. Figures 
 
Figure 3-1.  
Semi-automated lumen detection in cross sections. (A-C) User input was 
required in this program for accuracy due to occasional areas of dim CD31 
staining. The region outlined in white in (A) is enlarged in (B) and (C). Although 
the lumen indicated by the arrow is obvious to the eye based on CD31 staining 
(red; A), the program did not initially recognize the lumen due to a small area of 
dim staining, which left a gap in the binary image (B; circled). The program 
enabled the user to correct this error by connecting the ring of CD31 staining with 
a 1 pixel wide line (C; circled). Scalebar = 20 µm. (D-F) To eliminate some non-
lumens that were detected as lumens, the program compared intensity levels 
(obtained from the original image; D) between the lumen region (E) and the 
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region immediately surrounding the lumen (F). The region outlined in white in (D) 
is enlarged in (E) and (F). Lumen regions that had similar intensity values to their 
surrounding regions were determined to be non-lumens and eliminated. Scalebar 
= 20 µm. (G-I) User input was again required after lumens were detected to 
remove any non-lumens. The region outlined in white in (G) is enlarged in (H) 
and (I).  The area between lumens in the original image (G; arrow) was detected 
by the program as a lumen (H; arrow) due to the close proximity of the 
surrounding CD31+ structures. The user was able to delete this non-lumen prior 
to quantification (I; arrow), improving program accuracy. Scalebar = 20 µm. (J-L) 
The lumen image (J) resulting from these manipulations corresponded well to the 
original image (K). The lumen image are overlayed the original image for clarity 
(L). Scalebar = 100 µm. 
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Figure 3-2.  
Evaluation of support cell recruitment in cross sections. (A) The original image, in 
which CD31 staining is red, support cells are green and nuclei are blue. Scalebar 
= 100 µm. (B) The support cell image (green) was thresholded and noise 
removed. (C) The intersection between the support cell image and the CD31 
image, which defined recruitment. (D) Those PCs that coincided with ECs were 
considered recruited. 
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Figure 3-3.  
Quantification of network morphology in whole mount images. (A) The original 
CD31 image. Scalebar = 100 µm. (B) The binary image produced by thresholding 
and removal of rounded cells. (C) The binary image after skeletonization. Many 
small segments are present as artifacts of the sekeltonization process. (D) The 
binary image after bifurcation points and the small artifacts were removed. These 
segments correspond well to the original image. 
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Figure 3-4.  
Support cell recruitment quantification in whole mount images. (A) The original 
image, in which the red indicates CD31 staining, the green indicates support 
cells, and the blue indicates nuclei. (B) The binary image of support cells. (C) 
The intersection of the red and green staining, which indicates regions of 
adjacent ECs and PCs. (D) Those PCs identified in the intersection image were 
considered recruited. 
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Figure 3-5.  
Comparison of manual and automated quantitation methods. Lumen density was 
measured to evaluate the cross section program (A), and total vessel length was 
measured to evaluate the whole mount program (B). Network anisotropy (C) and 
mural cell recruitment (D) were quantified from the whole mount program as an 
indication of the accuracy of both programs, as the methodology is very similar 
between the two programs. All automated measurements demonstrated good 
agreement with their respective manual measurements. 
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Chapter 4. Alignment of Microvascular Networks formed in 
Fibrin Gel under Defined Conditions 
4.1. Introduction 
  The need for engineered microvasculature to overcome oxygen 
diffusion limitations in the growth of engineered tissues in vitro has been well 
established.114 In addition, engineered microvasculature would be of use for 
studying endothelial behavior in a more controlled environment than animal 
models. Examples include mechanisms of neovascularization, effects of anti-
angiogenesis drugs in cancer research, and endothelial inflammatory responses, 
among many other topics. Therefore, many researchers are investigating 
methods for producing engineered microvasculature in vitro. Several groups 
have demonstrated the ability of endothelial cells (ECs) to form monolayers on 
the inner surfaces of pre-formed tubes within a 3-dimensional scaffold, respond 
to shear stresses from fluid flow through the tubes,115 and recruit mural cells.59 
Although these models are useful for studying small numbers of vessels, it would 
be difficult to create networks of tubes similar to native capillary networks in size, 
geometry and density, which will be necessary for the delivery of oxygen to 
engineered tissues. Other investigators have studied the ability of ECs to sprout 
into 3-dimensional scaffolds from monolayers on the scaffold surface,61,116–119 
monolayers on embedded microspheres,62,120,121 or aggregates of ECs.63,76 
Though these models of angiogenesis are useful, it has yet to be demonstrated 
that they can produce large fully interconnected microvascular networks in vitro. 
The method most promising for achieving this goal is the vasculogenic self-
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assembly of ECs distributed throughout a scaffold into microvascular networks. 
This technique, which has been widely studied, has been historically limited by 
the tendency of ECs to form isolated capillary-like structures, but not assemble 
fully into a network.122,123 However, more recent studies have been much more 
successful in creating highly interconnected networks,54,56,124 including a set of 
studies from our laboratory in which human umbilical vein ECs (HUVECs) and 
pericytes (PCs) formed extensive networks in type I collagen gels under defined 
medium conditions.56,61,125 
 Many support cell types have been utilized in the self-assembly approach 
to microvascular network formation, including fibroblasts,124 mesenchymal stem 
cells (MSCs),54 and PCs.56 Although all of these cell types have been shown to 
improve EC network formation, PCs are a natural choice due to their association 
with native capillaries. In vivo, PCs are recruited to newly formed capillaries via 
PDGF-BB and HB-EGF49,125 and are essential to the maintenance of capillaries, 
so much so that the recruitment of PCs is indicative of the end of the plasticity 
window of neovessels, in which the microvessels are grown and pruned as 
necessary to maintain the appropriate level of tissue oxygenation.48 When 
recruited to capillaries, PCs promote the production of basement membrane47 
(which is produced by both ECs and PCs52) and produce the vessel-stabilizing 
protein angiopoietin-1 (Ang-1),51 both of which likely contribute to the PCs’ 
stabilizing effect. Additionally, the presence of PCs aids in the maintenance of a 
quiescent EC phenotype and prevents the dilation of capillaries beyond their 
physiologic diameters of 5-10 µm.50,126 The advantages of using PCs rather than 
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fibroblasts or MSCs for applications in EC biology or drug delivery are clear, as 
the network more closely mimic the in vivo environment. In addition, PCs can be 
isolated from dermis,127 making them a potentially autologous cell source, which 
is of critical importance for the development of engineered tissues with 
microvasculature. 
 The majority of research on self-assembled EC networks has involved the 
use of serum. Although culture medium containing serum is typically 
advantageous in terms of cost, it introduces many uncontrolled variables into 
tissue growth systems. This makes it difficult to elucidate biological mechanisms, 
and introduces additional experimental variability. In the worst scenario, a 
successful model of EC assembly using one serum lot yields much worse results 
using other lots due to the presence of unknown factors in the original lot. For 
these reasons, fully defined medium (i.e. containing no serum) is advantageous 
for engineering microvasculature in vitro, whether for EC biology or tissue 
engineering applications. 
 Our previously published system of HUVECs and PCs in collagen I gel56 
meets the above two criteria for the ideal engineered microvasculature, but it 
misses a third: a scaffold that is conducive to tissue growth. Collagen I gel has 
limited potential as a scaffold for engineered tissues. Although type I collagen is 
the major contributor to tissue strength in vivo, gels formed from the protein are 
quite weak and yield only limited production of additional collagen. Fibrin gels, in 
contrast, are also initially weak, but entrapped cells degrade the fibrin and 
produce an abundance of extracellular matrix including collagen I,42,128 which 
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ultimately leads to tissues strong enough for implantation into the pulmonary 
valve system.129,130 The results presented here demonstrate the ability of 
HUVECs and PCs to form fully interconnected microvascular networks in fibrin 
gel under defined conditions. 
 In addressing oxygen diffusion limitations in tissue engineering, fluid flow 
through engineered microvasculature will also be required. To achieve 
continuous non-stagnant fluid flow, microvessel alignment is also necessary: in 
an aligned network bifurcations occur at less sharp angles and microvessel loops 
that receive little flow because they are bypassed by a more streamlined vessel 
are rare. Aligned microvasculature provides natural inlet and outlet sides for flow 
as found in tissues such as muscle.65 Recent work by our laboratory has 
indicated that mechanically constrained cell-induced gel compaction is an 
effective means to align microvessels sprouting from EC aggregates during 
angiogenesis,63 and that this compaction improves microvessel density to within 
the physiologic range.131 The studies reported here harness this mechanism in a 
vasculogenic system, demonstrating the ability to create a highly interconnected 
aligned microvascular network via cell-induced gel compaction following 
microvessel self-assembly, which represents a critical step toward the creation of 
vascularized engineered tissues. 
 Studies were first undertaken to assess the effects of medium composition 
and PCs on the growth of HUVEC networks in fibrin gel. Studies then examined 
the effects of fibrin gel geometry and compaction on the HUVEC network 
alignment in defined medium. Finally, a hybrid approach of sequential use of 
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defined and serum-containing media was examined as a means to further 
improve network alignment. 
Methods 
4.1.1. Cell Culture 
 Human umbilical vein ECs (HUVECs) were purchased from Lonza and 
grown in “HUVEC medium,” which consisted of M199 with 20% FBS, 400 µg/ml 
endothelial cell growth supplement (ECGS), 100 µg/ml heparin salt (Sigma), 1% 
antibiotic/antimycotic (Gibco), and 10 µg/ml gentamicin (Gibco). HUVECs were 
used at passages 3-5. Approximately 16 hours prior to casting, the HUVECs 
were primed61 using M199 with 40 ng/ml FGFb, 40 ng/ml VEGF, 4 µl/ml reduced 
serum supplement (RSII), 1% antibiotic/antimycotic, and 10 µg/ml gentamicin. 
The ECGF and RSII were obtained from George Davis. 
 GFP-labeled human brain pericytes were obtained from George Davis. 
PCs were cultured in DMEM low glucose with 10% FBS, 1% 
penicillin/streptomycin (Gibco), and 10 µg/ml gentamicin (Gibco). Passages 6-8 
were used in these studies. 
4.1.2. Isotropic Construct Preparation 
 Fibrin gels containing HUVECs and PCs were cast in the wells of 96 well 
half-area plates with a final volume of 18 µL. Final cell concentrations were 3 
million/ml HUVECs and 0.6 million/ml PCs. The fibrin formulation included 7.5 
mg/ml plasminogen-depleted fibrinogen (EMD Chemicals), 75 µg/ml fibronectin 
(Sigma), 150 ng/ml of each of stem cell factor, interleukin 3, FLT3 ligand, stromal 
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derived factor, and basic fibroblast growth factor (FGFb; all R&D Systems), and 
2.75 U/ml thrombin (Sigma). Gels were covered with 100 µl “defined medium,” 
which consisted of M199 with 4 µl/ml RSII, 40 ng/ml FGFb, 50 µg/ml ascorbic 
acid, 2 KIU/ml aprotinin, 1% antibiotic/antimycotic, and 10 µg/ml gentamicin. 
Constructs were harvested after 3 days of culture. 
4.1.3. Aligned Construct Preparation 
 The same fibrin formulation and cell densities were used to cast 
constructs with aligned matrix in slab geometries. A rectangle measuring 1.75 cm 
x 0.5 cm was scored into the well of a 12 well plate. Two porous polyethylene 
spacers measuring 0.5 cm x 0.5 cm x 0.2 cm were fixed via sterile vacuum 
grease inside either end of the scored rectangle, leaving a rectangle measuring 
0.75 cm x 0.5 cm between them. The gel-cell mixture (50 µl) was pipetted into 
the region between the spacers, and the mixture seeped into the pores of the 
spacers. The dimensions were such that the slab had an aspect ratio 
(length/width) of 1.5. All aspect ratios reported herein refer to the initial slab 
dimensions. Two constructs were cultured in each well of a 12 well plate. 
Additional slabs with higher aspect ratios were also made in a similar manner by 
adjusting the length of the slab. Aspect ratios of 3 (1.5 cm x 0.5 cm) and 4.5 
(2.25 cm x 0.5 cm) were utilized, and these slabs were cultured in 6 well plates 
with 1 slab per well. After 1-3 days of culture in defined medium, the constructs 
were detached from the plate via the spacers and reattached to a new plate. This 
step eliminated the adhesion between the gel and the plate, enabling cellular 
traction forces to compact and align the matrix fibers. Compacted tissues were 
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harvested at day 6, while control constructs were harvested at day 3, prior to 
detachment. 
4.1.4. Compaction Studies 
 Several medium formulations were tested to determine whether or not a 
defined medium could induce substantial gel compaction of slabs of aspect ratio 
1.5. Slabs containing HUVECs and PCs were cultured as described above with 3 
days of defined medium followed by 3 days of the test medium. On day 6 of 
culture, macroscopic images were taken of the slabs, and the width across the 
middle of each slab was measured using ImageJ (NIH). A reduction in slab width 
was indicative of gel compaction. Test media included defined medium with 10 
ng/ml TGF-β1, defined medium with supplements from the EGM-2 bullet-kit 
(Lonza; includes VEGF, bFGF-2, EGF, IGF-1, heparin, hydrocortisone, 
ascorbate, and GA-1000), and EGM-2 with 2%, 5%, or 10% total FBS. 
4.1.5. Hybrid Approach 
 Slabs of aspect ratio 1.5 containing HUVECs and PCs were cast with the 
same concentrations and fibrin formulation as above. All constructs were cultured 
for 3 days in defined medium. On day 3 of culture, some constructs were 
harvested, and others were cultured for an additional 3 days in either defined 
medium or “EGM-2+,” which consisted of EGM-2 (Lonza) with an additional 8% 
FBS and 1% penicillin/streptomycin. 
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4.1.6. Fibril Orientation 
 Alignment of matrix fibrils in slabs was verified with polarimetry, as 
previously described.87 Briefly, the slabs were placed between 2 polarizers, and 
images taken as one of the polarizers rotated. A custom Matlab script measured 
light intensity at each polarizer angle, and output both an average retardation 
value (proportional to fibril alignment) and an alignment map, in which lines 
overlaying the slab image represented the local strength and direction of fibril 
alignment. The retardation was measured in the middle third of each slab, where 
alignment is strongest. Normalization to construct thickness yielded 
birefringence, a measure of fibril alignment. 
4.1.7. Microvascular Network Evaluation 
 Constructs created in 96 well plates (4 per condition) were fixed in 4% 
paraformaldehyde and stained whole with an antibody against CD31 (Dako). 
Hoecsht 33342 dye was used to label nuclei. Constructs were imaged using a 
Zeiss inverted epi-fluorescence microscope. 
 Images were automatically thresholded and analyzed using a custom 
Matlab code, which yielded network parameters including total network length 
and network alignment. For the purposes of this analysis, a “segment” was 
defined as a microvessel between two bifurcation points, and a “structure” was 
defined as a continuous set of microvessels and could be made up of multiple 
segments. Alignment was assessed by skeletonizing the network and measuring 
the length and angle of each segment. An anisotropy index (AI) was defined for 
each image such that 
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where    is the component of segment length in the direction parallel to 
alignment, and    is the component of segment length in the direction 
perpendicular to alignment. The direction of alignment was defined as the 
average angle of all segments. The area fraction of the image stained positively 
for CD31 (“CD31 fraction”) was taken as an indication of HUVEC density. PC 
density and recruitment levels were also evaluated in Matlab. A PC (identified by 
GFP-labeling) was considered recruited if any part of it was immediately adjacent 
to a CD31-positive microvessel. Total cell density measurements were based off 
of nuclear counts. 
 Due to the increased density (caused by compaction) and thickness of the 
slabs relative to the 96 well plate constructs, whole construct imaging was 
impossible. Instead, thick (40-60 µm) longitudinal sections were cut, stained for 
CD31 and imaged and analyzed as above. 
4.1.8. Lumen Formation 
 Constructs were frozen in OCT embedding medium and cross-sections (9 
µm) were stained for CD31. A second Matlab code detected lumens via a semi-
automated process previously described. Briefly, images were thresholded and 
potential lumens were detected as dark regions completely surrounded by white 
(CD31 staining). User input was allowed to either remove non-lumens that were 
detected (e.g. the space between nearby CD3+ structures), or connect CD31+ 
regions to enable the program to detect a lumen it previously missed (e.g. a 
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structure containing a small area of dim staining visible to the eye but below the 
threshold). A variety of network properties, including lumen density, average 
lumen area, cell density, and pericyte recruitment were assessed. 
4.1.9. Basement Membrane Deposition 
 Basement membrane deposition was evaluated via immunofluorescent 
staining of cross-sections using antibodies against collagen IV and laminin 
(Abcam). Average pixel intensities for exposure-matched images were calculated 
via Matlab to compare between experimental conditions. Four sections from 
different areas of the constructs were imaged per condition. 
4.1.10. Statistics 
 Data were analyzed in Minitab using either Student’s t-tests (if only two 
conditions were evaluated) or one-way ANOVAs with Tukey post-hoc tests (if 
more than two conditions were evaluated). Comparisons to control conditions 
were performed using Dunnett post-hoc tests. P values of less than 0.05 were 
considered significant. 
4.2. Results 
4.2.1. HUVECs and PCs form highly interconnected microvascular networks in 
fibrin gel under defined conditions. 
A small volume gel format (18 µl in 96 well half-area plates) was used to 
optimize conditions for HUVEC microvascular network formation using defined 
medium or EGM-2+ with or without co-culture with PCs. Representative images 
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of whole mount CD31 stains and quantification of the network characteristics are 
shown in Figure 4-1. HUVECs co-cultured with PCs in defined medium formed 
the best network in terms of total length and average connected structure length 
(a measure of network interconnectivity). Additionally, culture in defined medium 
produced a greater level of PC recruitment to microvessels than culture in EGM-
2+. 
4.2.2. Aligned microvascular networks were formed under defined conditions in 
slabs of high aspect ratio. 
The cell-induced gel compaction of fibrin gel slabs containing HUVEC 
networks was investigated under defined conditions using slabs of varying aspect 
ratio that were detached at day 3 of culture (i.e. gel compaction began on day 3). 
Macroscopic images of a slab with an initial aspect ratio of 4.5 and its alignment 
map are shown in Figure 4-2a-b. Representative images of the HUVEC networks 
are shown in Figure 4-2c-d. Slabs with an aspect ratio of 4.5 compacted much 
more (Figure 4-2e) and had more aligned matrix (Figure 4-2f) and microvessels 
(Figure 4-2g) than slabs of aspect ratio 1.5. No differences between aspect ratios 
were observed in total network length, average continuous structure length, or 
PC recruitment (Figure 4-2h-j). 
4.2.3. Compaction is detrimental to forming networks but not to previously formed 
networks. 
 Slabs of aspect ratio 4.5 were cultured in defined medium and detached 
from the culture plate (enabling compaction to begin) at days 1, 2 or 3. Images of 
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the resulting HUVEC networks are shown in Figure 4-3a-d. All of the detached 
slabs compacted more and were more aligned in terms of both matrix and 
microvessels (Figure 4-3e-g) than the day 3 control slabs that were never 
detached. Additionally the microvessels of the slabs detached at day 1 were 
more aligned than any other condition. No differences in total network length or 
PC recruitment were observed between any of the conditions, but the average 
structure length (a measure of network connectivity) was reduced in constructs 
detached at days 1 or 2 in comparison to the control. Constructs detached at day 
2 also had lower average structure length than those detached at day 3. The 
average structure length of constructs detached at day 3 was not different from 
that of controls (Figure 4-3h-j). 
 Slabs of aspect ratio 4.5 detached at day 3 were further analyzed for 
lumen formation and basement membrane deposition. They were compared to 
96 well plate controls (created at the same time and cultured for 3 days) for 
which the culture conditions were optimized. Representative images of CD31 and 
collagen IV staining are shown in Figure 4-4a-d. Analysis of CD31-stained 
images revealed that the lumen density, average lumen area and the cell density 
(including both HUVECs and PCs) were increased in the aligned slabs over the 
control, although no statistically significant differences were observed in either 
CD31+ area fraction or PC density (Figure 4-4e-i). No differences were observed 
in total staining intensity for either laminin or collagen IV staining, but a laminin 
staining per cell was decreased in the slabs (Figure 4-4j-m). 
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4.2.4. EGM-2+ improves compaction of slabs. 
 Additional medium formulations were tested to determine whether or not 
they could improve the limited compaction and alignment observed in slabs of 
aspect ratio 1.5. Slabs were cultured in defined medium for 3 days followed by 
the test medium for 3 days. The addition of TGF-β1 or growth factors provided by 
the EGM-2 bulletkit did not improve compaction, but serum-containing EGM-2+ 
did improve compaction, regardless of the serum concentration (Figure 4-5). 
4.2.5. Hybrid approach yields improved network characteristics over defined 
medium alone. 
Due to the relatively low compaction and lumen densities observed using 
defined medium, a hybrid approach was investigated in which slabs (aspect ratio 
1.5) were cultured in defined medium for 3 days followed by EGM-2+ for an 
additional 3 days. Constructs were detached on day 3. Representative images of 
the HUVEC networks are shown in Fig. 6a-c. Macroscopic images and alignment 
maps of day 6 constructs cultured in defined medium or EGM-2+ are shown in 
Figure 4-6d-g. In comparison to constructs cultured in defined medium for 3 or 6 
days, hybrid constructs compacted more and had higher matrix and microvessel 
alignment (Figure 4-6h-j). In addition, the total network length and average 
structure length were the same between the day 6 hybrid constructs and the day 
3 control, but reduced for the constructs cultured for 6 days in defined medium; 
PC recruitment was the same for all conditions (Figure 4-6k-m). 
Additional network characteristics were quantified from CD31-stained 
cross sections. Representative images are shown in Figure 4-7a-c. Lumen 
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density was improved in hybrid constructs over the day 3 control (Figure 4-7d), 
and mean lumen area was increased in day 6 defined medium constructs over 
the day 3 control (Figure 4-7e). The total cell density (based on nuclear counts) 
was increased in hybrid constructs over all other conditions (Figure 4-7f). The 
area fraction of CD31 staining (which corresponds roughly to EC density) was 
also increased in hybrid constructs over day 6 defined medium constructs (Figure 
4-7g). No differences were observed in PC density (Figure 4-7h). Basement 
membrane deposition was also examined using laminin and collagen IV stained 
cross sections. Representative images of collagen IV staining are shown in 
Figure 4-7i-k; laminin staining was similar and is not shown. A higher total 
intensity of laminin staining per area was observed in hybrid constructs as 
compared to day 6 defined medium constructs (Figure 4-7l), but this difference 
did not exist when the staining intensity was normalized to total cell density 
(Figure 4-7m). Total collagen IV staining per area was increased in hybrid 
constructs over both other conditions (Figure 4-7n), but collagen IV per cell was 
decreased in hybrid constructs in comparison to day 6 defined medium 
constructs. 
4.3. Discussion 
 The achievement of a highly interconnected microvascular network in 
fibrin gel under defined conditions is of utility for both EC biologists and tissue 
engineers. For EC biologists, this fibrin system complements our previously 
developed type I collagen system56 and enables the study of EC interactions with 
two different biopolymers of physiological relevance. For tissue engineers, the 
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fibrin gel system is much more advantageous than the collagen gel system 
because fibrin stimulates the production of extracellular matrix proteins that 
strengthen the tissue more so than collagen.42,128 It is interesting to note that in 
the fibrin gel system both the defined medium and the PCs were required to 
achieve a highly interconnected network; in the collagen gel system PCs were 
not required for the initial network formation. The presence of PCs improved the 
total network length in both media, but to a lesser degree in serum-containing 
EGM-2+. One possible explanation is that the serum provided some of the same 
factors as the PCs, accounting for the difference between medium types in the 
absence of PCs, and that in the presence of PCs, either the proximity of PCs to 
the ECs or the additional factors they provided improved the network formation. 
Additionally, the recruitment of the PCs to the EC microvessels was higher in 
defined medium. This is likely the result of an increase in local gradients of 
chemokines (e.g. PDGF-B) due to the relative lack of chemokines present in 
defined medium in comparison to EGM-2+. 
 Previous work has shown that the alignment of both matrix and sprouts 
from EC spheroids in an angiogenic system increases with slab aspect ratio,63 
and that appears to be true in this vasculogenic system as well. However, slabs 
of aspect ratio 3 in the previous report had birefringence values of over 8 x 10-5, 
whereas here slabs of higher aspect ratio (4.5) had birefringence values of only 1 
x 10-5. This is likely due to the relatively low level of gel compaction, which drives 
alignment, obtained in defined medium.  
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The compaction that did occur in defined medium had a deleterious effect 
on microvascular network formation. Constructs that were detached on days 1 or 
2, prior to the completion of network formation, formed some microvessels, but 
they were not as interconnected as the day 3 controls. Only day 6 constructs that 
were detached on day 3, after network formation had occurred, were identical to 
the day 3 controls in every network characteristic that was assessed. The fact 
that the total network length was the same across conditions suggests that any 
increased matrix density caused by compaction or reduction in local matrix 
tension caused by detachment from the plate had a minimal effect on 
microvessel growth. However, one possible explanation for the reduced network 
connectivity observed with premature detachment is that the increased matrix 
alignment of constructs caused by compaction during network formation 
prescribed a similar growth direction for all of the microvessels, reducing the 
probability that microvessels would connect to nearby microvessels. Another 
effect observed in constructs detached on varying days is that the network 
alignment was highest in the constructs detached on day 1. This is likely 
explained by the additional day(s) of compaction-induced alignment experienced 
by these constructs; constructs detached on day 3 cultured out to day 8 (an 
equivalent compaction time) would likely show a similar level of alignment. 
Another factor may be that the microvessels of constructs detached at days 1 or 
2 are forming as alignment is developing, enabling a greater role for contact 
guidance as compared to the constructs detached at day 3 that largely contain 
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formed microvessels that must reorient with the compacting network of ECM 
fibers. 
Despite the relatively low levels of compaction observed in defined 
medium, it is clear that the compaction that occurs in slabs of aspect ratio 4.5 
detached at day 3 is sufficient to achieve alignment of the microvascular network, 
as was the goal. Because this fibrin gel system was optimized for the 96 well 
plate constructs, comparison of the whole mount network characteristics between 
the aligned slabs and the 96 well plate constructs is of interest. Although the data 
(presented in Figure 4-1 and Figure 4-2) cannot be statistically compared 
because they resulted from separate experiments, the differences can give a 
general idea of how the microvessels compare. The data suggest that the slabs 
may have a lower total network length per area and a lower length per structure. 
It is unclear whether these differences are the result of actual network 
differences, experiment-to-experiment network variation, or differences in sample 
preparation for imaging (whole mounts, which were 400-500 µm thick, vs. 60 µm 
thick sections). It is certainly possible that connections between structures were 
missed in the slabs due to the relatively thin samples that were imaged. 
In contrast, the network characteristics obtained from sections (presented 
in Fig. 4) can be directly compared as the samples were from the same 
experiment, and they demonstrate improvement in the microvascular 
characteristics in the slabs over the 96 well plate constructs. The cause of this 
improvement cannot be determined due to the many differences between the 
conditions, including the sample geometry, the day of harvest, and the level of 
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compaction, which has been previously shown to increase lumen density.131 
Additionally, the deposition of basement membrane was assessed in the two 
construct types. Although there was no difference between conditions in total 
deposition of either laminin or collagen IV, a reduction in laminin staining per cell 
was observed in slabs. No difference was observed between conditions in 
collagen IV staining per cell. This suggests that the production of basement 
membrane by each cell was decreased in the slabs. This is particularly 
interesting due to the fact that the slabs were cultured for 3 days longer than the 
96 well plate constructs. 
Additional experiments were completed to determine whether or not 
additional factors could be added to the defined medium to induce more gel 
compaction. Higher levels of compaction would be desirable to increase the 
alignment and mechanical strength of engineered tissues. EGM-2+ was used as 
a positive control because it caused a high level of compaction in preliminary 
experiments. Despite the fact that TGF-β1 is known to increase cell 
contractility,132–134 the addition of TGF-β1 to defined medium did not increase 
compaction. Similarly, the addition of EGM-2 bulletkit components (except 
serum) to the defined medium in the same concentrations used in EGM-2+ did 
not increase compaction. Varying the amount of serum in EGM-2+ also did not 
affect compaction. It is unclear which component or combination of components 
of EGM-2+ induce high levels of compaction, and a more high throughput 
method than is currently available would be required to answer this question. 
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Because serum-containing medium was required to achieve high 
compaction levels, a hybrid approach was attempted in which slabs of aspect 
ratio 1.5 were cultured in defined medium for 3 days followed by EGM-2+ for 3 
days. This would enable microvascular networks to form prior to compaction 
induction by EGM-2+. This method succeeded in producing highly aligned 
microvascular networks; not only was the alignment of both matrix and networks 
stronger in these hybrid constructs than that of constructs cultured entirely in 
defined medium (birefringence/anisotropy index data presented in Figure 4-6), 
but it also appeared to be stronger than that of defined medium constructs of 
aspect ratio 4.5 cultured in defined medium (data presented in Figure 4-2). The 
fact that the network properties did not vary between the hybrid and day 3 control 
constructs suggests that the addition of EGM-2+ after network formation did not 
have a detrimental effect. 
Not only did the addition of EGM-2+ have no detrimental effects, it had a 
beneficial effect on lumen density, bringing the density to within the physiologic 
range for dermis.135,136 EGM-2+ also increased the overall cell density in 
comparison to the other conditions. This cell density is attributable to increased 
proliferation of the HUVECs as differences in PC density between conditions 
were not statistically significant. The density of basement membrane (both 
laminin and collagen IV) was increased in hybrid constructs; however this 
difference disappeared (laminin) or reversed (collagen IV) when the staining 
intensity was normalized to cell number, suggesting that the cellular production of 
these proteins was the same or lower in the EGM-2+. The high level of basement 
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membrane proteins were deposited by day 3 likely is part of the reason that 
these microvascular networks were relatively stable under compaction and the 
change of medium type. 
These results have demonstrated two methods for forming highly 
interconnected aligned microvascular networks within fibrin gel. The method 
involving only defined medium results in constructs with relatively low levels of 
compaction, but would be useful to EC biologists requiring full control over the 
culture conditions. The hybrid approach, although it relinquishes some control 
over the culture conditions, yields constructs with relatively high levels of 
compaction, which is of interest to tissue engineers. Therefore, the HUVEC and 
PC fibrin gel system developed here has the potential for widespread use. 
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4.4. Figures 
 
Figure 4-1.  
 (A-D) Representative images of whole mount CD31 stains of HUVECs (red) with 
(A-B) or without (C-D) PCs (green) in defined medium (A,C) or EGM-2+ (B,D) 
after 3 days of culture. Nuclei are stained blue. Scalebars = 100 µm. (E-G) 
Quantitation of vessel network properties. HUVECs grown with PCs in defined 
medium demonstrated improved total vessel length (E), average length per 
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continuous structure (F), and PC recruitment (G) over all other conditions. *p < 
0.05 in comparison to all other conditions. 
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Figure 4-2.  
 (A) Macroscopic image of a slab with an aspect ratio of 4.5 after compaction in 
defined medium. Scalebar = 5 mm. (B) Alignment map of the compacted slab 
shown in (A). The red segments indicate the local strength and direction of fibril 
alignment. (C-D) Representative images of CD31-stained (red) thick longitudinal 
sections of slabs with aspect ratios of 1.5 (C) and 4.5 (D). The long axes of the 
slabs are vertical. PCs are green and nuclei are blue. Scalebars = 100 µm. (E-G) 
Construct compaction (width at the middle of the slab; E), Matrix alignment 
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(birefringence; F), and microvessel alignment (anisotropy index; G) show that the 
slabs with higher aspect ratio that compacted more were also more aligned. (H-J) 
No differences were observed between slabs of different aspect ratio for a 
number of microvessel characteristics, including total vessel length per area (H), 
the average length per continuous structure (I), and the recruited PC fraction (J). 
*p < 0.05. 
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Figure 4-3.  
 (A-D) Representative images CD31 stains (red) of thick longitudinal sections of 
slabs cultured in defined medium that were never detached and harvested at day 
3 (A), or that were detached at day 1 (B), day 2 (C) or day 3 (D) and harvested at 
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day 6. The long axes of the slabs are vertical. PCs are green and nuclei are blue. 
Scalebars = 100 µm. (E-G) Measures of construct compaction (width at the 
middle of the slab; E), matrix alignment (birefringence; F), and microvessel 
alignment (anisotropy index; G) indicated that all of the detached slabs 
compacted and that both the matrix and the microvessels became aligned. (H-J) 
Measures of microvessel properties, including total microvessel length per area 
(H), average length per continuous structure (I), and PC recruitment (J), 
suggested that the aligned microvascular networks present in the slabs detached 
on day 3 were equivalent to those of the day 3 control slabs. *p < 0.05. $p < 0.05 
in comparison to the control.  
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Figure 4-4.  
 (A-D) Representative images of cross sections of constructs created in 96 well 
plates (A-B) or in the slab geometry (C-D) and cultured in defined medium 
stained for either CD31 (A,C) or collagen IV (B,D) in red. PCs are green and 
nuclei are blue. Arrows indicate the location of lumens. Scalebars = 100 µm. (E-
H) Quantification of microvessel properties from CD31-stained images, including 
lumen density (E), average lumen area (F), the total cell density (G), the area 
fraction of CD31 staining (indicative of EC density; H), and the PC density (I). 
The slabs contain more and larger lumens as well as a higher total cell density, 
although no differences were observed among conditions for either CD31 fraction 
or PC density. (J-M) Basement membrane deposition. No differences were 
observed in total staining intensity of sections stained for laminin (J) or collagen 
IV (L). However, laminin staining intensity normalized to cell density was reduced 
in the slab geometry (K). No difference was observed in collagen IV staining per 
cell. *p < 0.05. 
  
94 
 
 
Figure 4-5.  
Assessment of media were tested in an attempt to increase compaction in 
defined medium or reduce compaction speed in EGM-2+. The construct 
compaction results (width at the middle of the slab) suggest that all defined 
media caused similar compaction rates and all serum-containing media caused 
faster compaction rates, which were similar to each other. *p < 0.05 compared to 
all defined media. $p < 0.05 compared to all serum-containing media. 
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Figure 4-6.  
Analysis of the hybrid approach based on whole mount microvessel properties. 
(A-C) Representative images of thick longitudinal sections of constructs using the 
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hybrid approach, in which some constructs were harvested at day 3 (A) and 
others were cultured for an additional 3 days in either defined medium (B) or 
EGM-2+ (C). HUVECs were stained for CD31 (red), PCs were GFP-labeled 
(green) and nuclei were stained blue. The long axes of the slabs are vertical. 
Scalebars = 100 µm. (D-G) Macroscopic images (D,F) and alignment maps (E,G) 
of slabs cultured in defined medium (D-E) or EGM-2+ (F-G). The red segments in 
the alignment maps indicate the local strength and direction of fibril alignment. 
(H-J) Alignment and compaction parameters indicated that the constructs 
cultured in EGM-2+ had higher matrix alignment (birefringence; H), compacted 
more (smallest width at the middle of the slab; I), and had higher microvessel 
alignment (anisotropy index; J) than slabs cultured in defined medium. (K-M) 
Microvascular network characteristics, including total microvessel length per area 
(K) and average length per continuous structure (L) were similar between slabs 
cultured in EGM-2+ and the control slabs, but reduced in slabs cultured in 
defined medium. PC recruitment (M) was similar across all conditions. *p < 0.05. 
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Figure 4-7.  
Analysis of the hybrid approach based on cell densitites and basement 
membrane deposition. CD31, laminin and collagen IV staining of construct cross 
sections was performed. (A-C) Representative CD31 staining (red) of constructs 
cultured in defined medium for 3 days (A), 6 days (B) or defined medium for 3 
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days followed by EGM-2+ for 3 days(C). PCs are green and nuclei are blue. 
Arrows indicate examples of lumens that were characterized. Scalebars = 100 
µm. (D-H) Quantification of sections. The lumen density was improved in hybrid 
constructs over the control (D), and the average lumen area was larger in day 6 
defined medium constructs (E). The cell density (F) was highest in the hybrid 
constructs. The area fraction of CD31 staining (indicative of EC density; G) was 
increased in hybrid constructs over day 6 defined medium constructs, but the PC 
density (H) was constant across conditions. (I-K) Representative collagen IV 
staining of control (I), defined medium (J), and hybrid (K) constructs. Laminin 
staining was similar, and is not shown. (L-O) Quantification of basement 
membrane staining. More total laminin staining was present per area in hybrid 
constructs than day 6 defined medium constructs (L); however no difference was 
observed in staining intensity per cell (M). A similar trend was observed for 
collagen IV staining, except that the staining intensity per cell was decreased in 
hybrid constructs (N-O). 
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Chapter 5. A Mathematical Model for Understanding Fluid Flow 
in Engineered Tissues Containing Microvessels 
5.1. Introduction 
 The engineering of microvascular networks in vitro is of interest to basic 
scientists and tissue engineers alike. Much can be learned about endothelial cell 
(EC) biology from in vitro microvascular networks, which are more accessible 
and controllable than in vivo netowrks. In addition, engineered microvasculature 
is required to deliver nutrients to engineered tissue with high nutrient demand, 
such as myocardium. In vitro fluid flow through such an engineered 
microvascular network is an essential component of nutrient delivery, mimicking 
in vivo delivery. 
Although a wide variety of mathematical models have been developed to 
understand fluid flow and nutrient exchange through native capillary networks,137–
141 no models have been developed for vasculogenic engineered networks. 
Engineered microvasculature is often quite dissimilar to native microvasculature. 
Capillary-like structures (microvessels) are often isolated from other cellular 
structures, and lumens often do not extend the entire length of the 
structure.54,122,123,142 Branches may occur, but they are not necessarily at 
physiologically relevant angles. In addition, it appears that at times the ends of 
microvessels are open, enabling fluid from the interstitium to enter the lumen, 
and at other times are closed, creating lumenal space isolated from the interstitial 
fluid. 
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Theoretically, if the ends of microvessels were open, interstitial flow would 
drive fluid through their lumens because the lumens would provide less 
resistance to flow than the extracellular matrix (ECM). A model describing fluid 
flow through such an engineered microvaculature could be useful for determining 
parameters such as the density of structures that receive flow or the frequency of 
bifurcations within the microvessels, both of which may be difficult to directly 
measure. In addition, such a model could be extended to determine oxygen 
concentrations throughout the sample (an understanding of which could be 
critical to improving the engineered tissues) or the local shear stresses to which 
microvessels are exposed (which likely play a role in lumen formation when 
applied to the ablumenal surface and are known to affect EC phenotypes and 
disease processes when applied to the luminal surface143). 
Research in groundwater flow has led to the development of mathematical 
models for flow through fractured porous media, in which a porous medium, such 
as rock, contains fractures with a much higher permeability than the porous 
medium.144 One can see the analogy between fractured rock and ECM 
containing perfusable microvessels. However, some differences apply, making 
the groundwater flow models ill-suited for describing tissues with engineered 
microvessels. For example, fractures are assumed to be planar, rather than 
linear as they would be for microvessels. It is also assumed that fluid can enter 
from any side of the fractures, whereas in engineered microvessels, fluid should 
primarily enter through their ends. In addition, the models of fractured porous 
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media are relatively complex and have an associated large computational 
demand, which may not be necessary for the study of engineered microvessels. 
Therefore, we developed an idealized 2-dimensional flow model and 
corresponding finite difference approximation (FDA) model to describe pressure 
and fluid flow through the ECM and engineered capillary-like structures. The FDA 
model, coded in Matlab (Mathworks), includes tubes (linear “fractures”) that 
require fluid to enter from the surrounding ECM (“rock”) at only their ends, with a 
computational time that required only seconds. The model was internally 
validated and compared to a more accurate (but much more computationally 
intensive) 3-dimensional finite element approximation (FEA) model created in 
COMSOL Multiphysics. Example data based on our experience with engineered 
microvessels was used to demonstrate the potential uses of the model. 
5.2. Methods 
5.2.1. Idealized Model of Fluid Flow in Tissues Containing Engineered 
Microvessels 
 A simple 2-dimensional FDA model was developed in which the ECM was 
represented by a homogenous porous medium, and microvessels were 
represented by straight tubes, some with a single bifurcation, of infinitesimal 
radius between two nodes of the porous medium. Fluid flow in the ECM was 
governed by Darcy’s Law, 
          (1) 
where   is fluid velocity,    is the hydraulic conductivity of the ECM, and   is the 
pressure. The hydraulic conductivity, which is a property of the ECM and the 
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fluid, was related to the hydraulic permeability, which is a property only of the 
ECM, as follows: 
        (2) 
where    is the hydraulic permeability of the ECM and   is the fluid viscosity. 
Fluid flow within tubes followed the Hagen-Poiseuille Equation for steady laminar 
flow of a Newtonian fluid in a smooth cylindrical tube, 
   
     
   
, (3) 
where   is the volumetric flow rate,   is the radius of the tube,   is pressure, and 
  is the length of the tube. Fluid entering or exiting a tube was considered to be a 
point sink or source, respectively, of mass and linear momentum, which was 
handled by adding an additional term to the balance equations based on the 
length, radius (a finite radius for each tube was used to calculate resistance to 
flow), and orientation of the tube. The following are balance equations for the 
example of a node ( ) at which a tube begins: 
Mass      
  
   
, (4) 
  Momentum        
  
  
         , (5) 
  Momentum        
  
  
         , (6) 
in which    is the volumetric flow rate through the microvessel,    is the distance 
between nodes,     and vyi are the  - and  -components of velocity at node  , 
respectively,     and     are the ECM hydraulic conductivities in the   and   
directions, respectively,    is the velocity through the tube, and   is the angle of 
the tube relative to the   direction. As the equations indicate, at node   the 
103 
 
velocity through the tube and the ECM velocity are assumed to be independent 
in terms of magnitude and direction. For tubes containing one bifurcation, each 
portion of the tube was assigned a radius, and flow through each portion was 
determined by the pressure difference between the bifurcation point and the end 
open to the ECM. The pressure at the bifurcation point was determined by 
enforcing mass conservation through the tube. Mass and linear momentum 
balances were evaluated at each node, except at boundaries, using first order 
forward (or backward at some boundaries) finite difference approximations 
(Figure 5-1). (Centered finite differences were initially used but resulted in 
spatially periodic solutions due to the tube inflows and outflows that occurred at 
single nodes.) Boundary conditions applied were no flux through the sides of the 
tissue, fixed and uniform pressure at the tissue outlet, and fixed, uniform and uni-
directional flow at the tissue inlet. The system of linear equations was solved for 
velocity and pressure fields in Matlab (v. R2012b). 
 Microvessel density was specified as a total number of tubes, and tube 
location and dimensions could be specified directly or generated randomly based 
on an average and standard deviation of each tube parameter (length, radius, 
and angle). Specified tubes were used in model validation, and randomly 
generated tubes, based on parameters measured from engineered microvessels, 
were used to produce model results. The results from 6 randomly generated tube 
configurations were averaged to produce each data point. Parameters used for 
each case are listed in Table 5-1.  
Exact Model of Fluid Flow in Constructs Containing Engineered Microvessels 
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 A 3-dimensional finite element model was created in COMSOL 
Multiphysics (v. 4.2a) using the Free and Porous Medium module in order to 
compare and validate results from the FDA Model. Microvessels were again 
modeled as tubes within a porous ECM. Flow within the ECM was governed by 
the Brinkman Equations: 
 
 
  
      
 
  
          
 
  
           
  
   
        
 
 
            , (7) 
       , (8) 
where   is fluid density,    is ECM porosity,   is velocity,   is pressure,   is 
dynamic viscosity,   is permeability,   is effective viscosity,   is volumetric flow 
rate, and   is force. 
Flow within the tubes was governed by the Navier-Stokes Equations: 
                                 , (9) 
       , (10) 
in which the symbols represent the same variables as in the Brinkman Equations. 
At the interface between a tube end and the ECM, the normal stresses were 
equated: 
                        
 
  
              
   
, (11) 
where again the symbols represent the same variables. The boundary conditions 
for the FEA model were the same as those for the FDA model except that no slip 
boundary conditions were enforced at the sides of the ECM and all tube edges. 
 Only prescribed geometries (not randomized) were used in this model, as 
that enabled direct comparison of the two models. Water was used as the fluid 
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for the comparison. Once the geometry was defined, a tetrahedral mesh (with a 1 
µm element size) was applied, and the equations were solved for the pressure 
and velocity fields. Standard parameters for the FEA model are given in Table 5-
2. 
5.2.2. Internal Validation of the Models 
 Each model was validated internally by varying parameters one at a time 
and verifying that the results made intuitive sense.  A single tube was used for 
simplicity. While one parameter value was varied, all of the others were held 
constant at their standard values. Each parameter was examined at 5-7 values in 
a range that included its standard value. Parameters that were varied in both 
models included inlet velocity, ECM permeability, fluid viscosity, microvessel 
radius, and microvessel angle relative to the   direction. In the FDA model, the 
ECM anisotropy was also varied by decreasing the ECM permeability in the   
direction while holding the permeability in the   direction constant. This was not 
varied in the FEA model because a permeability tensor (which describes ECM 
anisotropy) was not supported in COMSOL’s Free and Porous Medium module. 
5.2.3. Comparison Between Models 
 Comparisons of the results of the FDA model to those of the FEA model 
were used to further validate the FDA model. First, the results of parameter value 
variations (described above) were compared between the models. Direct 
comparison was possible because the geometry assessed was identical between 
models and because the results were assessed for the same parameter values.  
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A second comparison was completed, in which the radius of the 
microvessel in a single tube geometry was varied over a much wider range than 
in the internal validation studies. The models were expected to agree in the limit 
as the tube radius approached zero. The only difference in the model geometries 
used was that the tube wall thickness could not be reduced below 1 µm in the 
FEA model (the FDA model assumes negligible wall thickness). The error 
between the models was studied for a variety of parameter values, including the 
percentage of total flow going through the tube, the fluid velocity within the tube, 
the pressure drop across the tube, the bulk velocity at the tissue inlet and outlet, 
and the fluid pressure at the tissue inlet. In addition, velocity vector and pressure 
plots were visually compared. Three tube angles (0°, 10° and 35°) and two tube 
lengths (100 and 150 µm) were evaluated in this radius comparison. Because the 
results were insensitive to variations in these parameter values, only the 
condition using the standard parameter values is presented here. 
A final comparison studied the effects of the separation distance between 
two tubes. The first tube was held at a constant location whereas the second 
tube was translated in the   direction to achieve varied distances between the 
outlet of the first tube and the inlet of the second tube. Standard parameter 
values were used for both tubes, and the outlet of the first tube and the inlet of 
the second tube were held at the same   value. The error between the models 
for the same parameter values used above for the single tube geometry was 
evaluated. Visual comparisons of velocity vector and pressure plots were also 
made. 
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5.2.4. Evaluation of Model Predictive Capability 
To evaluate the capability of the FDA model in predicting results, two 
output parameters were assessed over a range of input parameter values. The 
output parameters in each case were pressure at the tissue inlet and an effective 
hydraulic permeability for the tissue (i.e. including flow through both the ECM and 
tubes), which was obtained via Darcy’s Law (Eqns. 1-2), with the velocity set to 
the   velocity at the tissue inlet. Defined this way, the effective permeability is 
proportional to the inverse of the tissue inlet pressure. These were chosen 
because they could easily be measured experimentally. The input parameters 
that were varied included tube density, percentage of bifurcations, ECM 
anisotropy, tube anisotropy index, and tube length. Tube density was calculated 
assuming the model represented the projection of a 3-dimensional tissue with a 
square cross-section. The number of tubes crossing each column (  direction) of 
nodes was counted and averaged for the middle third of the tissue and 
normalized to the assumed cross-sectional area. The variation in microvessel 
densities calculated when using the same number of tubes is noted in Table 5-1. 
The ECM anisotropy was varied by decreasing the permeability in the   direction. 
The tube anisotropy index, a measure of tube alignment in the direction of flow, 
was defined as 
    
   
   
, (12) 
in which    is the tube length in the   direction, and    is the tube length in the   
direction. A higher anisotropy index reflects a higher degree of tube alignment. 
For each analysis, all parameters were kept constant aside from the varied 
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parameter. Standard parameter values are listed in Table 5-1.  Each data point 
represents the average of 6 runs in which the tubes were randomly generated 
based on an average radius, length and angle relative to the   direction. 
5.3. Results 
5.3.1. Model Validation. 
The FDA model was first internally validated using a single microvessel by 
varying parameter values independently and assessing the results intuitively. The 
results examined were the velocity through the microvessel and the average 
pressure at the tissue inlet. Example velocity vector plots and pressure maps 
using the standard parameter values are shown in Figure 5-2a-b. Results of 
varying the velocity at the tissue inlet are shown in Figure 5-2c. The linear 
relationships indicate that both the velocity through the microvessel and the 
pressure at the tissue inlet increased by the same factor as the velocity at the 
tissue inlet was varied. As the ECM permeability decreased, the inlet pressure 
remained constant near zero until a permeability on the order of 10-12 cm2, at 
which point it rapidly increased (Figure 5-2d). Fluid velocity through the 
microvessel increased as ECM permeability decreased until approximately the 
same permeability value, at which point further decreases in permeability did not 
increase the velocity. Variations in fluid viscosity had minimal effects on 
microvessel flow velocity, but high viscosities led to increased pressures at the 
tissue inlet (Figure 5-2e). Microvessel radius was varied in a small, 
physiologically-relevant range (Figure 5-2f). Tissue inlet pressure remained 
constant across radii, but the fluid velocity in the microvessel decreased slightly 
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with increasing radius. The angle of the microvessel relative to the  -direction 
had little effect on either the inlet pressure or the microvessel velocity (Figure 5-
2g). Little effect was observed on tissue inlet pressure when the ECM anisotropy 
(       ) was varied by decreasing    , but with increasing anisotropy the 
microvessel flow velocity decreased (Figure 5-2h). 
 The FEA model was then validated by varying the same parameter values 
(where possible) using the single microvessel. Example plots of velocity and 
pressure are shown in Figure 5-3a-b and parametric dependences are shown in 
Figure 5-3c-g. Linear relationships were observed between both tissue inlet 
pressure and microvessel velocity and velocity at the tissue inlet in a log-log plot 
(Figure 5-3c), indicating that the model results were changed by the same factor 
as the inlet velocity. Pressure at the tissue inlet remained low as ECM 
permeability increased until a permeability of order 10-12 cm2, after which the 
pressure dramatically increased. Velocity through the microvessel initially rose 
with increasing permeability, and then reached a plateau at a permeability near 
10-12 cm2 (Figure 5-3d). Variations in fluid viscosity had no effect on microvessel 
velocity, but tissue inlet pressure increased substantially when the viscosity was 
above 0.0089 P (Figure 5-3e). Variations in the microvessel radius did not affect 
either pressure at the tissue inlet or microvessel velocity (Figure 5-3f). 
Microvessel angle had no effect on the pressure at the tissue inlet, and only a 
minor decrease in microvessel velocity was observed with increasing angle 
(Figure 5-3g). 
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5.3.2. Comparison of Model Predictions 
The results of parameter value variations (internal validation) between 
models (Figure 5-2 and Figure 5-3) were compared. The parameters that could 
be varied in both models included the velocity at the tissue inlet, the ECM 
permeability, the fluid viscosity, the microvessel radius, and the microvessel 
angle. Of these, the results in terms of both the pressure at the tissue inlet and 
the velocity through the microvessel were very similar for most parameters. The 
largest discrepancy was that microvessel velocity decreased much more with 
increasing microvessel radius in the FDA model than in the FEA model. 
The differences between the FDA and FEA model predictions were 
quantified for several parameters at a variety of microvessel radii. Several single 
microvessel geometries spanning several microvessel lengths and orientations 
were considered. The results for these different microvessels were similar, so 
only the results using standard parameter values are presented here. The 
parameters investigated were the velocity through the microvessel, the 
percentage of the total flow traveling through the microvessel, the pressure 
difference across the microvessel, and the pressure at the tissue inlet. Although 
the models were expected to agree more closely as the vessel radius 
approached 0, an error minimum was observed for all output parameters at a 
radius of approximately 2.5 µm (Figure 5-4a). The differences at smaller radii 
were likely due to the fact that the wall thickness could not be made smaller than 
1 µm in COMSOL due to meshing limitations. Percent errors of the FDA model 
for various parameters are listed in Table 5-2. The percent error was below 30% 
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for all parameters studied, and close to 1% for one parameter (as shown), 
indicating good agreement. Reducing the node spacing of the FDA model or 
using higher order finite difference approximations had little effect on the errors 
calculated (data not shown). 
A second model involving two microvessels was also used to compare the 
FDA and FEA models. Both microvessels were defined by the standard 
parameter values, and the distance between the outlet of the first microvessel 
and the inlet of the second microvessel was varied. The velocity vector plots from 
each model (Figure 5-5a-b) demonstrated reasonable agreement. The percent 
error between the two models was quantified for the velocity through the 
downstream microvessel and the pressure at the tissue inlet. The percent error 
decreased with increased distance between the microvessels but was relatively 
low for all separation distances (Figure 5-5c). 
5.3.3. Evaluation of Model Predictive Capability 
The pressure at the tissue inlet and the effective permeability of the tissue 
(i.e. including flow through both the ECM and microvessels) were computed 
outputs from the FDA model with randomly generated microvessels while 
individual parameter values were varied. The percentage of bifurcations, 
microvessel anisotropy index and the microvessel length had little effect on either 
output parameter (Figure 5-6a-c). If the microvessels nearly spanned the tissue 
region (e.g. 230 µm in length), the outputs were affected, as expected. As ECM 
anisotropy increased, the tissue inlet pressure decreased, and the effective 
hydraulic conductivity increased (Figure 5-6d). A similar trend was observed with 
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increasing microvessel density (Figure 5-6e). Sample pressure plots for 
microvessel densities of approximately 25 and 550 microvessels/mm2 are 
provided in Figure 5-6f-g. 
5.4. Discussion 
 Overall, both intra- and inter-model validation suggested that the FDA 
model is reasonably accurate for experimentally-relevant parameter values. 
Internal validation of both models suggested that the microvessel flow velocity 
remained constant to changes in fluid viscosity and microvessel angle, as 
expected. Microvessel angle also had no effect on the pressure at the tissue 
inlet, but at high viscosities (beyond physiological), the pressure increased 
dramatically from near zero. This result is intuitive, as more viscous fluids would 
require larger pressures to drive the same flow rate. Microvessel flow velocity 
decreased with increasing ECM anisotropy, which may at first appear 
counterintuitive; however, examination of the velocity vector plots shows that fluid 
from a variety of   positions enters the tube. If flow is retarded in the   direction, 
less fluid would enter the microvessel. Increases in the inlet velocity were 
observed to cause proportional increases in inlet pressure and microvessel flow 
velocity, as expected. One of the more interesting internal validation plots is the 
one in which ECM permeability is varied. As the permeability was decreased, the 
microvessel flow velocity increased, which is logical because the ratio of 
resistance to flow between the microvessel and the ECM was decreasing; 
essentially the effective permeability of the tissue remained constant. However, 
near a permeability of 10-12 cm2, the microvessel velocity reached a plateau, and 
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the tissue inlet pressure, which had previously been low, increased substantially. 
This result is also logical because a high pressure will be required to drive flow 
through a tissue with a low permeability. The microvessel flow velocity plateau is 
somewhat less intuitive because the ratio of resistance to flow between the 
microvessel and the ECM was still decreasing. However, examination of the 
velocity vector plots at relatively high permeabilities indicates that the higher 
velocity through the microvessel required fluid to be diverted from a farther 
distance from the microvessel inlet. In the plateau region, it is logical that a 
balance was established between the decreasing ratio of resistance to flow and 
the increasing pressure required to divert fluid through the microvessel from 
further distances. The largest difference in the results of internal validation 
between models occurred in the radius variation. In both models, the inlet 
pressure remained constant, but in the FDA model the microvessel velocity 
decreased with increasing radius, whereas in the FEA model the microvessel 
velocity was nearly constant. Although the lack of agreement is somewhat 
disconcerting, the maximum difference is less than two-fold, a difference that 
may be acceptable for the computational speed enhancement and other benefits 
of the FDA model. 
 Validations between the models demonstrated that the FDA model was 
most accurate for a small range of microvessel radii. The minimum error between 
models occurred at a radius of 2.56 µm, which is within the physiologic range for 
capillaries (2.5-4 µm radius for human coronary capillaries;145 the radii of 
engineered microvessels are generally higher by several microns but the 
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physiological range is the target). Therefore, a radius of 2.5 µm was used for all 
subsequent evaluations. At a radius of 2.5 µm, the error for a variety of model 
outputs was less than 30%, indicating good agreement. Although, theoretically, 
the error between models should decrease with decreasing radius beyond 2.5 
µm, the microvessel wall thickness could not be decreased below 1 µm in the 
FEA model. Because the FDA model assumes negligible wall thickness, this 
could be the source of additional error at very small radii. Additionally, the 
differences in the  mesh size (1 µm) of the FEA model and the node spacing (5 
µm) of the FDA model may account for some error. 
At microvessel radii near 1.5 µm, the FDA model predicted reverse flow 
through the single microvessel geometry, which was not corroborated by the FEA 
model. These results were taken to be inaccurate, so radii near 1.5 µm were 
removed from randomly generated microvessel geometries by using a small 
range of radii centered on 3 µm. Reverse flow was also occasionally observed in 
one outlet portion of a bifurcating microvessel regardless of radius. Attempts 
were made to validate these results with the FEA model, but geometries resulting 
in reverse flow could not be recreated in COMSOL due to its limitations in 
prescribing microvessel bifurcation angle. Because these instances were rare 
and not necessarily counterintuitive, they were included in randomly generated 
geometries. 
 The error between models was also compared for a two microvessel 
geometry. As the separation distance between the microvessels was decreased, 
the error increased. However, at a separation distance of 5 µm (equivalent to one 
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node apart in the FDA model), the difference between models was well under 
two-fold, In addition, the velocity vector plots substantially agreed. These data 
suggest that the FDA model is relatively accurate even when the microvessels 
are in close proximity. 
 The rationale for developing the FDA model was for use in predicting the 
morphometric properties of microvessels within engineered tissues exposed to 
flow, which may be difficult to determine experimentally. With this goal in mind, 
the tissue inlet pressure and effective tissue permeability, which are both outputs 
of the model and easily measurable experimentally, were observed as 
microvessel morphometric parameters were varied. Several of these parameters 
had no effect on the inlet pressure or the effective permeability. These 
parameters include the percentage of microvessels containing a bifurcation, the 
microvessel anisotropy index, and the average microvessel length. These results 
suggest that the neither measured pressure at the tissue inlet nor the effective 
permeability can be used to predict any of these microvessel properties. It also 
suggests, however, that these parameter values need not be known in order to 
accurately predict other morphometric properties. 
 With increasing ECM anisotropy (       , varied by changing    ), the 
tissue inlet pressure increased and the effective permeability decreased. 
Previous modeling has indicated that even in tissues with high levels of 
anisotropy, the permeability only varies approximately 3-fold;146 therefore 
permeability differences greater than 5-fold were not assessed. The results 
suggest that the inlet pressure or the effectively permeability could be used to 
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predict the ECM anisotropy. However, ECM anisotropy is relatively simple to 
measure by taking permeability measurements in orthogonal directions. Thus, 
the main conclusion from this plot is that the ECM anisotropy must be known to 
predict other morphometric properties. 
As microvessel density increased, the inlet pressure decreased and the 
effective permeability increased. This result suggests that either the pressure or 
the permeability could be used to predict the density of perfusable microvessels. 
The FDA model assumes all microvessels are perfusable and since they have 
negligible radius, the model predictions are independent of non-perfusable 
microvessels. The density of perfusable microvessels, although extremely 
important in understanding the flow through the tissue, is extremely difficult to 
measure experimentally, because histologic examination does not make a 
distinction between microvessels that are perfusable and those that are not. The 
slope of the curve suggests that the model would be most accurate in predicting 
perfusable microvessel densities less than 500 lumens/mm2. Although 
myocardial capillary density is near 2000 capillaries/mm2,9 many other native 
capillary beds have lumen densities within this range, including skeletal muscle 
(200-300 capillaries/mm2).147,148 In addition, only recently have engineered 
tissues contained microvascular structures nearing 500 microvessels/mm2.131 
Therefore, the tissue inlet pressure or the effective permeability could be used to 
predict the microvessel density of perfused microvessels. A number of other 
parameters were shown to influence the pressure at the tissue inlet, so these 
must also be known to make an accurate prediction. These parameters include 
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fluid viscosity, the fluid velocity at the tissue inlet, the ECM permeability, the 
degree of ECM anisotropy, and the average microvessel radius and its standard 
deviation, all of which are relatively straightforward to measure experimentally. 
Microvessel length must also be known if it approaches the dimension of the 
engineered tissue; equivalently the dimension of the modeled tissue must be 
much greater than the length of a microvessel. Additionally, although the 
predicated tissue inlet pressure values are low, the modeled region represents 
only a small portion of the tissue; for example, the model would predict pressures 
in the range of 0.75 to 2.55 mmHg for a tissue 15 mm in length. 
If pressure at the tissue inlet cannot be measured precisely enough to 
make predictions, the residence time of a pulsed tracer within the tissue could be 
used. Theoretically, the tracer would reside in the tissue for a shorter time with a 
higher density of perfusable microvessels due to the faster velocities observed 
through the microvessels than in the ECM. However, this would require the 
extension of this model to include the species balance (convection and diffusion) 
equations for the tracer, which is beyond the scope of this work. Such an 
extension would also be useful in examining the oxygen distribution within the 
tissue, a prediction extremely relevant to tissue engineering. 
Despite being less accurate, the FDA model has many advantages over 
the FEA model. The main advantage is computational speed: the FDA model 
computed within several seconds, even for geometries with a large number of 
microvessels, whereas the FEA model took 15 minutes for the single microvessel 
geometry, and would be prohibitively long when many microvessels were 
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present. The FEA model also had several software limitations, including the 
inability to handle permeability tensors for the study of ECM anisotropy, a limited 
range of bifurcation angles, and meshing limitations when using small 
dimensions.  
Although the FDA model has been verified to be reasonably accurate and 
theoretically useful, it has limitations. One limitation is the restricted geometries: 
microvessels can either be straight or have one bifurcation. Additional 
bifurcations could be included using the same principles to define pressures at 
bifurcation points, but this would add coding complexity. A more general model 
would allow for true networks of microvessels by connecting microvessels that 
were randomly placed near to each other; this would enable the examination of 
percolation behavior and is more similar to the was microvessel networks form in 
vitro. Additional work is necessary to address these limitations. 
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5.5. Tables 
Tissue, Fluid and Boundary Parameters for FDA Model  
Parameter  Value  
Permeability  9.92 e-11 cm2  
Tissue Length (x-direction)  250 µm  
Tissue Width (y-direction)  200 µm  
Matrix Anisotropy  1  
Node Spacing  5 µm 
Viscosity  0.89 cP  
X-Velocity at Tissue Inlet  1.33 µm/s  
Pressure at Tissue Outlet  0  
Defined Microvessels (Validation Geometries with 1 or 2 Microvessels)  
Parameter  Value  
Microvessel Length  100 µm  
Microvessel Radius  2.5 µm  
Microvessel Angle  10°  
Randomly Generated Microvessels   
Parameter  Value  
Microvessel Radius (Standard Deviation)  3 µm (0.125 µm)  
Microvessel Length (Standard Deviation)  100 µm (10 µm)  
Microvessel Angle (Standard Deviation)  0 (20°)  
Lumen Density  275 (+/- 2.5%)  
Percentage Bifurcating Microvessels  50%  
 
 
Table 5-1.  
Standard parameter values used for the FDA model. 
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Single Microvessel FEA Model   
Parameter  Value  
Permeability*  9.92 e-11 cm2  
Tissue Length (x-direction)  250 µm  
Tissue Width (y-direction)  200 µm  
Matrix Anisotropy  1  
Tissue Porosity  0.95 
Viscosity*  0.89 cP  
Fluid Density  1000 kg/m3 
X-Velocity at Tissue Inlet  1.33 µm/s  
Pressure at Tissue Outlet  0  
Microvessel Length  100 µm  
Microvessel Radius  2.5 µm  
Microvessel Angle  10°  
Microvessel Wall Thickness  1 µm  
 
Table 5-2.  
Standard parameter values used for the FEA model. 
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5.6. Figures 
 
Figure 5-1.  
 (A) Schematic of a node ( ) at which a microvessel begins. The surrounding 
nodes were labeled     and     in the   direction and     and     in the   
direction, where   is the number of nodes spanning the tissue in the   direction. 
The microvessel is indicated by the red line, and the blue arrow indicates the fluid 
velocity in the microvessel (  ). An ECM velocity (  ) was also defined at node  , 
and is indicated by the green arrow.   represents the angle between the 
microvessel and the   direction. (B) The finite difference approximations used for 
the model are listed. 
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Figure 5-2.  
Internal validation of the FDA model using a single microvessel. (A) Velocity 
vector plot of the outlet of the microvessel (black) under standard conditions. The 
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green arrows represent ECM velocities, whereas the blue arrow represents the 
velocity through the microvessel. (B) Pressure map of the entire tissue under 
standard conditions. The black line represents the microvessel. (C-H) Evaluation 
of the velocity through the microvessel and the pressure at the tissue inlet as the 
following input parameters were varied: (C)   velocity at the tissue inlet, (D) 
ECMmatrix permeability, (E) fluid viscosity, (F) microvessel radius, (G) 
microvessel angle relative to the   direction, and (H) ECM anisotropy. For each 
plot, all other input parameters were kept at their standard values. 
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Figure 5-3.  
Internal validation of the FEA model using a single microvessel. (A) Velocity 
vector plot of the region near the microvessel outlet. The arrows indicating the 
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velocity through the microvessel were removed to more clearly show the ECM 
velocities. (B) Pressure map of the whole tissue (standard conditions were used). 
(C-I) Velocity through the microvessel and the pressure at the tissue inlet plotted 
against the following parameters: (C) x velocity at the tissue inlet, (D) ECM 
permeability, (E) fluid viscosity, (F) microvessel radius, and (G) microvessel 
angle relative to the x direction. Within each plot, all other input parameters were 
held at their standard values. 
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Figure 5-4.  
Comparison between the FDA and FEA models using a single microvessel. (A) 
The percent error in the microvessel velocity between the FDA and FEA models 
for varying microvessel radii. (B) The percent error in a variety of output 
parameters for a radius of 2.56 µm. 
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Figure 5-5.  
Comparison between the FDA and FEA models using two microvessels. (A) The 
percent error in the downstream microvessel velocity and pressure at the tissue 
inlet between the FDA and FEA models for a variety of separation distances 
between the two microvessels. (B) Velocity vector plot showing the FDA model 
results for a separation distance of 5 µm. Green arrows represent velocities in 
the ECM and blue arrows represent velocities through the microvessels. The 
black lines represent the microvessels. (C) Velocity vector plot results from the 
FEA model for a separation distance of 5 µm. No velocity vectors for flow within 
the microvessels are shown so that the ECM velocities can be observed more 
easily. The white rectangles represent the microvessels. 
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Figure 5-6.  
Evaluation of the FDA model predictive capability. Pressure at the tissue inlet 
and the effective hydraulic permeability are plotted for varying levels of the 
following parameters: (A) percentage of bifurcations, (B) microvessel anisotropy 
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index, (C) microvessel length, (D) ECM anisotropy, and (E) lumen density. (D-E) 
The data were best fit with power equations, which are shown on the plots. (F-G) 
Example pressure plots for tissues with microvessel densities near 25 (F) or 550 
(G) microvessels/mm2. The dark lines indicate the location of microvessels. The 
color scale is the same for both plots. 
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Chapter 6. Aligned Microvessels with High Lumen Density via 
Cell-Induced Fibrin Gel Compaction and Interstitial Flow 
6.1. Introduction 
Co-culture of endothelial cells (ECs) with other support cell types is 
frequently used in in vitro models of angiogenesis and vasculogenesis.53,62,120,149–
153 These support cells are often fibroblasts, which have been shown to improve 
angiogenic sprouting62 and vessel density153 within 3D scaffolds. Although use of 
these cells has been shown to provide advantages, fibroblasts are not the most 
logical choice for support cells because they do not associate with vessels in 
vivo. In contrast, pericytes (PCs) are defined by their association with 
microvasculature. 
PCs are mural cells located within the basement membrane of capillaries 
and in physical contact with multiple ECs.46 During physiological angiogenesis or 
vasculogenesis, PCs are recruited to newly formed microvessels via EC-derived 
PDGF-BB and HB-EGF49,125 and their arrival defines the end of the microvascular 
“plasticity window,” in which capillaries can undergo growth or regression in 
response to physiological stimuli such as hyperoxia.48 Therefore, PCs are 
extremely important in stabilizing newly formed capillaries. This stabilizing effect 
is at least in part due to the production of basement membrane (e.g. collagen IV 
and laminins) by PCs in contact with ECs.47 PC production of the capillary-
stabilizing molecule angiopoietin-1 (Ang-1) may also contribute.51 Studies of 
PDGF and PDGFR-β knockout mice indicate that the presence of PCs inhibits 
EC proliferation and maintains capillary diameter. The knockout mice initially had 
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normal microvasculature formation, developing hemorrhages perinatally, 
suggesting that PC recruitment is only involved in microvessel stabilization, not 
formation.50,126 
Recent work has shown PCs to induce microvascular network stabilization 
events in a vasculogenic model involving human umbilical vein ECs (HUVECs) in 
a type I collagen gel.56 PCs were recruited to the forming microvessels and 
stimulated the production of basement membrane proteins including collagen IV 
and laminins. PC recruitment and basement membrane production are 
considered the two indicators of microvessel maturity and stability in vivo.154  
The work reported here extends these findings of microvascular 
maturation induced by PCs to a system involving a type of circulating ECs, blood 
outgrowth ECs (BOECs), in fibrin gel. This extension is key to moving from using 
such vasculogenic models for studying EC biology to creating functional 
microvasculature to deliver oxygen to engineered tissues, as both BOECs and 
fibrin are more suitable for tissue engineering than HUVECs and collagen I. 
BOECs are potentially autologous because they are isolated from blood 
mononuclear cells. They have a high proliferative potential, are positive for 
myriad EC markers and are negative for monocyte markers.57 Likewise, fibrin is a 
better scaffold for tissue engineering than collagen I because it induces 
extracellular matrix (ECM) remodeling by entrapped tissue cells,42 yielding a 
stronger tissue, which will be required for the production of engineered tissues for 
human use. 
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Most previous work on engineered microvasculature has been in isotropic 
systems,53,54,56 and there is, as yet, no report of an engineered tissue with a 
microvasculature that is perfusable in vitro. However, an aligned network would 
be advantageous both in terms of mimicking aligned native tissue (e.g. 
myocardium65), and in terms of establishing flow through engineered 
microvasculature, as alignment creates natural inlet and outlet sides. Recent 
work has shown that contact guidance in response to aligned matrix fibers is 
sufficient to align sprouts from BOEC spheroids, and that cell-induced gel 
compaction resulted in both aligned fibers and sprouts.63 We now extend this 
work to engineered vasculogenic networks, formed by self-assembly of dispersed 
BOECs, showing that cell-induced gel compaction also aligns such networks and 
that the benefits of PC stabilization (i.e. basement membrane deposition and 
prevention of network regression) are maintained after alignment. 
Finally, in many engineered tissues, such as myocardium, a high capillary 
density will be required to support the highly metabolic cells. Indeed, in native 
adult myocardium, the average capillary density is 2000 capillaries/mm2, and the 
average intercapillary distance is around 20 µm.8,9 To date, no engineered 
microvascular network has achieved this density. Reported values range from 2-
100 lumens/mm2 for networks prior to implantation,149,152,155,156 although not all 
reports of engineered microvessels quantified cross-sectional lumen density. 
Total capillary density increases after implantation, with most studies reporting 
200-600 lumens/mm2.53,124,157 The best capillary density reported was by 
Shepherd and colleagues, who observed 1400 lumens/mm2 after entrapping 
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microvessel fragments in collagen I gel, culturing them for 7 days and implanting 
them over myocardial infarcts for 28 days in mice.156 In the studies reported here 
we demonstrate vastly increased microvessel density using the same 
compaction technique used to achieve aligned microvessels, attaining values 
similar to reported post-implantation values. However, our preliminary studies 
indicated that even after compaction the microvessels were not dense enough. 
Therefore, we examined interstitial flow as a method to increase capillary density 
further. 
Interstitial flow occurs physiologically due to pressure differences between 
the vascular and lymphatic systems and is estimated to occur at flow rates of 0.1-
2 µm/s.158 Previous reports have suggested that interstitial flow through 
engineered tissues containing ECs at superficial velocities of 0.17-15.8 µm/s 
improves microvessel density or EC sprout length, and evidence indicates that a 
synergy exists between VEGF stimulation and interstitial flow, leading to 
improved outcomes.118,119,123,159 The shear stresses applied via interstitial flow at 
these velocities were quite low (on the order of 0.01 dyne.cm2), leading the 
previous investigators to attribute improvements to local morphogen gradients 
created by flow rather than shear stresses.123 In addition to the improved 
microvessel density, some alignment of microvessels in the direction of interstitial 
flow was observed in an initially isotropic construct.123 However, these results 
were achieved by applying flow throughout the culture period, beginning prior to 
any sprout or microvessel formation; it is unclear from previous work whether or 
not interstitial flow can modulate an existing network. Our results demonstrate 
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that interstitial flow improved lumen density without affecting other network 
properties in an existing engineered microvascular network.  
The permeability of EC monolayers is affected by shear stresses. Acute 
shear stress (hours) on the order of 1-10 dyne/cm2 decreased electrical 
impedance and increased permeability of EC monolayers.160–163 Chronic shear 
stress (days), however, reduced permeability.163 The acute effect appears to be 
due to transient rearrangement of both tight and adherens junctions,164 whereas 
improvement of tight junction functionality explains the chronic effect.165,166 
However, the majority of studies in this area have observed EC monolayers 
under laminar flow; it is unclear if the results hold for engineered microvessels 
exposed to interstitial flow. Additionally, the shear forces applied in this study are 
2 orders of magnitude lower than those reported in the literature, which may not 
be large enough to affect the permeability. The data presented here suggest that 
chronic low shear stress can decrease the permeability of engineered 
microvessels. 
Shear forces are also known to affect the arterial or venous phenotype of 
ECs, as indicated by ephrin levels. EphrinB2 and EphB4 have been used to 
characterize arterial and venous identity both in development167,168 and in mature 
cells.169,170 EphrinB2 is a reliable marker of arterial endothelial cells, and may 
also be expressed on vascular smooth muscle cells, while its receptor EphB4 is 
used to identify venous endothelial cells.171 In addition to larger diameter vessels, 
even capillaries may have arterial or venous properties.172 Ephs and ephrins help 
regulate angiogenesis through involvement with endothelial cells, pericytes, and 
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vascular smooth muscle.173 For example, activation of EphB4 by ephrinB2 
increased endothelial progenitor cell (EPC) recruitment to sites of 
neovascularization in a hindlimb ischemia model.174 Additionally, several groups 
have reported the importance of ephrinB2 for mural cell association with 
microvessels.175 With the generation of an engineered microvasculature, the 
influence of flow on endothelial cell maturation towards an arterial or venous fate 
is of interest. The influence of shear stress on ephrinB2 expression is dependent 
on cell type, and has not yet been investigated in BOECs. In the case of stem 
and progenitor cells, shear stress increases ephrinB2 expression. For example, 
shear stress increased ephrinB2 protein and mRNA expression in ES cell-
derived VEGFR2+ cells while EphB4 mRNA decreased.176 When EPCs were 
subjected to shear stress, ephrinB2 mRNA (along with several other arterial 
endothelial markers) and protein increased, while EphB4 mRNA decreased.177 In 
the case of more mature cells, shear stress has the opposite effect.  When 
human endothelial cells (both HUVECs and human coronary artery ECs) were 
subjected to arterial levels of shear stress, ephrinB2 mRNA was down-regulated.  
However, venous levels of shear stress did not have an effect.178 However, again 
previous work has examined EC monolayers rather than engineered 
microvessels, so it is unclear if the effects of shear would be the same. The data 
presented here show that ephrinB2 levels are reduced in response to shear 
stresses in engineered microvessels. 
These studies have examined the effects of cell-induced gel compaction 
and interstitial flow on the characteristics of engineered microvasculature. 
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Constructs were formed in a custom chamber that enabled gel compaction 
followed by interstitial flow. Constructs were exposed to one of two rates of 
interstitial flow for 3 or 6 days, and compared to both time-matched and baseline 
controls. A variety of microvascular network properties were examined including 
lumen density, mural cell recruitment, basement membrane deposition, and 
arterial/venous phenotype. 
6.2. Methods 
6.2.1. Cell Culture 
 Human blood outgrowth endothelial cells (hBOECs) were supplied by Dr. 
Robert Hebbel at the University of Minnesota. hBOECs were cultured in type I 
collagen-coated flasks in “hBOEC medium,” which consisted of EGM-2 (Lonza) 
with an additional 8% FBS and 1% penicillin-streptomycin. Passages 9-10 were 
used for these experiments. 
 GFP-labeled human brain pericytes (PCs) were provided by Dr. George 
Davis at the University of Missouri. They were cultured in gelatin-coated flasks in 
DMEM with 10% FBS and 1% penicillin-streptomycin. Passages 6-8 were used 
for these experiments. 
6.2.2. Construct Preparation 
 Constructs were cast in custom 20 x 4.8 mm rectangular ultem wells with 
rounded corners (Figure 6-1a). At either end of the rectangle, a hole was made, 
and a glass capillary tube (1 mm outer diameter, 0.58 mm inner diameter) was 
inserted. The end of each capillary tube inside the well was flared to a diameter 
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of 2 mm. At casting, hBOECs and PCs were mixed with a solution of fibrinogen in 
HEPES-buffered saline, M199 and three growth factors: stromal-derived factor 
1α (SDF-1α), stem cell factor (SCF) and interleukin-3 (IL-3). Thrombin was then 
added, and the solution was pipetted into the wells. The 400 µl gel filled the 
bottom of the well and covered the glass capillary tubes. Final construct 
concentrations were 2.5 mg/ml fibrin, 1.25 U/ml thrombin, 62% v/v M199, 200 
ng/ml SDF-1α, 200 ng/ml SCF, 200 ng/ml IL-3, 2 million/ml hBOECs, and 0.4 
million/ml GFP-labeled PCs. After gelation for 30 minutes at 37°C, the bottom of 
each well was removed, and the constructs were covered with hBOEC medium, 
enabling nutrient transport from both sides. This was required because 
preliminary work showed cell death near the bottom of the well if medium was 
provided only on the top of the construct.  After 5 days of culture, some 
constructs were harvested, and others were detached from the edges of the well 
using dental picks. The glass capillary tubes were pushed inward slightly so that 
the constructs were only adherent to the glass. These glass tubes served to 
anchor the gel during compaction of the fibrin gel and alignment of the fibrin 
fibrils (Figure 6-1b-c). Control constructs were harvested at days 5, 8, 11, and 14 
(n=3). 
6.2.3. Application of Interstitial Flow to Aligned Constructs 
 On day 8 of culture, aligned constructs were embedded in 5% agarose 
gel, which had a permeability that was 3 orders of magnitude lower than the 
constructs. The well top and bottom were added and screwed down tightly to 
create a fully enclosed chamber. The glass capillary tubes were then connected 
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to a syringe pump (Harvard Apparatus) and flow of hBOEC medium begun. The 
presence of the agarose gel prevented fluid from exiting the tissue. Flow rates of 
0.015 µl/min (“low”) and 0.105 µl/min (“high”) were used, corresponding to 
superficial velocities of 0.33 µm/s and 2.33 µm/s, respectively. These flow rates 
were chosen because they fit within the range of shear stress conditions 
previously shown to improve lumen formation in engineered 
microvasculature.118,119,123,159 Constructs (from 3 separate castings; n=3), 
including controls that were not embedded in agarose or exposed to flow, were 
harvested at days 11 (3 days of flow) and 14 (6 days of flow). 
 Approximately 24 hours prior to the cessation of flow, gold nanoparticles 
(GNP; 15 nm diameter; Nanoprobes) were introduced to the inlet flow to evaluate 
the fluid path through the tissue. A 30 gauge needle was used to inject a 
concentrated GNP solution into the silastic tubing just proximal to the inlet glass 
capillary tube. The injection site was covered with sterile vacuum grease to 
prevent leakage. 
6.2.4. Hydraulic Conductivity Measurement 
 Day 8 constructs (n=3) were embedded in 5% agarose gel, sealed within 
the chamber, and connected to a flow circuit as described above, except that an 
in line pressure transducer (Harvard Apparatus) was placed immediately 
proximal to the construct. Flow was begun and pressure readings were taken 
every second until steady state was achieved. Steady state pressure and flow 
rate were compared for 3 flow rates on 3 separate constructs, and the hydraulic 
conductivity of each construct was calculated from Darcy’s Law  
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        , (1) 
where   is velocity,    is hydraulic conductivity, and   is pressure. The hydraulic 
conductivity,   , which depends both on tissue properties and fluid viscosity, is 
related to the hydraulic permeability,   , which is a property of the tissue only 
(including cellular components), by the equation 
       , (2) 
where   is the fluid viscosity. 
6.2.5. Viscosity Measurement 
The viscosity of hBOEC medium at 37°C was measured using a cone and 
plate viscometer according to the manufacturer’s instructions. Briefly, hBOEC 
medium was maintained at 37C via a circulating water bath, and the viscosity 
was measured at three shear rates. Four separate samples of hBOEC medium 
were tested. 
6.2.6. Estimation of Shear Stress 
 The shear stress experienced by the ECs was estimated using a formula 
derived by Wang and Tarbell:179 
    
  
    
, (3) 
where   is shear stress,   is fluid viscosity,   is volumetric flow rate,   is 
construct cross-sectional area,    is the effective hydraulic permeability of the 
construct, and   is a factor that depends on the volume fraction of the cells. 
When the volume fraction of cells is negligible,   is essentially 1; however, after 
compaction the cell volume fraction in the aligned constructs is relatively high, so 
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in this case the presence of cells could not be ignored. Therefore, the volume 
fraction of cells was estimated using the initial cell concentration, the reduction in 
construct volume following compaction, and assuming the cells took up the same 
volume as spheres of 10 µm diameter. The parameter   was then estimated 
based on the equation specified by Wang and Tarbell:179 
   
 
 
                         
                                 
, (4) 
Where   is the volume fraction of cells. 
6.2.7. Histology/Image Analysis 
 At the day of harvest, constructs were fixed in 4% paraformaldehyde and 
frozen in OCT tissue embedding medium. Longitudinal sections (4 µm thick) 
were taken, as well as cross-sections (9 µm thick). Cross-sections were taken 
from three construct regions (inlet, middle, and outlet; Figure 6-2b) to assess 
variations in hBOEC microvessel properties along the length of the constructs, 
which could be caused by flow-induced morphogen gradients. Care was taken to 
ensure that sections from the inlet and outlet regions were taken from compacted 
regions rather than the uncompacted regions immediately adjacent to the glass 
capillary tubes. 
 Cross-sections were immunostained with an antibody for CD31 (Dako) 
and imaged at 20x using confocal microscopy (Zeiss). A custom Matlab code 
(See Chapter 3) detected lumens, defined as dark areas completely surrounded 
by CD31 positive staining. The program automatically thresholded each image, 
and allowed for user input to correct any obvious errors. For example, some 
lumens were surrounded by CD31 staining that was in part dimmer than the rest, 
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so that the thresholded image contained most of the ECs surrounding the lumen, 
but not all of it. This was corrected by drawing a line on the thresholded image to 
connect the CD31 staining. The program then after processing produced a final 
lumen image, from which a user could delete lumens if necessary. For example, 
when EC structures were in close proximity, the program occasionally recognized 
the space between structures as lumens. The program then used the updated 
lumen image and output various parameters of interest, including microvessel 
density (number of lumens per square millimeter), average lumen area and 
structure density (number of CD31+ structures per square millimeter). The 
analysis code also detected cell density based on Hoechst 33342 staining and 
determined the level of recruitment of the GFP-labeled pericytes. A PC was 
considered recruited if any part of it was co-localized with or immediately 
adjacent to a microvessel. The results of 6 images were averaged for each 
sample. 
Cross-sections were also stained using antibodies for collagen IV, laminin, 
and ephrinB2 using standard immunofluorescence protocols. EphrinB2 staining 
and imaging was completed by Jessica Dries-Devlin, a post-doctoral fellow. 
Sections were imaged on an inverted Zeiss confocal microscope, and 3 images 
were taken per sample using a 20x objective. Images were analyzed using a 
custom Matlab script in which the total intensity of fluorescent staining 
corresponded to a given level of ECM deposition (collagen IV and laminin) or 
protein expression (ephrinB2). Basement membrane staining data were 
normalized to the average non-lumen area of each sample, as differences were 
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seen in total lumen area between conditions. Because both PCs and BOECs 
expressed ephrinB2, the co-localization of ephrinB2 staining and the GFP-
labeling of PCs was used to separate expression levels for each cell type. The 
BOEC ephrinB2 expression was normalized to the fraction of sections stained 
positively for CD31. Serial sections were used to obtain the CD31 fraction values; 
the average CD31 fraction value for each construct was used for normalization. 
Longitudinal sections of aligned constructs were stained with the CD31 
antibody (Dako) and images were taken using a 20x objective on an inverted 
Zeiss confocal microscope. The average angle and length of each microvessel 
was quantified using a custom Matlab code. An anisotropy index for each image 
(n = 6 per sample) was defined as the ratio of the average x-component of length 
to the average y-component of length, and was used as a measure of 
microvessel alignment. 
Additional longitudinal sections were stained with HQ Silver (Nanoprobes), 
which deposited silver particles on the GNP, enlarging them so that they were 
visible under transmitted light with high magnification. Although only the samples 
exposed to interstitial flow contained GNP, control samples were also stained as 
a negative control. 
6.2.8. Endothelial Barrier Function Assessment 
 Endothelial barrier function was assessed using GNP in control constructs 
at days 8 and 11, as well as low flow constructs at day 11. Constructs (n=3) were 
embedded in agarose, and a GNP solution pumped into the constructs at a flow 
rate of 1 µl/min (22 µm/s) for 30 minutes. Flow of GNP was required due to the 
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presence of a cell layer on the surface of day 11 control constructs which 
prevented diffusion of GNP into the constructs from a bath. Although this was not 
ideal due to the potential effects of acute shear stress, all constructs experienced 
a large step increase in shear stress, and flow was stopped for 30 minutes in low 
flow constructs prior to the flow of GNP. Constructs were then fixed, frozen, 
sectioned longitudinally, and stained with HQ Silver as above. Because the 
constructs were not at steady state, only lumens at a defined distance from the 
inlet were analyzed. 
6.2.9. Fibril Orientation 
Fibrin fibril orientation was determined by polarized light imaging.87 
Samples were placed between two quarter-wave plates, and images taken 
through the plates while one plate rotated. The images were processed using a 
custom Matlab script to determine the average birefringence (a measure of fibril 
alignment) of each construct. Optical density was also measured from these 
images by averaging the pixel intensity of the region of interest. 
6.2.10. Cross-sectional Area Measurements 
The thickness of tissue constructs was measured using a linear variable 
differential transformer, in which the height of a pin correlated with the voltage 
output of a multimeter. A second multimeter was connected to a pressure 
transducer. The construct was placed on the stage and the pin lowered until it 
touched the construct (as indicated by the pressure transducer output). The 
voltage (height) of the first multimeter was recorded and compared to that of a 
baseline measurement of the voltage (height) of the stage. Three measurements 
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were averaged for each construct. The width of each construct at the locations of 
the thickness measurements was measured with a caliper. 
6.2.11. Statistics 
Data from days 11 and 14 were analyzed in Minitab using two-way 
ANOVA with Tukey post-hoc tests. Comparisons between all control conditions 
(days 5, 8, 11 and 14) were made using one-way ANOVA with Tukey post-hoc 
tests. Data from flow conditions was compared to day 8 values using one-way 
ANOVA with Dunnett post-hoc tests. In comparing data from different construct 
regions, two-way ANOVA with Tukey post-hoc tests was used for data from days 
11 and 14. Data from days 5 and 8 were analyzed separately with one-way 
ANOVA with Tukey post-hoc tests. In all cases, p values of less than 0.05 were 
considered significant. 
6.3. Results 
Figures 2 and 3 detail the effects of compaction and interstitial flow on 
microvessel characteristics. Representative images of longitudinal and cross 
sections (from the center of the constructs) stained for CD31 are shown in Figure 
6-2c-j and Figure 6-3a-h, respectively. 
6.3.1. Cell-induced gel compaction results in aligned fibrils and aligned 
microvessels and increases lumen density. 
 Uncompacted constructs demonstrated weak fiber alignment as observed 
via alignment mapping, whereas strong fiber alignment in the longitudinal 
direction was observed in compacted constructs (Figure 6-2a-b, k). Longitudinal 
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sections (Figure 6-2c-e, h, l) showed that the BOEC microvessels were also 
highly aligned longitudinally in compacted constructs. 
Cross-sections (Figure 6-3a-c, f) revealed a decrease in lumen size with 
compaction. Assuming circular lumens, the mean lumen diameter was 14 µm for 
uncompacted constructs and 7 µm for compacted constructs. 
The lumen density of day 8 constructs (after 3 days of compaction) was 
equivalent to that of day 5 constructs (prior to gel compaction; Figure 6-3j), 
despite the fact that the density of CD31+ structures was increased (data not 
shown). After further culture, at days 11 and 14, the lumen density of control 
constructs was increased over both day 5 and day 8 controls. Using the 
measured construct cross sectional areas and assuming all of the lumens 
present in the day 5 constructs would be present in the day 8 constructs, the 
lumen density of compacted constructs was predicted to be 1285 lumens/mm2. 
6.3.2. Low interstitial flow increases microvessel lumen density while maintaining 
other microvessel properties. 
Lumen density, as measured in cross sections from the center of 
constructs stained for CD31, increased with low interstitial flow over control at 
both days 11 and 14 (Figure 6-3j). This increase was not seen with high 
interstitial flow. Lumen density remained constant within conditions between days 
11 and 14, and lumen area was the same between compacted constructs (Figure 
6-3k). 
 Some differences in cell number between flow conditions were observed, 
although no main effects of day or flow existed (Figure 6-3l). Pericyte density was 
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substantially reduced in both flow conditions (Figure 6-3m), but the fraction of the 
section stained positively for CD31 (indicative of EC density) did not vary 
between the conditions yielding compacted constructs, which includes all of the 
day 8, 11 and 14 conditions. Pericyte recruitment remained constant at 30-35% 
among all conditions (Figure 6-3n). 
 Both fibril and microvessel alignment remained constant among all 
conditions yielding compacted constructs, regardless of flow condition or time 
point (Error! Reference source not found.k-l). Birefringence values were near 
5, and AI values were near 5, both indicating high levels of alignment. Among 
constructs exposed to low flow for 3 days (day 11), lumens extending greater 
than 200 µm in the plane of the section were frequently observed. 
6.3.3. High levels of basement membrane were produced by the cells. 
 Figure 6-4a-h show representative images of laminin staining of cross-
sections from construct centers. The total fluorescent intensity per non-lumen 
area was quantified from images of both laminin and collagen IV staining (Figure 
6-4i-j). For both basement membrane proteins, staining intensity was decreased 
with interstitial flow (for both flow rates) in comparison to time-matched controls. 
However, visual inspection of the images suggests that the higher basement 
membrane levels in the controls are due to increased levels of laminin and 
collagen IV in the interstitium, rather than within the perivascular region. 
6.3.4. Microvessel properties varied along the length of the construct. 
 Variations in some network properties were observed in cross sections 
taken from the inlet, middle and outlet regions of the constructs. At day 11, the 
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lumen density was substantially higher in the middle region than in either the inlet 
or outlet region for all conditions (Figure 6-5a), but the average lumen area did 
not depend on position (Figure 6-5b). At day 14, both lumen density and lumen 
area were increased in the middle region (data not shown). Despite the variation 
in lumen density across tissue regions, low interstitial flow increased lumen 
density within each region. In addition, when data from all regions were 
combined for flow conditions and their time-matched controls, an increase in 
lumen density was still observed with low interstitial flow. Interestingly, at days 5 
and 8, no differences in lumen density (Figure 6-5c) or lumen area (data not 
shown) were observed between regions. PC recruitment, matrix alignment and 
tissue optical density did not depend on position at any time for all conditions. 
6.3.5. EphrinB2 expression increases over time in the absence of flow and is 
reduced in the presence of flow. 
 Images of ephrinB2 expression are shown in Figure 6-6a-b and the 
ephrinB2 expression of BOECs (obtained by normalizing BOEC ephrinB2 
intensity to CD31+ area fraction data shown in Figure 6-3i) is quantified in Figure 
6-6c. The data show that ephrinB2 expression in BOECs increased over time in 
control constructs, and that the application of low interstitial flow reduced BOEC 
ephrinB2 expression. 
6.3.6. Low interstitial flow increased endothelial barrier function. 
 Fluid flow through the constructs was tracked using GNP added to the 
perfusate during interstitial flow. GNP were observed throughout the interstitium 
in longitudinal sections, indicating that fluid was traveling through the constructs 
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rather than channeling between the constructs and the agarose gel. However, 
GNP were rarely observed within lumens. This observation prompted an 
experiment to test the endothelial barrier function after flow exposure. Constructs 
exposed to low flow for 3 days as well as controls at days 8 and 11 were 
exposed to a solution containing GNP, and the number of GNP present within 
lumens at the same distance from the construct inlet (the input location of the 
GNP solution) was counted. Lumens within both control constructs contained 
substantially more GNP than those within constructs exposed to low flow, which 
rarely contained GNP (Figure 6-7). 
6.3.7. Cells experienced low levels of shear stress during interstitial flow. 
The viscosity of the BOEC medium was measured with a cone and plate 
viscometer at 37°C, yielding an average viscosity of 0.89 cP. Construct hydraulic 
conductivity was measured using a syringe pump to control flow rate and an in-
line pressure transducer to measure pressure just proximal to the construct. 
Average hydraulic conductivity was then calculated from Darcy’s Law (Eqn. 1) to 
be 1.83 x 10-5 cm2*mmHg/s. This hydraulic conductivity was converted to a 
hydraulic permeability via Eqn. 2 for use in Eqn. 3. The final volume of each 
construct was calculated by measuring the thickness and width of each construct 
after fixation, and assuming the construct length was 1.5 cm. The average 
thickness of compacted constructs was 627 µm, and the average width was 1.26 
mm, yielding a cross-sectional area of 0.0075 cm2, and a volume of 0.0112 cm3. 
These values corresponded to a cross-sectional area after compaction that was 
10% of the original. 
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Due to the relatively high concentration of cells in the compacted 
constructs, the parameter B of Eqn. 3 was estimated using Eqn. 4. To obtain the 
volume fraction of cells, each cell was assumed to take up the volume of a 
sphere 10 µm in diameter. Using the initial cell concentration, 2.4 million/ml, the 
initial construct volume (400 µl), and the final measured volume of the construct, 
0.0112 cm3, the cell volume fraction was calculated to be 0.045, and Eqn. 3 
yielded a value of 1.274 for the parameter B. 
The above parameter values were then substituted into Eqn. 3 along with 
the volumetric flow rates to estimate shear stresses on the cells. For low flow 
(0.015 µl/min), shear stress was 0.033 (+/- 0.016) dyne/cm2, and for high flow 
(0.105 µl/min), shear stress was 0.23 (+/- 0.12) dyne/cm2. 
The COMSOL model of flow around a cylinder embedded in porous 
medium indicated that the shear stress was 0.012(+/-5.7 x 10-4) dyne/cm2 for low 
flow and 0.056 (+/- 4.1 x 10-3) dyne/cm2 for high flow. These values are 3-fold 
lower than those estimated above; the true shear stress experienced by the cells 
is likely between the estimated values. 
6.4. Discussion 
 A major finding of this work is that cell-induced compaction can be used to 
align microvessels in a vasculogenic model (previous work had shown this to be 
possible in an angiogenic model63). Strong microvessel alignment not only 
mimics native microvasculature (e.g. myocardium65), but also provides natural 
inlet and outlet sides of the network for flow. In addition to producing aligned 
microvessels, construct compaction provided a number of other improvements to 
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the BOEC microvessels. Compaction caused a reduction in average lumen size, 
placing the diameter within the typical coronary capillary range of 5-8 µm.145 In 
addition, both the CD31+ structure density and the lumen density increased with 
compaction. Although the CD31+ structure density increased quickly, present at 
all time points after compaction, lumen density increase was delayed, only 
present at days 11 and 14. These results suggest that initially compaction 
caused some lumens to collapse, but once compaction had subsided, the lumens 
were re-established. IT is clear, however, that only approximately a third of the 
lumens were re-established with compaction alone, based on the predicted 
lumen density. Previous studies suggested that flow can induce alignment;123 
however, increased alignment with flow was not observed here. This may merely 
indicate that compaction and associated fibrin fibril alignment provided a much 
stronger alignment effect via contact guidance, and that the additional alignment 
produced by flow was either present but negligible or was not present due to the 
fact that the fibrils and cells were highly aligned prior to the onset of flow. The 
fact that the microvessel anisotropy index was above 1 for isotropic samples is 
likely due to the fact that the anisotropy index was defined relative to the average 
angle of microvessels in that image. This was necessary because it was 
impossible to image all of the sections with the longitunal axis of the construct at 
the same angle. Because the microvessel density was low in the isotropic 
samples, one long microvessel could skew the average angle and therefore the 
anisotropy index as well. 
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 A second major finding of this work is that interstitial flow can modulate the 
properties of existing microvessels. Previous work demonstrated the ability of 
interstitial flow to increase microvessel formation in engineered microvessels 
when the onset of flow was at the time of casting rather than after initial 
microvessel formation.118,119,123,159 The results presented here indicate that at the 
flow rate used can substantially affect the results. Low flow (0.015 µl/min; 0.33 
µm/s) produced an increase in lumen density over statically cultured controls, 
whereas high flow (0.105 µl/min; 2.33 µm/s) did not. However, similar to previous 
reports,123 the effects of shear stress and flow-induced morphogen gradients in 
producing the improvements could not be distinguished. 
The lumen density observed in these constructs (both control and flow 
conditions) is substantially higher than previously reported for in vitro engineered 
tissues. At day 14, constructs exposed to low flow achieved a lumen density of 
nearly 650 lumens/mm2 in the middle region, more than 6 times higher than any 
previous report,149,152,155,156 and equivalent or greater than most reports of 
engineered microvessels after implantation.53,124,157 It is still shy of the 2000 
lumens/mm2 of native adult human myocardium,9 but is greater than that of adult 
human skeletal muscle (200-300 lumens/mm2)147,148 In addition, lumen density 
has been reported to increase dramatically upon implantation (14-fold or 
more149,156), suggesting that these constructs would likely reach the goal of 2000 
lumens/mm2 soon after implantation, presumably with similar strong alignment. 
 An unexpected result was that lumen density was greater in the middle 
region of constructs in comparison to the inlet and outlet regions. This was true 
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for both control and flow conditions at days 11 and 14, indicating that it is not an 
effect of flow. Additionally, this effect is not present in controls at days 5 or 8, nor 
is there any difference in birefringence (indicating differential levels of matrix 
alignment) or optical density (indicating differential levels of matrix density) 
between construct regions at any time point. However, the means for most inlet 
and outlet regions at day 11 fall within the 100-200 lumens/mm2 range, as do 
means for all regions at days 5 and 8. This suggests that the increases in lumen 
density observed both with additional days of compaction in static culture (after 
day 8) and with low flow occurred substantially in the middle region of the 
construct. 
Lumens greater than 200 µm in length were frequently observed in 
longitudinal sections of constructs exposed to low flow for 3 days (day 11). 
However, due to the potential tortuosity of the lumens and the possibility that 
sections were not taken exactly parallel to the alignment direction, it is unclear 
exactly how far the lumens extended. Attempts to image constructs under 
multiphoton confocal microscopy yielded data only to a depth of approximately 
200 µm, likely due to the construct density and opacity, providing no further 
information about lumen length. 
 The increase in ephrinB2 expression by BOECs over time in control 
constructs suggests that they were maturing towards an arterial phenotype. 
Additionally, the fact that shear stress induced a reduction in ephrinB2 
expression in BOECs indicates that the BOECs were more similar to a mature 
EC than and EPC when flow began. 
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Fluid tracking via GNP indicated that fluid was traveling through the 
construct interstitium, as expected. The fact that few GNP were found within 
lumens suggests that fluid was not entering and flowing through lumens, but 
rather was limited to the interstitium. This suggests that in these constructs the 
lumen ends are not open to flow, so other mechanisms of achieving microvessel 
perfusion will need to be explored. Additionally, this result prevented the 
comparison of the predictions of the mathematical model developed in Chapter 5 
to experimental results. Interestingly, however, an increase in EC barrier function 
was observed after 3 days of low flow exposure. This result extends previous 
reports of the increased barrier function of EC monolayers exposed to laminar 
shear flow163,165,166 to include ECs cultured as microvessels in 3 dimensions. The 
shear stress in this study was applied ablumenally, evidently, and at a level not 
previously studied in monolayers (approximately 100-fold lower than previous 
reports), suggesting that either the effect of chronic shear stress on EC barrier 
function is similar over a wide range of shear stresses and application methods, 
or that tight junction formation occurs differently in microvessels versus 
monolayers. 
The data presented here demonstrate the success of using PCs as a 
support cell for BOECs in a remodeled fibrin gel. PCs were recruited to the 
BOEC microvessels, and abundant basement membrane was formed. As noted 
earlier, mural cell recruitment and basement membrane formation are the 
hallmarks of microvessel stability in vivo, and thus the PC recruitment and 
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basement membrane formation observed here likely contributed to the stability of 
the microvessels over a two week period, even in statically cultured constructs. 
The exposure of constructs to interstitial flow at either flow rate reduced 
the number of PCs. Because the PC density was high at day 8, it is clear that this 
difference is the result of PC loss. The fact that the fraction of recruited PCs 
remained constant across conditions suggests that PCs were lost equally from 
recruited and unrecruited positions. The reason for this loss is not clear; 
however, it may be related to the relatively low levels of culture medium received 
by the constructs during flow exposure (greater than 100-fold lower than that of 
control constructs for low flow). The fact that the ECs were not negatively 
affected under such conditions is remarkable. Regardless of the mechanism, it is 
not clear that a high density of PCs is required for microvessel stability in this 
system due to the deposition of basement membrane. In fact, qualitative 
assessment of laminin and collagen IV staining suggests that flow conditions had 
lower levels of staining in the interstitium, which may be related to the presence 
of fewer PCs (both PCs and ECs produce basement membrane proteins52). 
 The system used in these studies is highly relevant for tissue engineering. 
The human BOECs are isolated from peripheral blood, and thereby represent a 
potentially autologous source of ECs. Although the human brain PCs used here 
are not an autologous source, PCs can be isolated from dermis, which could be 
autologous.127 Fibrin, due to its role in in vivo wound healing, is degraded by cells 
and stimulates them to produce ECM.42 Therefore, a fully mature tissue 
engineered formed from a fibrin gel could in fact be completely cell-produced.180 
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If autologous cells are used, extremely low immune reactivity of the engineered 
tissue is expected. If the small amount of fibrin remaining after culture proved to 
be immunogenic, autologous fibrinogen (isolated from peripheral blood) could be 
used to prepare the tissue. Finally, these constructs have the potential to achieve 
physiological strength by using fibrin gel that can be remodeled into a tissue in 
vitro. The results presented herein make strides towards the production of 
vascularized tissue comprising aligned microvessels of a size and strength 
relevant to humans. 
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6.5. Figures 
 
Figure 6-1.  
 (A-D) Schematics of interstitial flow chamber design. (A) The chamber bottom 
snapped into the well for casting, at which point the well measured 20 mm (l) x 
4.8 mm (w) x 4 mm (h). Flared glass capillary tubes (1 mm outer diameter, 0.58 
mm inner diameter) were inserted into the small holes in the sides of the well. 
The chamber bottom and top were used to enclose the gel during interstitial flow. 
The pieces were tightened together using a screw at each corner. (B) Top view 
of a construct at casting. (C) Side view of a construct at casting. The gel (pink) 
filled the entire well and covered the glass capillary tubes. (D) Top view of a 
construct after compaction, prior to embedding with agarose gel. The construct 
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was only adherent to the glass capillary tubes. (E) A compacted construct after 8 
days of culture. Scalebar = 5 mm. 
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Figure 6-2.  
 (A-B) Representative alignment maps of uncompacted (day 5; A) and 
compacted (day 8; B) constructs, in which the red lines indicate the local 
direction and strength of alignment. Scalebars = 1 mm. The black lines in (B) 
indicate the approximate locations of inlet, middle and outlet cross sections. (C-J) 
Representative longitudinal sections stained for CD31 (red) of control and flow 
constructs. PCs were GFP-labeled (green), and nuclei were stained with Hoechst 
33342 (blue). The axial direction is vertical. The arrows in (C-D) indicate some of 
the microvessels with lumens. Scalebars = 100 µm. (G) Birefringence (a 
measure of fibril alignment), quantified from polarimetry, increased with 
compaction, but did not vary among compacted conditions, suggesting that flow 
did not have an effect on fibril alignment. (F) Microvessel anisotropy index, a 
measure of microvessel alignment obtained from images, also increased with 
compaction but did not vary among compacted conditions. $p < 0.05 in 
comparison to day 5 control. +p < 0.05 in comparison to day 8 control. 
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Figure 6-3.  
(A-H) Representative cross-sections stained for CD31 (red) from the middle 
region of constructs from all days and flow conditions studied. PCs were GFP-
labeled (green), and nuclei were stained with Hoechst 33342 (blue). Scalebars = 
50 µm. (I-N) Quantification of images. (I) The fraction of the section stained 
positively for CD31 remained constant across all compacted conditions. (J) The 
number of lumens per square millimeter was increased by low flow relative to 
time-matched controls but not by high flow. (K) The mean cross sectional area of 
lumens decreased with compaction but was independent of day or flow condition. 
(L) The cell number per square millimeter, based on Hoechst 33342 staining, 
was somewhat variable between conditions, but no trends emerged. (M) The 
number of PCs per square millimeter, was reduced with exposure to either flow 
rate. (N) The fraction of pericytes that were recruited to CD31+ microvessels was 
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the same across all conditions. *p < 0.05. $p < 0.05 in comparison to day 5 
control. +p < 0.05 in comparison to day 8 control. 
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Figure 6-4.  
 (A-H) Representative cross sections from the middle region of constructs in all 
day and flow conditions studied, stained for laminin (red). PCs were GFP-labeled 
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(green), and nuclei were stained with Hoechst 33342 (blue). Scalebars = 50 µm. 
Collagen IV staining was similar and therefore is not shown. (I-J) Quantification 
of the total staining intensity per non-lumen area for laminin (I) and collagen IV 
(J). The increased staining in control constructs appeared to be due to additional 
protein in the interstitial space rather than the perivascular region. *p < 0.05 for 
main effect. 
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Figure 6-5.  
Quantification of CD31 stained cross-sections from various tissue regions. (A) At 
day 11, lumen density was increased in the middle region over the inlet and 
outlet regions. However, even when all of the data was combined, the increase in 
lumen density with low flow remained. (B) Average lumen area at day 11 did not 
vary by tissue region, but was larger in constructs exposed to low flow. (C) No 
differences in PC recruitment occurred between regions or flow conditions at day 
11. (D) At days 5 and 8, no differences in lumen density occurred across tissue 
regions. *p < 0.05 for main effects. $p < 0.05 for main effects between control 
and low flow. +p < 0.05 for main effects between low and high flow. 
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Figure 6-6.  
 (A-B) Representative images of sections of control (A) and low flow (B) 
constructs from day 14 stained for ephrinB2 (red). PCs are green and nuclei are 
blue. Scalebars = 50 µm. (C) Quantification of BOEC ephrin staining, normalized 
to values of CD31 fraction obtained from staining of nearby sections (data shown 
in Figure 6-3i). 
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Figure 6-7.  
Endothelial barrier function assay. (A-C) Representative images of lumens within 
control constructs at days 8 (A) and 11 (B) as well as constructs exposed to low 
flow for 3 days (from day 8 to day 11; C). Scalebar = 10 µm. (D) Quantification of 
the GNP present with the lumens; low levels of GNP within lumens of constructs 
exposed to low flow indicated strong EC barrier function. 
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Chapter 7. Conclusions and Future Directions 
7.1. Major Contributions 
The work presented in this dissertation has contributed substantially to the 
field of engineered microvasculature. Five manuscripts have been published or 
are in preparation, in addition to numerous oral and poster presentations at 
international and local meetings. The major conclusion and contributions to the 
literature are summarized here. 
7.1.1. Endothelial Capillary Structures Can Be Aligned via Cell-Induced 
Compaction 
One of the largest contributions is that cell-induced compaction of fibrin 
gel can be utilized to align microvascular structures of multiple types. This topic 
was addressed in three chapters. Data from magnetically-aligned fibrin in 
Chapter 2 suggested that fibril alignment alone was sufficient to align sprouts 
from EC spheroids, and that those sprouts could also be aligned by cell-induced 
compaction. This basic research provided the foundation for inducing alignment 
of both HUVEC microvessels (Chapter 4) and BOEC microvessels (Chapter 6). 
Interestingly, it was determined that serum was a critical to the compaction 
process and that both cell types (ECs and PCs) were required for compaction. 
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7.1.2. Development of Semi-Automated Image Analysis Programs to Quantify 
Microvascular Network Properties 
Prior to this work, the quantification of microvessel density and other 
properties of the microvasculature in our laboratory was limited to manual 
counting, and many reports in the literature used manual quantification 
techniques. Chapter 3 describes the development of Matlab scripts to analyze 
images of tissue sections and whole mount preparations stained for CD31. The 
programs were mostly automated, but a small amount of user input modifying the 
lumens detected by the program to more closely match the original image yielded 
highly accurate results. The programs output a variety of microvessel properties 
including lumen density, average lumen area, total microvessel length and 
microvessel alignment. Additionally, if nuclei and support cells were also stained, 
the programs provided information about cell density and mural cell recruitment. 
Automated quantification of mural cell recruitment and microvessel alignment are 
entirely novel in the field. These programs not only save time in quantifying 
images, but also reduce the subjectivity of the results, which is especially 
important in analysis of engineered microvasculature in which not all EC 
structures contain well-formed lumens and EC debris is often present. 
7.1.3. Highly Interconnected Microvascular Networks in Fibrin Gel can be 
Formed under Defined Conditions and Aligned via Cell-Induced Gel Compaction 
Cell culture in defined medium (i.e. medium containing no serum) is 
advantageous because the unknowns of the culture conditions are limited, 
leading to more reproducible results. Therefore, with the aid of collaborators at 
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the University of Missouri, the ability of HUVECs to form fully interconnected 
microvascular networks in fibrin gel was assessed. The results of these studies, 
described in Chapter 4, demonstrated that highly interconnected networks were 
only formed in the presence of PCs and defined medium (ie. medium containing 
no serum); the absence of PCs or presence of serum disrupted the network 
formation. These results suggest that the PCs provide paracrine factors that 
direct the HUVECs and that the myriad cytokines present in serum mask these 
effects. Although cell-induced gel compaction was detrimental to network 
formation, the mechanism could be harnessed to align networks that had already 
been formed either in defined medium or serum-containing medium, suggesting 
that the networks are quite stable after formation. 
7.1.4. Development of an Idealized Mathematical Model of Fluid Flow through 
Engineered Microvessels 
Chapter 5 describes the development of a two-dimensional finite difference 
model of flow through a tissue containing engineered microvessels. The tissue 
matrix was modeled as a porous medium, and the microvessels were modeled 
as straight tubes. The inlets and outlets of the microvessels were treated as point 
sinks and sources, respectively, of fluid mass and momentum in the governing 
equations. The model assumed that the microvessels were open to flow at their 
ends, which turned out not to be accurate at this time in the tissues studied in 
Chapter 6, but other researchers have reported open lumens at the ends of 
microvessels. The model demonstrates a methodology for determining the 
percentage of perfused microvessels, a parameter that may be difficult to 
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determine experimentally. In addition, the model would provide estimates of flow 
rates through the microvessels and could be coupled with solute diffusion 
equations to estimate the delivery of nutrients and oxygen throughout the tissue. 
7.1.5. Compaction of Fibrin Gel Containing Microvasculature Improves Lumen 
Density 
Cell-induced compaction of fibrin gel was chosen not only for its ability 
align microvessels, but also because it increases tissue density. In and of itself, 
increase tissue density is critically important for achieving the necessary 
mechanical properties in engineered tissues, but we also hypothesized that the 
lumen density would be improved after compaction because the same number of 
microvessels would be condensed into a smaller volume. This hypothesis turned 
out to be correct (as evidenced by the data from Chapter 6), although 
interestingly, the compaction initially led to lumen collapse. At early time points, 
the lumen density remained constant despite a reduction in tissue volume and an 
increase in CD31+ staining density. However, by later time points, the lumens 
had reformed and the lumen density had improved 3.2-fold over uncompacted 
controls. 
7.1.6. Interstitial Flow at Specific Flow Rates Applied to an Existing Microvascular 
Network Improves Lumen Density 
Despite the improvement in lumen density observed with compaction 
alone, lumen density was still 5-fold lower than that of adult human myocardium. 
Interstitial flow was examined as a means to further improve lumen density. The 
174 
 
results described in Chapter 6 indicated that interstitial flow improved lumen 
density, achieving densities 65% higher than statically cultured controls after 6 
days of flow. This result was especially interesting because all previous reports of 
the effects of interstitial flow on microvessel formation had used flow throughout 
the culture period, whereas here flow was begun after microvessel formation. 
Therefore, these results suggest that interstitial flow can modulate an existing 
network. Furthermore, a second (higher) flow rate was used in the same system, 
and did not improve lumen density over controls. This suggests that ECs are 
exquisitely sensitive to the rate of interstitial flow. 
7.2. Future Directions 
Despite the progress made toward the goal of vascularized engineered 
myocardium, much work remains. The perfusion system was designed to enable 
gel compaction and perfuse both the interstitium and the microvessels, and while 
it performed well at the first two, it failed to perfuse microvessels. In addition, 
although the lumen density under interstitial flow was greatly improved over 
controls, the final lumen density was still 3-fold lower than that of native human 
myocardium. Finally, vascularized engineered myocardium requires both 
microvasculature and cardiomyocytes, so additional work will be necessary to 
combine the two. 
7.2.1. Hybrid Approaches to Perfuse Engineered Microvasculature 
The major limiting factor to the perfusion of microvessels in the system 
described here is that the fluid within the lumens was separated from the fluid 
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pumped through the system. Although it is exciting that the engineered 
microvessels exhibited strong barrier function, this prevented fluid from flowing 
through them. Most likely a hybrid approach in which other methods of 
engineering microvasculature are combined with EC self-assembly will be 
necessary to open the lumens to perfusion. For example, one could seed ECs on 
the surfaces of the gel that are present inside the glass capillary tubes. Given the 
right conditions, these ECs could sprout into the gel and anastomose with the 
self-assembling EC network. These sprouts would then form a direct connection 
between the chamber’s inlet flow and the lumenal space of the microvascular 
network. Literature reports suggest sprouting into a gel can occur from a 
monolayer on the surface of the gel in response to VEGF or interstitial 
flow.61,118,119 Another possibility would be to create channels lined with ECs that 
extend partway into the gel from both the inlet and outlet sides. Sprouting could 
occur from these channels,59 or self-assembled EC structures could intersect 
these channels. This would create a situation similar to in vivo capillary beds, 
which are filled and drained by larger vessels. In either case, once the lumenal 
space of the engineered microvasculature is directly connected with the inlet and 
outlet fluid, perfusion of the vessels should be straightforward. 
7.2.2. Cyclic or Static Strain to Further Improve Lumen Density 
In order to reach 2000 lumens/mm2, the lumen density of adult human 
myocardium, additional methods instead of or in addition to interstitial flow will be 
required. One possible method is cyclic or static strain. A number of animal 
studies have suggested that capillary density is increased in skeletal muscle 
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when it is permanently stretched (i.e. static strain).181–183 Although it is unclear 
whether these results will translate to an in vitro model of microvasculature under 
static strain, it is worth investigating. In addition, static stretch could easily be 
combined with interstitial flow in this system for possibly additive or even 
synergistic effects. Limited data exist on cyclic stretch of engineered 
microvasculature, but one group found that it disrupted EC cord formation on top 
of Matrigel.184 However, many reports suggest that the angiogenic capability of 
ECs is improved when they are stretched in monolayer.185–187 In addition, cyclic 
stretching of EC monolayers has been shown to increase production of various 
pro-angiogenic cytokines including Ang-2, PDGF-BB, VEGF along with several 
associated receptors.185,187–189 These results suggest that ECs exposed to cyclic 
strain prior to entrapment in fibrin may form more extensive networks and/or 
recruit PCs more strongly (recruitment is regulated by PDGF-BB). Cyclic pre-
stretch in combination with static stretch after network formation could be a 
potent method for further increasing lumen density. 
7.2.3. Tri-culture of ECs, PCs, and Cardiomyocytes 
Although a goal has been to engineer microvascular networks with lumen 
densities similar to that of native myocardium, the real test of whether or not the 
microvessels are dense enough will be functional: they are dense enough when 
they can support the density of cardiomyocytes within the tissue. Indeed, this is 
the ultimate goal, to combine the engineered microvasculature with the 
engineered myocardium to create beating tissues that are sustained via 
perfusion of the microvascular network. This will require the tri-culture of ECs, 
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PCs, and cardiomyocytes, which may prove quite challenging. Although the 
achievement of this goal may still be far in the future, the work presented in this 
dissertation has made critical steps toward revolutionizing the treatment of 
myocardial infarction. 
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Appendix A. Protocols 
A.1 BOEC Culture 
1. Collagen Coating 
a. Using the concentration listed on the collagen bottle (which varies 
by lot), calculate the volume of collagen solution needed to obtain 
25 mg collagen. It should be around 6-7 ml. 
b. Subtract this volume from 500 and measure out this volume of 
ddH2O using a 500 ml graduated cylinder. 
c. Add 0.575 ml glacial acetic acid to the ddH2O. 
d. Sterile filter the water/acid solution using a 0.22 µm filter. 
e. Add 25 mg collagen and mix. Final concentration is 0.05 mg/ml. 
 
2. Coating Flasks 
a. Add 5 ml (T75) or 10 ml (T175) of 0.05 mg/ml collagen to each flask 
and make sure the solution covers the entire bottom of the flask. 
b. Incubate at 37°C for at least 10 min (can be much longer, even up 
to several days). 
c. Aspirate collagen and rinse flasks with 5 ml HBSS. Aspirate HBSS. 
d. At this point the flasks can be used immediately or stored at 4°C for 
up to 2 weeks. 
 
3. Thawing Cells 
a. Warm 10 ml (T75) or 23 ml (T175) of BOEC medium to 37°C. 
b. Take vial of hBOECs from liquid nitrogen. From here, move as 
quickly as possible. 
c. Warm the cells for 2 min. at in the 37°C waterbath. 
d. In the hood, open the vial and add warm BOEC medium to the vial. 
Pour contents of vial into the conical of medium. 
e. Repeat step d until the entire contents of the vial are transferred to 
the conical. At this point, one no longer needs to move as quickly 
as possible. The cells have been warmed to 37°C, and the DMSO 
in the freezing solution has been diluted. 
f. Transfer contents of the conical to a collagen-coated flask. 
g. Change the medium the next day to remove residual DMSO. 
 
4. Splitting Cells 
a. Thaw 2.5-3 ml (T75) or 5 ml (T175) 0.5% trypsin per flask. 
b. Rinse flasks twice with 5 ml HBSS. 
c. Add trypsin and incubate at 37°C for 3 minutes. 
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d. Quickly view flasks to make sure the cells have lifted. 
e. Add 0.5 ml (T75) or 1 ml (T175) FBS to quench the trypsin. 
f. Pipette cells into a 50 ml conical tube. Rinse each flask twice with 
HBSS (serial rinses are fine), pipetting the rinse solution into the 
conical. 
g. Centrifuge at 220xg for 5 minutes. 
h. Resuspend cells in BOEC medium. Aim for about 1 M/ml for easy 
counting. Expect 1-2 M (T75) or 3-4 M (T175) per flask. 
i. Add 50 µl cell solution to a trypan blue aliquot (75 µl trypan blue + 
125 µl PBS). Add 10 µl of this solution to a hemocytometer and 
count cells. 
     
  
 
          
 
          
4 represents the average of the 4 boxes counted, 5 is the dilution of 
the cells in trypan blue, and 10,000 is the multiplier based on the 
design of the hemocytometer. 
j. Plate into collagen-coated flasks at a 1:4 split. This should be about 
0.4-0.5 M cells per T75 or 0.8-1 M cells per T175. 
 
5. Freezing Cells 
a. Split cells as usual. Resuspend at twice the desired concentration 
in BOEC medium. (eg. for 1 M aliquots, each having 1 ml of 
solution, resuspend at 2 M/ml.) Place cells on ice. 
b. Make a solution of 10% DMSO in FBS. Make 0.5 ml for each 
aliquot. The introduction of an aqueous solution to DMSO produces 
heat, so put this solution on ice and do not use until it is cold. 
c. Mix cells and DMSO/FBS at a 1:1 ratio and pipette 1 ml into each 
pre-labeled cryovial. DMSO protects cells during freezing, but is 
toxic to cells at warmer temperatures, so move as quickly as 
possible after mixing cells and DMSO. 
d. Transfer vials to a Mr. Frosty filled with isopropyl alcohol and place 
at -80°C overnight. Mr. Frosty ensures a steady drop of 1°C per 
minute, which is optimal for most cell types. 
e. Transfer vials to liquid nitrogen. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Collagen BD Biosciences 354236  4   
Glacial Acetic Acid Fisher Scientific BP2401-212  25   
HBSS Gibco 14175  25   
BOEC medium Lonza CC-3162  EBM-2: 4, 
Bullet Kit: -20, 
BOEC 
Medium: 4 
BOEC medium good 
for ~2 wk at 4C. Do 
not freeze. 
 
Trypsin Gibco 25300  -20 0.5%  
FBS Hyclone “Characterized”  4 for 
quenching 
  
DMSO Sigma D2438  25   
Isopropyl Alcohol Sigma W292907  25   
Trypan Blue Gibco 15250  25   
Equipment       
Mr. Frosty Sigma C1562     
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A.2 HUVEC Culture 
1. Gelatin Coating 
a. Mix 500 mg gelatin with 500 ml PBS. Place in 37°C water bath until 
gelatin is dissolved. 
b. Sterile filter using a 0.22 µm filter. 
c. Final concentration is 1 mg/ml. 
 
2. Coating Flasks 
a. Add 7 ml (T75) or 15 ml (T175) of 1 mg/ml gelatin to each flask and 
make sure the solution covers the entire bottom of the flask. 
b. Incubate at RT for at least 30 min (can be much longer, but do not 
leave overnight). 
c. Aspirate gelatin. Do not rinse. Use immediately. 
 
3. Thawing Cells 
a. Warm 9 ml and 20 ml supermedium to 37°C in separated tubes. 
b. Take vial of HUVECs from liquid nitrogen. From here, move as 
quickly as possible. 
c. Warm the cells for 2 min. at in the 37°C waterbath. 
d. In the hood, open the vial and add warm PC medium to the vial. 
Pour contents of vial into the conical of medium. 
e. Repeat step d until the entire contents of the vial are transferred to 
the conical. At this point, one no longer needs to move as quickly 
as possible. The cells have been warmed to 37°C, and the DMSO 
in the freezing solution has been diluted. 
f. Spin cells at 350xg for 5 minute. 
g. Resuspend in 5 ml. 
h. Spin cells again at 350xg for 5 minute. 
i. Resuspend in 15 ml. 
j. Transfer contents of the conical to a gelatin-coated T75 flask. 
k. Change medium every 2-3 days. Use 30 ml supermedium for a 
T175 flask. 
 
4. Priming Cells 
a. Typically done in the late afternoon on the day prior to casting. 
b. Warm 9 ml antibiotic M199 for a T75 (scale everything up 
proportionally for a T175). 
c. Add 36 µl RSII, 9 µl FGF, and 36 µl VEGF to the M199. 
d. Replace supermedium in the flask with the priming medium. 
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5. Splitting Cells 
a. Thaw 2 ml (T75) or 5 ml (T175) 0.5% trypsin per flask. 
b. Rinse flasks with 10 ml (T75) or 23 ml (T175) PBS. 
c. Add trypsin and incubate at 37°C for 1 minute. 
d. Quickly view flasks to make sure the cells have lifted. 
e. Add 2 ml (T75) or 5 ml (T175) FBS to quench the trypsin. 
f. Add 6 ml (T75) or 14 ml (T175) aM199 to the flask. Pipette cells 
into a conical tube. 
g. Centrifuge at 350xg for 5 minutes. 
h. Resuspend cells in PC medium. Aim for about 1 M/ml for easy 
counting. Expect 2 M (T75) or 5 M (T175) per flask. 
i. Add 50 µl cell solution to a trypan blue aliquot (75 µl trypan blue + 
125 µl PBS). Add 10 µl of this solution to a hemocytometer and 
count cells. 
     
  
 
          
 
          
4 represents the average of the 4 boxes counted, 5 is the dilution of 
the cells in trypan blue, and 10,000 is the multiplier based on the 
design of the hemocytometer. 
j. Plate into gelatin-coated flasks at a 1:6 split. 
k. Use only fully confluent cells for experiments. HUVECs may be 
confluent for several days prior to casting. Use up to passage 5. 
 
6. Freezing Cells 
a. Split cells as usual. Resuspend at twice the desired concentration 
in antibiotic M199. (eg. for 1 M aliquots, each having 1 ml of 
solution, resuspend at 2 M/ml.) Place cells on ice. 
b. Make a solution of 20% DMSO and 20% FBS in PC medium. Make 
0.5 ml for each aliquot. The introduction of an aqueous solution to 
DMSO produces heat, so put this solution on ice and do not use 
until it is cold. 
c. Mix cells and DMSO/FBS/PC medium at a 1:1 ratio and pipette 1 
ml into each pre-labeled cryovial. DMSO protects cells during 
freezing, but is toxic to cells at warmer temperatures, so move as 
quickly as possible after mixing cells and DMSO. 
d. Transfer vials to a Mr. Frosty filled with isopropyl alcohol and place 
at -80°C overnight. Mr. Frosty ensures a steady drop of 1°C per 
minute, which is optimal for most cell types. 
e. Transfer vials to liquid nitrogen. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Gelatin Sigma G2500  25   
PBS Mediatech 21-031-CM  25   
Supermedium    4 See protocol  
Trypsin Gibco 25300  -20 0.5%  
FBS Hyclone “Characterized”  4 for 
quenching 
  
DMSO Sigma D2438  25   
Isopropyl Alcohol Sigma W292907  25   
Trypan Blue Gibco 15250  25   
Antibiotic M199     See protocol  
RSII     Obtained from Davis 
lab 
 
FGF R&D Systems 233-FB/CF  -20 Stock 40 µg/ml, use at 
1:1000 dilution (40 
ng/ml) 
 
VEGF R&D Systems 293-VE/CF  -20 Stock 10 µg/ml, use at 
1:250 dilution (40 
ng/ml) 
 
Equipment       
Mr. Frosty Sigma C1562     
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A.3 nhDF Culture 
1. Thawing Cells 
a. Warm 15 ml (T75) or 30 ml (T175) of nhDF medium to 37°C. 
b. Take vial of nhDFs from liquid nitrogen. From here, move as quickly 
as possible. 
c. Warm the cells for 2 min. at in the 37°C waterbath. 
d. In the hood, open the vial and add warm nhDF medium to the vial. 
Pour contents of vial into the conical of medium. 
e. Repeat step d until the entire contents of the vial are transferred to 
the conical. At this point, one no longer needs to move as quickly 
as possible. The cells have been warmed to 37°C, and the DMSO 
in the freezing solution has been diluted. 
f. Transfer contents of the conical to a gelatin-coated flask. 
g. Change the medium the next day to remove residual DMSO. 
 
2. Splitting Cells 
a. Thaw 2.5-3 ml (T75) or 5 ml (T175) 0.5% trypsin per flask. 
b. Rinse flasks twice with 5 ml PBS. 
c. Add trypsin and incubate at 37°C for 3 minutes. 
d. Quickly view flasks to make sure the cells have lifted. 
e. Add 0.5 ml (T75) or 1 ml (T175) FBS to quench the trypsin. 
f. Pipette cells into a 50 ml conical tube. Rinse each flask twice with 
PBS (serial rinses are fine), pipetting the rinse solution into the 
conical. 
g. Centrifuge at 220xg for 5 minutes. 
h. Resuspend cells in nhDF medium. Aim for about 1 M/ml for easy 
counting. Expect 3-4 M (T75) or 7-8 M (T175) per flask. 
i. Add 50 µl cell solution to a trypan blue aliquot (75 µl trypan blue + 
125 µl PBS). Add 10 µl of this solution to a hemocytometer and 
count cells. 
     
  
 
          
 
          
4 represents the average of the 4 boxes counted, 5 is the dilution of 
the cells in trypan blue, and 10,000 is the multiplier based on the 
design of the hemocytometer. 
j. Plate 1.5 M/T175. 
 
3. Freezing Cells 
a. Split cells as usual. Resuspend at twice the desired concentration 
in nhDF medium. (eg. for 1 M aliquots, each having 1 ml of solution, 
resuspend at 2 M/ml.) Place cells on ice. 
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b. Make a solution of 10% DMSO in FBS. Make 0.5 ml for each 
aliquot. The introduction of an aqueous solution to DMSO produces 
heat, so put this solution on ice and do not use until it is cold. 
c. Mix cells and DMSO/FBS at a 1:1 ratio and pipette 1 ml into each 
pre-labeled cryovial. DMSO protects cells during freezing, but is 
toxic to cells at warmer temperatures, so move as quickly as 
possible after mixing cells and DMSO. 
d. Transfer vials to a Mr. Frosty filled with isopropyl alcohol and place 
at -80°C overnight. Mr. Frosty ensures a steady drop of 1°C per 
minute, which is optimal for most cell types. 
e. Transfer vials to liquid nitrogen. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
PBS Mediatech 21-031-CM  25   
nhDF medium    4 See protocol  
Trypsin Gibco 25300  -20 0.5%  
FBS Hyclone “Characterized”  4 for 
quenching 
  
DMSO Sigma D2438  25   
Isopropyl Alcohol Sigma W292907  25   
Trypan Blue Gibco 15250  25   
Equipment       
Mr. Frosty Sigma C1562     
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A.4 Pericyte Culture 
1. Gelatin Coating 
a. Mix 500 mg gelatin with 500 ml PBS. Place in 37°C water bath until 
gelatin is dissolved. 
b. Sterile filter using a 0.22 µm filter. 
c. Final concentration is 1 mg/ml. 
 
2. Coating Flasks 
a. Add 7 ml (T75) or 15 ml (T175) of 1 mg/ml gelatin to each flask and 
make sure the solution covers the entire bottom of the flask. 
b. Incubate at RT for at least 30 min (can be much longer, but do not 
leave overnight). 
c. Aspirate gelatin. Do not rinse. Use immediately. 
 
3. Thawing Cells 
a. Warm 9 ml and 18 ml PC medium to 37°C in separated tubes. 
b. Take vial of PCs from liquid nitrogen. From here, move as quickly 
as possible. 
c. Warm the cells for 2 min. at in the 37°C waterbath. 
d. In the hood, open the vial and add warm PC medium to the vial. 
Pour contents of vial into the conical of medium. 
e. Repeat step d until the entire contents of the vial are transferred to 
the conical. At this point, one no longer needs to move as quickly 
as possible. The cells have been warmed to 37°C, and the DMSO 
in the freezing solution has been diluted. 
f. Spin cells at 350xg for 5 minute. 
g. Resuspend in 5 ml. 
h. Spin cells again at 350xg for 5 minute. 
i. Resuspend in 13 ml. 
j. Transfer contents of the conical to a gelatin-coated T75 flask and 
add 2 ml freshly thawed FBS. 
k. Change medium every 2-3 days, always using freshly thawed FBS. 
Use 26 ml DMEM + 4 ml FBS for a T175 flask. 
 
4. Splitting Cells 
a. Thaw 2 ml (T75) or 5 ml (T175) 0.5% trypsin per flask. 
b. Rinse flasks with 10 ml (T75) or 23 ml (T175) PBS. 
c. Add trypsin and incubate at 37°C for 1 minute. 
d. Quickly view flasks to make sure the cells have lifted. 
e. Add 2 ml (T75) or 5 ml (T175) FBS to quench the trypsin. 
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f. Add 6 ml (T75) or 14 ml (T175) aM199 to the flask. Pipette cells 
into a conical tube. 
g. Centrifuge at 350xg for 5 minutes. 
h. Resuspend cells in PC medium. Aim for about 1 M/ml for easy 
counting. Expect 2 M (T75) or 5 M (T175) per flask. 
i. Add 50 µl cell solution to a trypan blue aliquot (75 µl trypan blue + 
125 µl PBS). Add 10 µl of this solution to a hemocytometer and 
count cells. 
     
  
 
          
 
          
4 represents the average of the 4 boxes counted, 5 is the dilution of 
the cells in trypan blue, and 10,000 is the multiplier based on the 
design of the hemocytometer. 
j. Plate into gelatin-coated flasks at a 1:6 split. 
k. Use only overconfluent cells for experiments (achieved by growing 
flasks for ~10 days between splits), as subconfluent or confluent 
cells will not recruit well. Use up to passage 8. 
 
5. Freezing Cells 
a. Split cells as usual. Resuspend at twice the desired concentration 
in PC medium. (eg. for 1 M aliquots, each having 1 ml of solution, 
resuspend at 2 M/ml.) Place cells on ice. 
b. Make a solution of 20% DMSO and 20% FBS in PC medium. Make 
0.5 ml for each aliquot. The introduction of an aqueous solution to 
DMSO produces heat, so put this solution on ice and do not use 
until it is cold. 
c. Mix cells and DMSO/FBS/PC medium at a 1:1 ratio and pipette 1 
ml into each pre-labeled cryovial. DMSO protects cells during 
freezing, but is toxic to cells at warmer temperatures, so move as 
quickly as possible after mixing cells and DMSO. 
d. Transfer vials to a Mr. Frosty filled with isopropyl alcohol and place 
at -80°C overnight. Mr. Frosty ensures a steady drop of 1°C per 
minute, which is optimal for most cell types. 
e. Transfer vials to liquid nitrogen. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Gelatin Sigma G2500  25   
PBS Mediatech 21-031-CM  25   
PC medium    4 See protocol  
Trypsin Gibco 25300  -20 0.5%  
FBS Hyclone “Characterized”  4 for 
quenching 
  
DMSO Sigma D2438  25   
Isopropyl Alcohol Sigma W292907  25   
Trypan Blue Gibco 15250  25   
Equipment       
Mr. Frosty Sigma C1562     
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A.5 Culture Media 
1. BOEC Medium 
a. Thaw Bullet Kit components at RT except FBS, which can be 
thawed in a 37°C waterbath. Thaw an additional 40 ml FBS and 5 
ml penicillin/streptomycin (P/S). 
b. Centrifuge growth factors at 220xg for 5 min to ensure all liquid is at 
the base of the vial. 
c. Using a 1000 ml pipette, carefully pipette each growth factor into a 
freshly opened bottle of EBM-2. 
d. Add all FBS (total of 50 ml), and 5 ml P/S. Swirl to mix. 
e. Store at 4°C for up to 2 weeks. Do not freeze. 
f. When feeding, only warm up the amount needed for that feeding. 
Discard any extra that was warmed and not used. 
 
2. PC Medium 
a. Thaw 5 ml penicillin/streptomycin (P/S). 
b. Add 5 ml P/S and 500 µl gentamicin to a freshly opened bottle of 
DMEM low glucose. 
c. Store at 4°C. 
d. When feeding, only warm up the amount needed for that feeding. 
Discard any extra that was warmed and not used. Freshly thawed 
FBS is added to each flask at the time of feeding. 
 
3. nhDF Medium 
a. Thaw 50 ml FBS and 5 ml P/S. 
b. Add FBS and P/S to a freshly opened bottle of DMEM/F-12. 
c. Store at 4C for up to 4 weeks. 
d. When feeding, only warm up the amount needed for that feeding. 
Discard any extra that was warmed and not used. 
 
4. Supermedium 
a. Thaw 100 ml FBS and 5 ml antibiotic/antimycotic. 
b. Weigh 200 mg bovine brain extract and 50 mg heparin salt and add 
them to a freshly opened 500 ml bottle of 1x M199. Mix well. 
c. Place the M199 in a 37°C waterbath for at least 30 min. 
d. Sterile filter the M199 through a 0.22 µm filter. 
e. Add FBS and antibiotic/antimycotic. 
f. Add 600 µl Gentamicin. 
g. Store at 4°C. 
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h. When feeding, only warm up the amount needed for that feeding. 
Discard any extra that was warmed and not used. 
 
5. Antibiotic M199 
a. Add 5 ml antibiotic/antimycotic and 500 µl gentamicin to a freshly 
opened bottle of M199. 
b. Store at 4C. 
c. When using, only warm up the amount needed. Discard any extra 
that was warmed and not used. 
 
6. Defined Medium 
a. At the time of feeding, add 4 µl RSII, 1 µl FGF, 10 µl ascorbic acid, 
and 0.25 µl aprotinin per 1 ml of 1x antibiotic M199. 
b. FGF can be stored at 4°C for up to 4 weeks. AA can be refrozen 
many times. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
BOEC medium Lonza CC-3162  EBM-2: 4, 
Bullet Kit: -20, 
BOEC 
Medium: 4 
  
FBS HyClone “Characterized”  -20   
Penicillin/Streptomycin Gibco 15140  -20   
Gentamicin Gibco 15710  25   
DMEM low glucose Gibco 11885  4   
Antibiotic/antimycotic Gibco 15240  -20   
Heparin salt Sigma H3393 H3393-
100KU 
4   
Bovine brain extract    4 Obtained from Davis 
lab 
 
1x M199 Gibco 11150  4   
Gentamicin Gibco 15710 15710064 25   
RSII    4 Obtained from Davis 
lab 
 
FGF R&D Systems 233-FB/CF  -20 Stock 40 µg/ml, use at 
1:1000 dilution (40 
ng/ml) 
 
Ascorbic acid Sigma A5960  -20 Stock 5 mg/ml, use at 
1:100 dilution (50 
µg/ml) 
 
DMEM/F-12 Mediatech 10-090-CV  4   
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A.6 BOEC Spheroid Experiments 
1. Gel Formulation – Magnetically Aligned Constructs 
For 1 ml Gel (3.3 mg/ml)  For 3 Gels   
µl Component  µl Component    
112 Fibrinogen 
(30 mg/ml 
stock)  1188 F solution    
680 EBM-2+GF  128 ECs    
85 EC Spheroids  128 PCs    
85 nhDF  4.8 Thrombin    
3.2 Thrombin (50 
U/ml stock) 
      
   1500 Total    
 
2. Gel Formulation – Cell-Aligned Constructs 
For 1 ml Gel 
(3.3 mg/ml)  For Aspect Ratio 1  
µl Component  µl Component  
112 Fibrinogen (30 mg/ml stock)  198 F solution  
680 EBM-2+GF  21 EC Spheroids  
85 EC Spheroids  21 nhDF  
85 nhDF  12.
5 
Thrombin  
50 Thrombin (50 U/ml stock)     
   250 Total  
 
For Aspect Ratio 2  For Aspect Ratio 3 
µl Component  µl Component 
396 F solution  594 F solution 
42 EC Spheroids  64 EC Spheroids 
42 nhDF  64 nhDF 
25 Thrombin  37.
5 
Thrombin 
     
500 Total  750 Total 
 
3. Making Methylcellulose Medium 
a. Autoclave 1.2 g methylcellulose (Sigma M0512) and a stir bar in a 
100 ml glass bottle. 
b. Add 100 ml EBM-2 (Lonza). 
c. Stir at 4C for about 1 hour. 
d. Using a sterilized small spatula, break up clumps. 
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e. Stir at 4C overnight. 
f. Divide evenly between 2 50 ml conical tubes. 
g. Centrifuge at 3200xg for 3 hours. 
h. Pipette all except the bottom 5 ml from each tube into a new bottle. 
 
4. Making Spheroids 
a. Split hBOECs as usual and stain the appropriate number of cells 
with celltracker dye if desired. 
b. Resuspend the cells in “spheroid medium” (80% BOEC medium, 
20% methylcellulose medium) at a concentration of 20,000 cell/ml. 
c. Transfer the cells to a sterile reagent reservoir for multichannel 
pipettes (e.g. Costar 4870). 
d. Using a multichannel pipette, transfer 25 µl drops of cell solution 
onto the top of a 150 mm petri dish (e.g. Corning 430597). Using 
the top is critical as the drops spread out on tissue-culture treated 
surfaces. 12 rows of 12 drops fit well. 
e. Culture overnight at 37°C with the drops hanging down from the top 
of the dish. 
f. Invert the dish and view under transmitted light to verify spheroid 
formation. 
 
5. Harvesting Spheroids 
a. Add 5 ml HBSS (Gibco 14175) to the top of the petri dish containing 
spheroid drops. 
b. Tilt the dish to spread the HBSS across the entire surface. 
c. Gently pipette the solution either into a 15 ml conical tube or onto 
another petri dish containing spheroid drops. 
d. Allow spheroids to settle to the bottom of the 15 ml conical tube for 
at least 20 minutes. 
e. Aspirate off some medium to enable a micropipette tip to reach the 
bottom of the tube 
f. With the micropipette tip at the bottom of the tube, collect as much 
volume as needed, moving the tip around the bottom as the plunger 
is let up. It is possible to see spheroids as tiny dots within the tip 
g. If spheroids are seen to be broken apart, try pipetting more gently 
in steps (c) and (f) or cutting off the tip of a micropipette tip with a 
sterile scissors. 
 
6. Making Magnetically-Aligned Constructs 
a. Arrange 1 hour of time on the magnet(s) at CMRR. If multiple 
magnets are needed, they can be used during the same hour. 
b. Make spheroids the day before going to CMRR. 
c. Prepare the wells: Use a cotton-tipped sterile applicator to put 
vacuum grease on one end of 2 autoclaved Teflon rings (1.5 cm 
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diameter). Place an autoclaved 24x60 mm glass coverslip on top of 
the rings. Use another cotton-tipped sterile applicator to press the 
coverslip onto the rings. Make sure the seal is tight. Wrap glass 
coverslips in kim wipes during autoclaving to prevent them from 
sticking together. Place wells in plastic jars, cushioned by 
autoclaved kim wipes, for transport to CMRR. 
d. Take fibrinogen and thrombin out of the freezer 1.5 hours before 
first use at the magnet. Allow them to thaw at RT for 20 minutes, 
then keep on ice. 
e. Split nhDF according to standard protocol and resuspend at 3 
million/ml. Keep on ice. 
f. Harvest spheroids into 2 conical tubes per magnet condition. 
g. Transfer the appropriate volume of spheroids into a sterile 
microcentrifuge tube and keep on ice. 
h. Transfer the appropriate volume of nhDFs into microcentrifuge 
tubes and keep on ice. 
i. Transfer the appropriate volume of thrombin into microcentrifuge 
tubes and keep on ice. 
j. Combine enough fibrinogen and EBM-2 + GF for the entire 
experiment. Aliquot the appropriate volume into microcentrifuge 
tubes and keep on ice. 
k. Pack fibrinogen solution, thrombin, spheroids, nhDF, pipettors and 
tips, several well plate covers, wells and a microcentrifuge tube 
rack for transport to CMRR. 
l. At CMRR, place the wells for a give magnet on top of a well plate 
cover placed on the spot that will be in the magnet’s isocenter when 
the platform is moved in. 
m. Mix components for half of the wells (~3 gels) and pipette 500 µl 
into each well. Cover wells with another well plate cover. 
n. As soon as possible, move the platform into the magnet and leave 
there for 15 minutes. 
o. Move the platform out of the magnet and mix the components for 
the rest of the wells. Pipette 500 µl into each well and cover with 
the well plate cover. 
p. As soon as possible, move the platform into the magnet and leave 
there for 15 minutes. 
q. Back at the lab, make isotropic control gels and allow to gel for 15 
min at RT. 
r. Add 1 ml BOEC medium to each well, and transfer wells to an 
autoclaved pyrex dish for easier incubation. Use a piece of foam in 
the bottom of the dish to prevent the coverslips from sticking to the 
bottom. 
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7. Making Cell-Aligned Constructs 
a. Make slab molds in the desired aspect ratios. Use the metal stamp 
to make score marks in the plastic of a well plate or petri dish. Draw 
the rectangle on the underside of the plate and use this as a guide 
to make score marks. Using a sterile cotton-tipped applicator, apply 
a dollop of sterile vacuum grease inside the left and right edges of 
each score mark. Attach a porous polyethylene spacer to each 
dollop, keeping the rougher side up. To prepare for lifting the slabs, 
mark the outside of a new well plate or petri dish with dots to 
indicate where vacuum grease will go, and lines to mark where the 
outer edge of the spacer should go. Apply dollops of vacuum 
grease to the dots. 
b. Prepare and harvest spheroids. 
c. Thaw fibrinogen and thrombin at RT. When thawed, keep on ice. 
d. Split nhDF according to standard protocol and resuspend at 3 
million/ml. Keep on ice. 
e. Mix enough fibrinogen and EBM-2 + GF for the entire experiment 
and aliquot out enough for each slab. Keep on ice. The standard 
slab (gel size: 1.5 cm x 1 cm) requires 400 µl of gel. 
f. For each slab, add the appropriate volumes of spheroids and 
nhDFs. Warm the vial briefly, then add thrombin. Mix gently for 
approximately 30 seconds. 
g. Pipette the solution into the mold. Drip some solution directly onto 
the inner edge of the spacer to ensure good penetration of the gel 
into the spacer. Ideally gellation occurs simultaneously with the end 
of pipetting. This timing minimizes the number of spheroids that 
sink to the bottom of the gel. After lifting, spheroids at the bottom of 
the gel form a monolayer at the bottom of the gel rather than 
sprouting. 
h. Cover the slabs with BOEC medium (3 ml for a standard slab in a 6 
well plate). Multiple sizes of gels can also be made in a 150 mm 
petri dish and Teflon spacers used to minimize medium usage. 
i. The next day, aspirate the medium, and use sterile blunt-end 
forceps to gently loosen the top and bottom edges of the gel from 
the score mark. Grab both spacers simultaneously using forceps 
and move the spacers toward each other. The gel should easily 
loosen from the plate. Move the spacers left and right to ensure that 
the gel is completely free. Then transfer the gel to the new plate. 
Place the spacers on the dollops of vacuum grease and make sure 
the edge of the spacer is aligned with the line. Add new BOEC 
medium. 
 
8. Harvesting Constructs 
a. Fix in 4% PFA for 10 min. 
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i. For magnetically-aligned constructs, aspirate medium and 
add 1 ml PFA to each well. 
ii. For cell-aligned constructs, lift each gel via the spacers 
and place into a well containing PFA. Make sure the 
construct is not wrinkled or folded during fixation. 
b. Rinse 3x with PBS for 5 min each. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Methylcellulose Sigma M0512  25   
HBSS Gibco 14175  25   
EBM-2 + GF Lonza CC-3162  EBM-2: 4, 
bullet kit: -20, 
made up 
solution: -20 
Same as BOEC 
medium, but with no 
FBS or P/S 
 
Fibrinogen Sigma F8630  -20 30 mg/ml stock  
Thrombin Sigma T7513  -80 25 U/ml stock  
4% PFA Electron 
Microscopy 
Sciences 
15710  16% stock: 4, 
4% -20 
Make up 4% solution 
from 16% by combining 
with 1.33x PBS 
 
Supplies       
Kim Wipes UStores  CX21272   X 
Glass Coverslips Gold Seal 3322    X 
Vacuum grease Dow Corning    High vacuum grease X 
Microcentrifuge tubes UStores  CX13136   X 
Cotton-tipped applicator UStores  MS01172    
Sterile Gloves UStores  CX40770    
Equipment       
Teflon Rings Custom    ~12 well plate size. 
Inner Diameter = 1.5 
cm, Height = 2.4 cm 
X 
Metal stamp Custom    Makes rectangle 1x2.5 
cm 
X 
Porous PE spacers unknown    Cut to 0.5x1cm X 
Spatula UStores  87731    
Blunt forceps UStores  CX12372    
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A.7 HUVEC PC Fibrin Experiments 
1. Gel Formulation 
For “1 ml” Gel (“10 
mg/ml”) Actually 1.359 
ml, 7.4 mg/ml 
 For 6 A/2 Gels  For 1 Slab 
µl Component  µl Component  µl Component 
1000 Fibrinogen  148 F solution  41 F solution 
4 SCF  26 ECs  7.2 ECs 
4 IL-3  5.3 PCs  1.47 PCs 
4 FLT3 Ligand  6.43 Thrombin  1.78 Thrombin 
2 SDF       
5 FGF  180 Total  50 Total 
100 Fibronectin       
200 ECs       
40 PCs       
36 Thrombin       
 
2. Gel Preparation 
a. Weigh enough fibrinogen for the amount of gels being made. Use 
at least 5 mg extra to make up for that lost in filtering. 
b. Add chilled PBS to the fibrinogen to make a 10 mg/ml solution and 
place on ice for 10 minutes. 
c. Filter solution through a 0.22 µm filter. 
d. Mix enough fibrinogen, SCF, IL-3, FLT3L, SDF, FGF, and 
fibronectin for all of the gels planned (“F solution”). This ensures 
pipetting the largest volumes of the growth factors possible, which 
is more accurate. 
e. Aliquot the F solution into sterile microcentrifuge tubes. Make one 
aliquot for each perfusion chamber or 6 A/2 gels. Casting in small 
aliquots ensures that the solution will not gel during pipetting. 
f. Split cells as usual, resuspending in 1x antibiotic M199 for counting. 
Spin cells again and resuspend at 10 M/ml in 1x antibiotic M199. 
 
3. Casting A/2 Gels 
a. Add ECs, PCs and thrombin to an F solution aliquot. 
b. As soon as the thrombin is added, pipette 28 µl into each of 6 wells 
of a 96 well half area (A/2) plate. Avoid bubbles. Repeat for all 
aliquots. Center the gels in the plate; do not use more than 32 wells 
in a plate (making sure to leave rows of at least 2 wells around the 
edges of the plate). 
c. Incubate the plates at 37°C for 30 minutes. 
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d. Pipette sterile ddH2O into the unoccupied wells and spaces 
between wells. This helps keep humidity high near the gels and 
prevents evaporation of culture medium. 
e. Add 100 µl defined medium to each gel. At subsequent feedings, 
remove and replace 60 µl medium. 
 
4. Slab Molds 
a. Prior to splitting cells, assemble molds. 
b. Draw 2 rectangles 1.75 cm x 0.5 cm on the bottom of each well of a 
12 well plate. One long edge can overlap. 
c. In the hood, heat the straight edge of the large spatula and press 
into the bottom of each well, tracing the long edges of the 
rectangles. Reheat as necessary. 
d. Place dollops of sterile vacuum grease at either end of each 
rectangle using a cotton tipped applicator. 
e. Using sterilized forceps, place an autoclaved porous polyethylene 
spacer on top of each vacuum grease dollop, and press down 
gently, moving the spacer so it is in line with the edges of the 
rectangle. 
f. On the back of another 12 well plate, draw lines 1.75 cm apart, and 
4 dots inside the lines by 0.25 cm. This will be the plate the slabs 
will be put in after detachment. 
g. Using a cotton-tipped applicator, place dollops of vacuum great on 
top of the dots 
 
5. Casting Slabs 
a. Add ECs, PCs, and thrombin to an F solution aliquot. 
b. As soon as the thrombin is added, mix and pipette 50 µl into the 
slab mold. Pipette some gel solution onto the spacers to encourage 
attachment. Avoid bubbles. Repeat for all aliquots. 
c. Incubate at 37°C for 30 minutes. 
d. Feed with 1.5 ml defined medium 
  
6. Detaching Slabs 
a. Typically done on day 3. 
b. Place culture medium from one well into another well of the plate 
(or aspirate if it is a feeding day). 
c. Sterilize 2 forceps in the hood. Grab one of the spacers of a slab 
with each of the forceps, and carefully slide the spacers toward 
each other. 
d. Eventually the gel will detach (may need to slide spacers left and 
right; keep the spacers close together so as not to rip the gel. 
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e. When the gel is detached, lift the gel by both spacers and place 
spacers on top of vacuum grease in the new plate. Gently spread 
the gel via the spacers so the spacers are lined up with the lines on 
the plate. 
f. Add medium (either saved from the well or fresh) 
g. Repeat steps b-f for all slabs. 
 
7. Harvesting Gels 
a. Remove the gels from their wells and submerge in 4% PFA for 10 
min. 
i. For A/2 gels, carefully slide jeweler’s forceps in the closed 
position around the edge of the well, detaching the gel 
from the edge. Carefully draw the forceps into the center 
of the well at various locations around the edge to detach 
the gel from the bottom of the well. Grab the gel with the 
forceps, squeezing as small a portion of the gel as 
possible (the squeezed portion will be damaged), and 
place into PFA. 
ii. For slabs, slide jeweler’s forceps in the closed position 
along the interface between the tissue and the spacer, 
separating the two. Transfer tissue to PFA, squeezing as 
little as possible. 
b. Rinse 3x with PBS for 5 min each. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Fibrinogen EMD Chemicals 341578  4 Make fresh for each 
casting (10 mg/ml in 
PBS) 
 
Thrombin Sigma T9549  -20 750 U/ml stock in 
ddH2O, dilute 1:20 prior 
in ddH2O to use 
 
Antibiotic M199     See protocol  
SCF R&D Systems 255-
SC/CF 
 -20 50 µg/ml in PBS, 20 µl 
aliquots 
 
IL-3 R&D Systems 203-IL/CF  -20 50 µg/ml in PBS, 20 µl 
aliquots 
 
SDF-1α R&D Systems 350-
NS/CF 
 -20 100 µg/ml in PBS, 10 µl 
aliquots 
 
FLT3 Ligand R&D Systems 308-
FK/CF 
 -20 50 µg/ml in PBS, 20 µl 
aliquots 
 
FGF R&D Systems 233-
FB/CF 
 -20 40 µg/ml, 25 µl aliquots; 
see protocol 
 
Fibronectin Sigma F2006  -20 1 mg/ml in PBS, 100 µl 
aliquots 
 
Sterile ddH2O    25 Filter through 0.22 µm  
4% PFA Electron 
Microscopy 
Sciences 
15710  16% stock: 4, 
4% -20 
Make up 4% solution 
from 16% by combining 
with 1.33x PBS 
 
Supplies       
Microcentrifuge tubes UStores  CX13134   X 
96 well A/2 plates Costar 3697 7200334    
Vacuum grease Dow Corning    High vacuum grease X 
Cotton-tipped applicator UStores  MS01172    
Equipment       
Spatula UStores  87731    
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Jeweler’s Forceps UStores  CX12376  Sharp tips  
Blunt Forceps UStores CX12372     
Porous Spacers ? ? ?  Porous Polyethylene X 
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A.8 BOEC PC Fibrin Experiments 
1. Gel Formulation 
For 1 ml Gel (2.5 mg/ml)  For 6 A/2 Gels  For 1 Perfusion Gel 
µl Component  µl Component  µl Component 
85 Fibrinogen  129 F solution  287 F solution 
622 1x M199  36 ECs  80 ECs 
4 SCF  7.3 PCs  16 PCs 
4 IL-3  9 Thrombin  20 Thrombin 
2 SDF       
200 ECs  180 Total  400 Total 
40 PCs       
50 Thrombin       
 
2. Gel Preparation 
a. Thaw fibrinogen and thrombin at RT. Put on ice immediately after 
thawed. Do not let the reagents get warm. 
b. Mix enough fibrinogen, 1x M199, SCF, IL-3 and SDF for all of the 
gels planned (“F solution”). This ensures pipetting the largest 
volumes of the growth factors possible, which is more accurate. 
c. Aliquot the F solution into sterile microcentrifuge tubes. Make one 
aliquot for each perfusion chamber or 6 A/2 gels. Casting in small 
aliquots ensures that the solution will not gel during pipetting. 
d. Split cells as usual, except resuspend in 1x M199 instead of BOEC 
medium for counting. Spin cells again and resuspend at 10 M/ml in 
1x M199. 
 
3. Casting A/2 Gels 
a. Add ECs, PCs and thrombin to an F solution aliquot. 
b. As soon as the thrombin is added, pipette 28 µl into each of 6 wells 
of a 96 well half area (A/2) plate. Avoid bubbles. Repeat for all 
aliquots. Center the gels in the plate; do not use more than 32 wells 
in a plate (making sure to leave rows of at least 2 wells around the 
edges of the plate). 
c. Incubate the plates at 37°C for about 10 minutes. 
d. Pipette sterile ddH2O into the unoccupied wells and spaces 
between wells. This helps keep humidity high near the gels and 
prevents evaporation of culture medium. 
e. Add 100 µl BOEC medium to each gel. At subsequent feedings, 
remove and replace 60 µl medium. 
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4. Perfusion Molds 
a. Prior to splitting cells, put together perfusion molds. Wear sterile 
gloves. 
b. Place glass tubes into holes in piece 4, with the flare on the inside. 
c. Using a piece of scrap Teflon to hold the glass tube in place at the 
flared end, place a silicon o-ring over the straight end of the glass 
tube. 
d. Slide the o-ring down using the blunt-tipped forceps. 
e. Gently push the o-ring into the hole with one arm of a blunt-tipped 
forceps. Be very careful not to break the glass tube. Aim to have 
the o-ring flush with the ultem. 
f. Snap the bottom piece into the bottom of the middle piece. The 
bottom piece only fits into the side of the middle piece that has the 
greater distance from the glass tube to the edge. Once the bottom 
piece is in place, the glass tube is equidistant from the top and 
bottom of the well. 
g. Place molds into a sterile plastic culture jar (6 per jar). 
 
5. Casting Perfusion Gels 
a. Fill the glass tubes of each perfusion chamber with BOEC medium 
using a pipette. 
b. Add ECs, PCs, and thrombin to an F solution aliquot. 
c. As soon as the thrombin is added, mix and pipette 400 µl into a 
perfusion chamber. Avoid bubbles. Repeat for all aliquots. 
d. Incubate at 37°C for about 10 minutes. 
e. Wearing sterile gloves, use a sterile razor blade to pop out the 
bottom of the well. Add sterile plastic screws and nuts to each 
chamber (to keep the gel off the bottom of the jar). The top of the 
well during casting should be the bottom of the well during culture. 
On this side the gel is aligned with the top of the chamber, and so 
prevents bubbles from forming between the culture medium and the 
gel when placing the chambers into culture medium. 
f. Use a 500 ml plastic culture jar for 6 perfusion chambers. Cover 
with 70 ml BOEC medium. Replace all medium at feedings. 
 
6. Detaching Perfusion Gels 
a. Typically done on day 5. Wear sterile gloves and use sterile 
instruments. 
b. Slide dental pick 3 down and carefully along the long edges of the 
chamber, detaching the gel from the ultem.  
c. Carefully run dental pick 1 around the corners of the well. 
d. Use dental pick 2 to detach the gel from the ultem near the glass 
tubes. Use dental pick 2 from both the top and bottom of the 
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chamber to get all sides near the glass tubes. Be careful not to 
detach the gel from the flare of the glass tube. 
e. Push in each glass tube about 1-2 mm, being careful not to break 
the glass. 
f. Place the chamber back in the medium. 
g. Repeat steps b-f for all chambers. 
h. Inspect each gel in the culture medium, where some contraction is 
likely to have already occurred. If any parts of the gel are not fully 
detached, use an appropriate instrument to detach it. 
 
7. Harvesting Gels 
a. Remove the gels from their wells and submerge in 4% PFA for 10 
min. 
i. For A/2 gels, carefully slide jeweler’s forceps in the closed 
position around the edge of the well, detaching the gel 
from the edge. Carefully draw the forceps into the center 
of the well at various locations around the edge to detach 
the gel from the bottom of the well. Grab the gel with the 
forceps, squeezing as small a portion of the gel as 
possible (the squeezed portion will be damaged), and 
place into PFA. 
ii. For perfusion gels, mark one end of the tissue near the 
glass tube with Verhoeff’s stain. This mark the top and 
inlet side of the tissue for future reference. Carefully 
detach the gel from the glass tubes and transfer to PFA, 
squeezing as little as possible to avoid damage to the gel. 
Preferably use a plate with wells large enough so that the 
gels can be fixed straight. 
b. Rinse 3x with PBS for 5 min each. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Fibrinogen Sigma F8630  -20 30 mg/ml stock  
Thrombin Sigma T7513  -80 25 U/ml stock  
1x M199 Gibco 11150  4   
SCF R&D Systems 255-SC/CF  -20 50 µg/ml, 20 µl aliquots  
IL-3 R&D Systems 203-IL/CF  -20 50 µg/ml, 20 µl aliquots  
SDF-1α R&D Systems 350-NS/CF  -20 100 µg/ml, 10 µl 
aliquots 
 
Sterile ddH2O    25 Filter through 0.22 µm  
4% PFA Electron 
Microscopy 
Sciences 
15710  16% stock: 4, 
4% -20 
Make up 4% solution 
from 16% by combining 
with 1.33x PBS 
 
Verhoeff Stain     Use waste  
Supplies       
Microcentrifuge tubes UStores  CX13134   X 
Razor Blade UStores  CX40381   X 
96 well A/2 plates Costar 3697 7200334    
Sterile Gloves UStores  CX40770    
Equipment       
Perfusion chambers Custom    See Figure 6-1 X 
Plastic Culture Jars UStores  029251H   X 
Polycarbonate Screws McMaster Carr 93140A109     
Polycarbonate Nuts McMaster Carr 94905A005     
Dental Pick 1 Fine Science 
Tools 
10140-01   Straight tip X 
Dental Pick 2 Fine Science 
Tools 
10140-02   Small bend X 
Dental Pick 3 Fine Science 
Tools 
10140-03   Large bend X 
Spatula UStores  87731   X 
Jeweler’s Forceps UStores  CX12376  Sharp tips X 
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Silicone O-rings McMaster Carr 9396K101   1/32” ID X 
Scrap Teflon     Cut to ~.4x.4x2 cm X 
Glass Tubes World Precision 
Instruments 
1B100-4   I mm OD, 0.58 mm ID. 
Cut to 1.4 cm length, 
flare end to 2 mm OD 
X 
PEEK O-ring Applicator Custom    Cylinder with ~1.5 mm 
ID 
X 
Blunt Forceps UStores CX12372    X 
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A.9 Perfusion Experiments 
1. Making Agarose Gel 
a. Pipette 20 ml PBS into a wide mouth 100 ml bottle. 
b. Weigh 1g agarose. 
c. Slowly add the agarose to the PBS, swirling the solution 
continuously. This prevents large clumps of agarose, which are 
difficult to get into solution. 
d. Immediately warm the solution in the microwave. Make sure the 
cap is loose. Remove from the microwave before the solution 
bubbles over. Swirl the solution and let cool a few moments. Return 
to the microwave. Repeat until the agarose is fully dissolved. 
e. Store at RT until needed. 
 
2. Beginning Perfusion 
a. Typically done on perfusion chamber gels that are 8-14 days old. 
After autoclaving the tubing, attach a 2 cm segment of tubing to a 
luer lock fitting (need 1 per chamber). 
b. Add BOEC medium to the microcentrifuge tube caps. Sterilize 
dental pick 3 and let cool. 
c. Wearing sterile gloves, remove the plastic screws. 
d. Dry the chamber with sterile kim wipes. 
e. Snap in the bottom chamber piece (it only fits on the side of the 
chamber with the larger distance between the edge of the chamber 
and the hole for the glass tube). 
f. Place a microcentrifuge tube cap over the end of each glass tube, 
making sure the fluid in the cap covers the glass tube. This 
prevents evaporation of fluid from the glass tubes (any evaporation 
would cause a bubble when connecting the glass tube to the plastic 
tubing). 
g. Add fresh BOEC medium to the chamber to keep the tissue moist 
using the sterile transfer pipette. If any leaks out, replace as 
needed. 
h. Repeat steps c-f for each chamber. After this point, gloves no 
longer need to be sterile, as only the outside of the chambers will 
be touched. 
i. Prepare the needle and syringe. Place metal screws in the four 
corners of the chamber, heads down. 
j. Complete the following step relatively quickly, as the agarose will 
gel rapidly. Melt agarose in the microwave. In the hood, draw up 
the agarose, use the dental pick to lift the gel off the bottom of the 
chamber (to ensure that agarose will flow underneath the gel), and 
dispense agarose into the chamber. Cover the chamber with the 
top chamber piece, and screw the nuts on by hand. Small bubbles 
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are ok. Tighten with the screwdriver and wrench. The screws need 
to be tight to prevent leaking. 
k. Place a microcentrifuge tube cap over the end of each glass tube, 
making sure the fluid in the cap covers the glass tube. 
l. Repeat steps h-j for each chamber. 
m. Fill one syringe per chamber with warm BOEC medium. Use 
different size syringes to get different flow rates with the same 
pump. 
n. Connect the plastic tubing to the syringes via luer lock fittings. 
o. Bring the syringe pump, Styrofoam block, and tray into the hood 
and place the pump and block on the tray. 
p. Place all syringes in the syringe pump. Run the syringe pump 
(infuse) until medium has reached the end of all plastic tubing. 
Catch drips with sterile kim wipes. 
q. Remove the microcentrifuge tube caps from one chamber. Place 
chamber on top of the Styrofoam block, lining it up with the furthest 
back syringe. 
r. Squeeze the plastic tubing so a drop appears at the end. Carefully 
slide the glass tube into the plastic tubing, avoiding bubble 
formation as much as possible. If a small bubble forms, leave it 
rather than starting over (which usually just leads to larger 
bubbles). Small bubbles often are trapped in the flare of the glass 
tube and don’t enter the tissue. 
s. Tie the plastic tube over the glass tube with dental floss. This needs 
to be tight to prevent leaks. Forceps can be helpful. Blot any excess 
medium with sterile kim wipes. 
t. Slide a 15 cm segment of plastic tubing over the outlet glass tube 
and tie with dental floss. 
u. Repeat steps p-t for each chamber. 
v. Direct the outlet tubing into a collection device (e.g. 50 ml conical 
tube). Seal with parafilm. 
w. Transfer the entire set-up into the incubator. Thread the pump 
power cord through the incubator port and plug in. Turn on the 
pump and begin perfusion. 
 
3. Medium Changes 
a. Due to the extremely low flow rate used, fresh medium provided 
would not reach the tissue within 2-3 days. Therefore, no medium 
changes were provided throughout the 6 day culture period. 
However, the tissue received a continuous supply of “fresh” 
medium through flow. 
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4. Adding Gold Nanoparticles 
a. Add gold nanoparticles (GNP) to flow ~24 hours prior to harvest. 
Their purpose is to track the path of fluid flow at the end of 
interstitial flow. 
b. Stop the pump and bring the entire tray into the hood. 
c. Fill a 1 ml syringe with a 1:200 solution of GNP in BOEC medium. 
Attach a 30 gauge needle to the end. 
d. Mark a spot on the plastic tubing approximately 5 mm from the 
glass tube inlet with sharpie. Repeat for each chamber. 
e. Carefully slide the needle into the plastic tubing at the marked 
location. Slowly inject a small volume of GNP solution. Repeat for 
each chamber. 
f. Place a dollop of sterile vacuum grease on the tube to cover the 
opening using a cotton-tipped applicator. Repeat for each chamber. 
g. Return the tray to the incubator and resume flow. 
 
5. Harvesting Gels 
a. Stop the pump and remove the entire setup from the incubator. 
Record the amount of fluid in the outlet line (length past the glass 
capillary tube). 
b. Remove the screws and the top chamber piece. 
c. Observe tissue through the agarose. A long bubble parallel to the 
tissue indicates extensive channeling. The tissue will also be very 
thin in this region. For some flow rates, GNP can be seen within the 
tissue. 
d. Slide jeweler’s forceps carefully into the agarose and along the 
sides of the tissue. Be carefully not to damage the tissue. Separate 
the tissue completely from the agarose. Use a pipette tip to put a 
small amount of Verhoeff’s dye onto the tissue near one end. This 
enables tracking of top/bottom and inlet/outlet sides of the tissue. 
e. Place tissues into 4% PFA for 10 min. Preferably use a plate with 
wells large enough to fix the gel in a straight position. 
f. Rinse 3x with PBS for 5 min each. 
g. Prepare samples for whole mount staining or sectioning. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Agarose Sigma A9539  25   
4% PFA Electron 
Microscopy 
Sciences 
15710  16% stock: 4, 
4% -20 
Make up 4% solution 
from 16% by combining 
with 1.33x PBS 
 
Gold Nanoparticles Nanoprobes 1115  4 15 nm diameter  
Supplies 
Kim wipes UStores  CX21274   X 
Needle 15 gauge Monoject 200029 CX41000    
Needle 30 gauge Becton Dickinson 305106 MS57786    
6 ml syringes (and other 
sizes if testing different 
flow rates) 
UStores  MS71050    
Dental floss       
Sterile Gloves UStores  CX40770    
Vacuum grease Dow Corning    High vacuum grease X 
Transfer Pipette UStores  055560  Sterile  
Equipment 
Chamber Pieces 1 and 6 Custom    See drawing X 
Metal screws and nuts McMaster Carr 91772A116   1-1/4” 4-40 Stainless 
Steel 
X 
Microcentrifuge tube 
caps 
UStores  CX13134  Cut cap off tube X 
Silastic tubing Dow Corning 508-005   1 2 cm segment and 1 
15 cm segment per 
chamber 
X 
Female Luer lock fittings Value Plastics FTLL004-1   1 per chamber X 
Wrench     1/4"  
Screwdriver     Philips head  
Dental Pick 3 Fine Science 
Tools 
10140-03   Large bend  
227 
 
A.10 Immunofluorescent Staining 
1. Antibodies 
Antigen Source Host 1º 
Dilution 
2º Antigen 
Retrieval 
Stock 
Conc 
Final 
Conc 
5B5 Abcam 
(ab44971) 
Mouse 1:100 DAM 0.1% Triton 
X-100 
150 µg/ml 1.5 µg/ml 
VE-
Cadherin 
Santa Cruz 
sc-6458 
Goat 1:200 DAG None or 0.1% 
Triton X-100 
for 1 min 
200 µg/ml 1 µg/ml 
Collagen 
IV 
Abcam 
(ab6586) 
Rabbit 1:200 DAR None 1 mg/ml 5 µg/ml 
Laminin Abcam 
(ab11575) 
Rabbit 1:100 DAR None 500 µg/ml 5 µg/ml 
Collagen 
I 
Abcam 
(ab6577) 
Rabbit 1:1000 DAR None 1 mg/ml 1 µg/ml 
CD31 Dako 
(m0823) 
Mouse 1:40 DAM None or 0.1% 
Triton X-100 
212 µg/ml 5.3 µg/ml 
 
2. Whole Mount Stain 
a. Complete all steps on an orbital shaker at RT. This protocol can be 
paused at any step by keeping at 4°C overnight. Keep slides in the 
dark as much as possible by covering plate with aluminum foil. 
b. If permeabilization is required, complete this step. If not, move on to 
step c. 
c. Incubate samples in Triton X-100 for 5 minutes. 
d. Rinse 3x 5 minutes in PBS. 
e. Incubate in 5% normal donkey serum for 2 hours. 
f. Incubate in primary antibody diluted in 5% normal donkey serum for 
1 hour. 
g. Rinse 3x 5 minutes in PBS. 
h. Incubate in secondary antibody diluted in 1 µg/ml Hoechst 33342 
dye for 1 hour. 
i. Rinse 3x 5 minutes in PBS. 
j. Store in PBS; image within a few days. 
 
3. Stain of Sections 
a. This protocol can be paused at any step by keeping at 4°C 
overnight. Keep slides in the dark as much as possible. Do not let 
the sections dry out (for each section, aspirate the previous solution 
and immediately fill with the next solution). Fill the troughs of the 
staining box with water if leaving overnight. 
b. If permeabilization is required, complete this step. If not, move on to 
step c. 
c. Incubate samples in Triton X-100 for 5 minutes. 
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d. Rinse 3x 5 minutes in PBS. 
e. Incubate in 5% normal donkey serum for 2 hours. 
f. Incubate in primary antibody diluted in 5% normal donkey serum for 
1 hour. 
g. Rinse 3x 5 minutes in PBS. 
h. Incubate in secondary antibody diluted in 1 µg/ml Hoechst 33342 
dye for 1 hour. 
i. Rinse 3x 5 minutes in PBS. 
j. Coverslip using mounting medium. Image within a few days. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Triton X-100 Amresco 0694  25   
PBS Mediatech 21-031-
CM 
 25   
Normal Donkey Serum Jackson Immuno 017-000-
121 
 Lyophilized: 4, 
Reconstituted:     
-20 in aliquots 
Reconstitute in ddH2O  
Hoechst 33342 Dye Invitrogen H3570  Stock: -20, 
diluted: 4 
Dilute to 1 µg/ml in PBS  
Mounting Medium Dako S3023  4   
Glycerol Sigma G7893  25   
Secondary Antibodies    -20 Dilute 1:1 in glycerol  
Donkey Anti-Mouse 
Green 
Jackson Immuno 715-545-
150 
  AlexaFluor 488 
Use at 1:200 dilution 
 
Donkey Anti-Mouse Red Jackson Immuno 715-585-
150 
  AlexaFluor 594 
Use at 1:200 dilution 
 
Donkey Anti-Mouse Far 
Red 
Jackson Immuno 715-605-
150 
  AlexaFluor 647 
Use at 1:200 dilution 
 
Donkey Anti-Rabbit 
Green 
Jackson Immuno 711-545-
152 
  AlexaFluor 488 
Use at 1:200 dilution 
 
Donkey Anti-Rabbit Red Jackson Immuno 711-585-
152 
  AlexaFluor 594 
Use at 1:200 dilution 
 
Donkey Anti-Rabbit Far 
Red 
Jackson Immuno 711-605-
152 
  AlexaFluor 647 
Use at 1:200 dilution 
 
Donkey Anti-Goat Green Jackson Immuno 805-545-
180 
  AlexaFluor 488 
Use at 1:200 dilution 
 
Donkey Anti-Goat Red Jackson Immuno 805-585-
180 
  AlexaFluor 594 
Use at 1:200 dilution 
 
Donkey Anti-Goat Far 
Red 
Jackson Immuno 805-605-
180 
  AlexaFluor 647 
Use at 1:200 dilution 
 
Supplies       
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Pap Pen Invitrogen 00-8877     
Equipment       
Staining Box Evergreen 
Scientific 
240-9020-
Z10 
  “Immunostain Moisture 
Chamber” 
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A.11 H&E Stain 
1. Stain 
a. Begin with frozen sections on slides. Arrange them in a staining 
rack. For each step, transfer rack to a staining dish with the 
appropriate solution. Timing is critical, so prepare dishes ahead of 
time. 
b. Filter hematoxylin. This removes clumps that build up over time. 
c. Rinse slides briefly in distilled water. 
d. Stain in hematoxylin for 8 minutes. 
e. Wash in warm running tap water for 10 minutes. The ions present 
in the tap water enhance the stain. 
f. Rinse in distilled water. 
g. Rinse in 95% alcohol, 10 dips. Blot on paper towels. 
h. Counterstain in eosin for 1 minute. Blot on paper towels. 
i. Dehydrate through 95% alcohol and 2 changes of 100% alcohol, 5 
minutes each. Blot on paper towels between each step. 
j. Clear in 2 changes of xylene, 5 minutes each. Blot on paper towels 
between each step. 
k. Mount in permount; cover with a coverslip. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Mayer’s Hematoxylin Sigma MSH128  25   
Eosin-Y Sigma HT110332  25   
95% Alcohol Decon Labs 2801  25   
100% Alcohol Decon Labs 2701  25   
Xylene Fisher Scientific X5SK  25   
Permount Fisher Scientific SP15  25   
Supplies       
Filter paper Fisher Scientific 09-795F     
Coverslips Gold Seal 3322     
Equipment       
Staining Rack Wheaton Science 
Products 
900204     
Staining Dish Wheaton Science 
Products 
900201     
233 
 
A.12 Silver Stain 
1. Theory 
a. The purpose of this stain is to visualize gold nanoparticles within a 
section. The reagents of the silver stain (HQ Silver) are deposited 
on gold, physically enlarging the nanoparticle. The particles are 
then visible under high power (63x) as black dots. 
 
2. Stain 
a. Begin with frozen sections on slides. Set them up in a staining box. 
b. Use a pap pen to draw hydrophobic circles around each section. 
c. Add 50 mM glycine to cover each section. Incubate 5 minutes at 
RT. 
d. Set up 3 staining dishes filled with ddH2O. Transfer slides to a 
staining rack and dip the rack in each dish about 15 times. Do not 
use a metal handle, as ions could transfer from it to the water. Any 
ions in the solution can cause self-nucleation of the silver reagents, 
leading to background staining. Transfer slides back to the staining 
box. 
e. Mix silver reagents. First mix solutions M and I, then add solution A. 
As soon as the solutions are mixed, move as quickly as possible 
until the slides are rinsed of silver reagents, as after a certain length 
of time the silver reagents will start self-nucleating, causing 
background staining. 
f. Add silver reagents to each section and incubate 10 minutes at RT. 
g. Fill staining dishes with fresh ddH2O. Transfer slides to the staining 
rack and dip the rack in each dish about 15 times. Transfer slides 
back to the staining box. 
h. Continue with immunostaining, H&E staining or coverslip. 
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 Supplier Product 
Number 
UStores 
Number 
Storage (°C) Description Autoclaved? 
Reagents       
Glycine Fisher Scientific BP381  25   
HQ Silver Nanoprobes 2012  -20 3 components, store in 
aliquots. Mix equal 
amounts of each. 
 
Supplies       
Pap Pen Invitrogen 00-8877     
Equipment       
Staining Box Evergreen 
Scientific 
240-9020-
210 
    
Staining Rack Wheaton Science 
Products 
900204     
Staining Dish Wheaton Science 
Products 
900201     
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A.13 Alignment Mapping 
1. Physical Set-up 
a. This set-up is in the same area as the Instron Biaxial mechanical 
testing device and can be used simultaneously with that. Sign up 
for a time on the Yahoo! calendar. Sign in as username: 
umn_biaxial, password: instron 
b. Position light at the center of the table. The lamp intensity should 
be set between 3 and 4. 
c. Place quarterwave plate over the light. 
d. Use blocks to set a clean plastic tray over the quarterwave plate. 
e. Place a few drops of PBS in the tray over the light and place a 
sample in the PBS. 
f. Position the rotating polarizer over the sample and screw in place. 
g. Position the camera above the rotating polarizer so that the sample 
is in the viewing field. Adjust the focus. 
h. Adjust the quarterwave plate so that half of the image is covered by 
it and half is not. Make sure PBS is visible in both regions (these 
will be control areas). 
 
2. Computer Set-up 
a. Open Phantom 5.4.7 
b. Acquisition → Setup and Recording 
c. Make sure the settings are correct: exposure time 7532, sample 
rate 20, post trigger 20 
d. Center the sample in the frame. 
e. Open HSMotor, a LabView program that controls the rotating 
polarizer. Set it to 1 Hz, 20 steps. Press run until the brightest 
image is on the screen (use -20 steps to go backward). 
f. Adjust the light intensity to avoid washout. 
 
3. Calibration 
a. Set HSMotor to 1 Hz, 20000 steps. 
b. Click Capture in Phantom. 
c. Click Run in HSMotor. 
d. Click Trigger in Phantom. 
e. Save images 20 images starting at image 0 as a .cin file (use 
calibration in the file name) 
f. File → Convert and Process 
g. Click on the .cin file and hit ok. 
h. Save as TIF 8 with the name “filename_!5.tif” This saves each 
image as a TIFF file. 
 
236 
 
4. Image Capture 
a. Cover the entire image with the quarterwave plate. 
b. Repeat steps 3b-3h for each sample. 
 
5. Troubleshooting 
a. The rotating polarizer often somehow becomes disconnected from 
the computer. If this occurs, perform the following steps to 
reconnect it. 
b. Check the control boxes (on the top shelf above the computer, on 
the left). The smaller box should have a green light nearest you, 
and the larger box should have a green light next to input 1. If the 
lights are correct proceed to step c. If not, unplug both boxes, wait 
about 30 seconds and plug them back in. 
c. Close all programs, then open Motion Architect from the start 
menu. 
d. Click on Terminal. 
e. Transfers → Send Motion Program. 
f. Select “sg_1.prg” 
g. Close the program, save as YOURNAME.ter 
h. Under My Computer, click on C:MA6000/EM6000. 
 
6. Image Analysis 
a. The analysis is done in Matlab. The files needed are in the 
rpmscripts folder. Choose regions when specified below by clicking 
the upper left and lower right corners of a box. 
b. Type “kmrpmstart” (change this file to have your own initials so you 
can edit the location to which it changes the directory) 
c. Type “rmpcalSG_hs” 
i. Enter the calibration filename (‘filename_’). 
ii. Choose a region above the sample within the PBS. The 
ions in the PBS contribute to light scattering, so it is 
necessary that the control areas are covered in the same 
solution that the sample is sitting in. 
iii. Choose a region below the sample within the PBS. 
iv. Check to see that the image is using a large range of 
pixels and that the max/min of the points and line are 
similar 
v. Check circular analyzer: slow axis should be ~45+/-5, 
retardation should be ~90+/-10 
d. Type “rpmcalSG_qw” 
i. Enter the sample filename (‘filename_’). 
ii. Choose a background region within the PBS. 
iii. If the line and points are offset by 90º, type 
pa1=pa1+90;pa2=pa2+90; 
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e. Type “rmpSG” 
i. Choose a region containing the sample or part of the 
sample. 
f. The output of this program is an alignment image as well as 
retardation values and the average alignment angle (in an excel 
file). The retardation value includes all areas in the image, so if the 
image includes regions outside the sample, the retardation value 
may be artificially low. For comparison between samples, convert 
retardation values to birefringence using the tissue thickness (see 
Tower and Tranquillo87). 
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A.14 Image Analysis – Sections Stained for CD31 
1. Matlab Codes Required 
a. CD31.m 
b. CD31manual.m 
c. CD31frombw.m 
d. drawline.m 
e. subtractregion.m 
f. overlay.m 
g. ECMstart.m 
 
2. Analyzing Images 
a. Note: These files can be used for either cross or longitudinal 
sections. 
b. Prior to beginning the analysis, edit the file ECMstart.m to 
recognize your file locations. 
c. Run ECMstart; this program enables Matlab to find the analysis 
files while in the folder containing images. 
d. Run CD31.m 
i. Enter the appropriate information. 
ii. The program displays the final lumen image; check each 
image against the original to verify accuracy. 
iii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
e. Run CD31manual.m on any images that were not accurate. 
i. Enter the appropriate information. 
ii. Compare the binary image to the original image. If any 
rings of CD31 staining are incomplete on the binary 
image, click “Draw Line.” Zoom in as necessary; then 
press the spacebar. Click on the endpoints a line that 
would complete the ring. A new image appears showing 
the line. Repeat until all incomplete rings are completed; 
then click “Done.” 
iii. Compare the lumen image to the original image. If any 
non-lumens are present in the lumen image, click 
“Subtract Region.” Zoom in as necessary; then press the 
spacebar. Click on the vertices of a polygon surrounding 
the lumen(s) to be deleted. The vertices can be modified; 
for more information see “roipoly” in the help menu. 
Double-click on the first vertex to complete the polygon. 
Continue removing lumens until the lumen image is 
accurate; then click “Done.” 
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iv. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
f. Both CD31.m and CD31manual.m save the final lumen image as 
“originalimagename_2.” If the lumen image needs to be analyzed 
again, run CD31frombw.m. 
i. Enter the appropriate information. 
ii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
g. Average the results for each construct, and analyze those data 
statistically. 
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A.15 Image Analysis – Sections Stained for Basement Membrane 
1. Matlab Codes Required 
a. BasementMembrane.m 
b. ECMstart.m 
 
2. Analyzing Images 
a. Prior to beginning the analysis, edit the file ECMstart.m to 
recognize your file locations. 
b. Run ECMstart; this program enables Matlab to find the analysis 
files while in the folder containing images. 
c. Use ImageJ to determine an appropriate threshold for the images. 
i. In the Image menu, click Type → 8-bit. 
ii. In the Image menu, click Adjust → Threshold. Use the 
interactive tool to find an appropriate threshold. 
iii. Repeat for several images obtain a threshold that will 
work for all of the images. 
d. Run BasementMembrane.m. 
i. Enter the appropriate information. 
ii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
e. Average the results for each construct, and analyze those data 
statistically. 
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A.16 Image Analysis – Sections Stained for EphrinB2 
1. Matlab Codes Required 
a. ephrin.m 
b. ECMstart.m 
 
2. Analyzing Images 
Prior to beginning the analysis, edit the file ECMstart.m to recognize your 
file locations. 
Run ECMstart; this program enables Matlab to find the analysis files while 
in the folder containing images. 
Use ImageJ to determine an appropriate threshold for the images. 
i. In the Image menu, click Type → 8-bit. 
ii. In the Image menu, click Adjust → Threshold. Use the 
interactive tool to find an appropriate threshold. 
iii. Repeat for several images obtain a threshold that will 
work for all of the images. 
Run ephrin.m. 
i. Enter the appropriate information. 
ii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
iii. Average the results for each construct, and analyze those 
data statistically. 
To normalize to CD31 staining levels quantified from other sections, divide 
the results for the total staining intensity of ECs by average value of 
CD31+ fraction obtained for that construct. 
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A.17 Image Analysis – Whole Mounts Stained for CD31 
1. Matlab Codes Required 
a. QuantifyingGrowthofVessels.m 
b. CropQuantifyingGrowthofVessels.m 
c. croptopoly.m 
d. findendpoints.m 
e. findjunctions.m 
f. WMstart.m 
 
2. Analyzing Images 
a. Note: This code can be used to analyze images of whole mount 
stains or stains of thick (40-60 µm) longitudinal sections that yield 
images similar to whole mount stains. 
b. Prior to beginning the analysis, edit the file WMstart.m to recognize 
your file locations. 
c. Run WMstart; this program enables Matlab to find the analysis files 
while in the folder containing images. 
d. Run QuantifyingGrowthofVessels.m. 
i. Enter the appropriate information. 
ii. The code outputs 2 images: a binary image of CD31 
staining, and an image in which black lines representing 
the skeletonized image (from which microvessel lengths 
are measured) overlays the grayscale image. Compare 
the two images to the original image. 
iii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
e. Strong background staining (e.g. due to a bright but out of focus 
microvessel) will lead to inaccurate results. If this is present in any 
area of the image, run CropQuantifyingGrowthofVessels.m 
i. Enter the appropriate information. 
ii. Click on the vertices of a polygon on the image that 
excludes the problem area. The vertices of the polygon 
can be edited; for more information go to “roipoly” in the 
help menu. Double click on the first vertex to complete the 
polygon. 
iii. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. 
f. Average the results for each construct, and analyze those data 
statistically. 
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A.18 Image Analysis – Optical Density 
1. Matlab Codes Required 
a. opticaldensity.m 
b. kmrpmstart.m 
 
2. Analyzing Images 
a. Note: This code is designed for use with images taken for 
alignment mapping. 
b. Prior to beginning the analysis, edit the file kmrpmstart.m to 
recognize your file locations. 
c. Run kmrpmstart; this program enables Matlab to find the analysis 
files while in the folder containing images. 
d. Run opticaldensity.m. 
i. Enter the root of the image file e.g. ‘Image1_’. 
ii. Click on the vertices of a polygon in the background. This 
determines the image with the brightest light intensity. 
iii. Click on the endpoints of a vertical line slightly larger than 
the width of the tissue. This will indicate the distance the 
program will translate the region(s) of interest to obtain 
background light information (used to correct for light 
intensity variation across the field of view). 
iv. Enter the number or regions of interest to be measured. 
v. Click on the vertices of a polygon to define your region of 
interest. The vertices of the polygon can be edited; for 
more information go to “roipoly” in the help menu. Double 
click on the first vertex to complete the polygon. 
vi. The quantification results are output to an Excel file that 
will be overwritten each time the code is run; copy the 
results to a new file to save them. The outputs will be in 
order of the locations of the regions of interest (top left to 
bottom right) regardless of the order in which they are 
chosen. 
e. Average the results for each construct, and analyze those data 
statistically. 
 
3. Outputs 
a. Normalized Optical Density – The mean pixel value of the region of 
interest normalized to account for variations in light intensity. The 
each region of interest is translated in the positive and negative y 
direction to obtain background values. These values are then 
averaged and the ratio of each to that of the first region of interest 
(the most top and left) is used for normalization.   
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Appendix B. Image Analysis Codes 
B.1 CD31.m 
%This script analyzes images of sections of gels containing ECs and 
pericytes  
%stained for CD31. It outputs data on endothelial structures, lumens, 
and  
%pericyte recruitment. 
  
%This file is written for images taken on the LHI confocal, which 
outputs 
%images that contain each channel separately along with a merged image. 
  
%Prior to running the code, run the file ECM start. This adds search 
paths 
%so you will be able to run this code while in the folder containing 
your 
%images. 
  
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
final=n+initial-1; 
result=zeros(n,23); 
  
fname='Image%03d.tif'; 
fname2='Image%03d_2.tif'; 
for k=initial:final 
if exist(sprintf(fname2,k),'file')==1 
    continue 
end 
    I=imread(sprintf(fname,k)); 
    I=rgb2gray(I); 
  
    [m1,n1]=size(I); 
    rect=[0 m1/2+1 n1/2-1 m1/2-1]; 
        %for images with red in lower left, green in top right 
%     rect=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in top right, green in top left 
    Icrop=imcrop(I,rect); 
% %%%%%use the code below if you have separate image files for each 
channel. 
% fname='Image%04d_C003.tif'; 
% fname2='Image%04d_C002.tif'; 
% for k=initial:final 
%     I=imread(sprintf(fname,k)); 
%     Icrop=rgb2gray(I); 
  
    [m2,n2]=size(Icrop); 
    sectionarea=m2*n2; 
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%To accurately identify as many lumens as possible, multiple ways of  
%thresholding the image are used. 
  
    I2b=imadjust(Icrop); 
    level = graythresh(I2b); 
    bwx = im2bw(I2b,level); 
     
    level = graythresh(Icrop); 
    bwy = im2bw(Icrop,level); 
     
    se=strel('disk',1); 
    bwza=imdilate(bwx,se); 
    bwz=imerode(bwza,se); 
     
    se1=strel('disk',2); 
    bwzb=imdilate(bwx,se1); 
    bww=imerode(bwzb,se1); 
     
% The following steps fill small holes in the images (large holes are 
% lumens). 
    filledx = imfill(bwx,4,'holes'); 
    holesx = filledx & ~bwx; 
    bigholesx = bwareaopen(holesx,5); 
    smallholesx = holesx & ~bigholesx; 
    bwx2 = bwx|smallholesx; 
    bwx3 = bwareaopen(bwx2,20,8); 
    ccx = bwconncomp(bwx3,8); 
    numberofstructures=ccx.NumObjects; %number of interconnected CD31+ 
structures in the image. 
    ccxlabel=labelmatrix(ccx); 
     
    filledy = imfill(bwy,4,'holes'); 
    holesy = filledy & ~bwy; 
    bigholesy = bwareaopen(holesy,5); 
     
    filledz1 = imfill(bwza,4,'holes'); 
    holesz1 = filledz1 & ~bwza; 
    bigholesz1a = bwareaopen(holesz1,5); 
    bigholesz1=imdilate(bigholesz1a,se); 
     
    filledz2 = imfill(bwz,4,'holes'); 
    holesz2 = filledz2 & ~bwz; 
    bigholesz2 = bwareaopen(holesz2,5); 
     
    filledz3 = imfill(bwzb,4,'holes'); 
    holesz3 = filledz3 & ~bwzb; 
    bigholesz3a = bwareaopen(holesz3,5); 
    bigholesz3=imdilate(bigholesz3a,se1); 
     
    filledz4 = imfill(bww,4,'holes'); 
    holesz4 = filledz4 & ~bww; 
    bigholesz4 = bwareaopen(holesz4,5); 
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%This step determines the level of CD31 staining. 
    totalCD31=sum(sum(bwx3))*scale^2; %units=um^2 
    fractionofsectionwithCD31=sum(sum(bwx3))/sectionarea; %Fraction of 
the section with positive CD31 staining 
  
%This step merges all the lumens identified in the various thresholded 
%images and removes any small lumens. 
    
lumens1=bigholesx|bigholesy|bigholesz1|bigholesz2|bigholesz3|bigholesz4
; 
    lumens=bwareaopen(lumens1,5); 
  
% This step compares the mean intensity of the lumen to the mean 
intensity 
% of the area immediately surrounding the lumen. A true lumen will have 
a 
% high ratio of surrounding intensity to lumen intensity. 
    cclumen = bwconncomp(lumens,8); 
    lumenlabel=labelmatrix(cclumen); 
    lumenstat=regionprops(cclumen,Icrop,'MeanIntensity'); 
    lumenintens=[lumenstat.MeanIntensity]; 
    lumens2=lumens; 
    se2=strel('disk',3); 
    outerintens2=zeros(1,cclumen.NumObjects); 
    size1=zeros(1,cclumen.NumObjects); 
    ratio=zeros(4,cclumen.NumObjects); 
    for i=1:cclumen.NumObjects 
        single=zeros(size(lumens1)); 
        single(lumenlabel==i)=1; 
        size1(i)=sum(sum(single))/i; 
        single2=imdilate(single,se); 
        single3=imdilate(single,se2); 
        outer=single3-single2; 
        ccouter = bwconncomp(outer,8); 
        outerstat=regionprops(ccouter,Icrop,'MeanIntensity'); 
        outerintens=[outerstat.MeanIntensity]; 
        outerintens2(i)=mean(outerintens); 
        ratio(1,i)=mean(outerintens); 
        ratio(2,i)=lumenintens(i); 
        ratio(3,i)=mean(outerintens)/lumenintens(i); 
        if mean(outerintens)/lumenintens(i)<2 %this number can be 
edited to fit the image set 
            lumens2(lumenlabel==i)=0; 
        else 
            outer2=zeros(size(outer)); 
            for j=1:(m1/2-1)*(n1/2-1) 
                if outer(j)==1 
                    outer2(j)=ccxlabel(j); 
                end 
            end 
            uniq=unique(outer2); 
            [s1,s2]=size(uniq); 
            ratio(4,i)=s1; 
        end 
        outerlabel=labelmatrix(ccouter); 
    end 
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%This step calculates properties of the true lumens (those identified 
by 
%the previous step). 
    stats=regionprops(lumens2,'Area'); 
    numlumens=length([stats.Area]); %Number of lumens in the image 
    numlumensper=numlumens/sectionarea/scale^2*1e6; %Number of lumens 
per mm^2 
    avglumenarea=mean([stats.Area])*scale^2; %units=um^2; Average area 
of a lumen 
    totlumenarea=sum([stats.Area])/sectionarea; %Lumen area as a 
fraction of the area of the sec 
  
    biglumens2=bwareaopen(lumens2,200,8); %only large lumens are used 
here because they are the most important 
    stats=regionprops(biglumens2,'Eccentricity','MajorAxisLength'); 
    ecc=mean([stats.Eccentricity]); %Eccentricity - a measure of how 
round the lumen is (scale from 0 to 1 where 0 is a circle and 1 is a 
line segment) 
    mal=mean([stats.MajorAxisLength])*scale; % Major Axis Length - a 
measure of the lumen length 
  
 %This step fills in all lumens and calculates the anisotropy index for 
each 
%structure identified. The anisotropy index is calculated based on the  
% average angle of the structures. This is meant for use with 
longitudinal  
% sections of aligned tissues. 
    filledx2=lumens2|bwx3; 
    filledx3=imfill(filledx2,'holes'); 
    stats2=regionprops(filledx3,'MajorAxisLength','Orientation'); 
    a={stats2.Orientation}; 
    p={stats2.MajorAxisLength}; 
    a2=cell2mat(a); 
    p2=cell2mat(p); 
    for i=1:length(a2) 
        if a2(i)<0 
            a2(i)=a2(i)+180; 
        end 
    end 
    avga=ones(1,length(a2)).*mean(a2); 
    AIx=p2.*abs(cos(deg2rad(a2-avga))); 
    AIy=p2.*abs(sin(deg2rad(a2-avga))); 
    AI=sum(AIx)/sum(AIy); %Anisotropy Index 
  
%This step calculates how much of the structures are lumenized. 
    ccfilled=bwconncomp(filledx3,8); 
    filledlabel=labelmatrix(ccfilled); 
    count1=0; 
    count2=0; 
    areacount1=0; 
    filledx4=zeros(size(filledx3)); 
    filledx5=zeros(size(filledx3)); 
    filledarea=zeros(1,ccfilled.NumObjects); 
    [m2,n2]=size(filledx3); 
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    for i=1:ccfilled.NumObjects 
        for j=1:m2 
            for l=1:n2 
                if filledlabel(j,l)==i && biglumens2(j,l)==1 
                    count1=count1+1; 
                    count2=count2+1; 
                elseif filledlabel(j,l)==i && lumens2(j,l)==1 
                    count1=count1+1; 
                end 
                if filledlabel(j,l)==i 
                    areacount1=areacount1+1; 
                end 
            end 
        end 
        if count1>0 
            filledx4(filledlabel==i)=1; 
            filledarea(i)=count1/areacount1; 
        end 
        if count2>0 
            filledx5(filledlabel==i)=1; 
        end 
        count1=0; 
        count2=0; 
        areacount1=0; 
    end 
    filledx4=logical(filledx4); 
    filledx5=logical(filledx5); 
    ccfilled2=bwconncomp(filledx4,8); 
    fractionnumlumen=ccfilled2.NumObjects/ccfilled.NumObjects; 
%Fraction of structures that contain lumens. 
    lumenareapercentavgper=mean(filledarea); %average percentage of 
each structure filled with lumens 
    lumenareapercent=sum(sum(lumens2))/sum(sum(filledx4)); %area 
percentage of structures that are lumens (only includes structures that 
are lumenized) 
    stats3=regionprops(filledx5,'MajorAxisLength'); 
    
lengthlumenized=sum([stats.MajorAxisLength])/sum([stats3.MajorAxisLengt
h]); %fraction of structure length covered with lumens (only includes 
lumenized structures) 
     
%This step thresholds the pericyte image. 
    rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in lower left and green in top right 
%     rectPC=[0 0 n1/2-1 m1/2-1]; 
        %for images with red in top right and green in top left 
    IcropPC=imcrop(I,rectPC); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelPC = graythresh(IcropPC); 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    ccPC = bwconncomp(bw3PC,8); 
    [m3,n3]=size(bw3PC); 
  
%This step determines the level of PCs. 
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    totalPC=sum(sum(bw3PC))*scale^2; %units=um^2 
    fractionofsectionwithPC=sum(sum(bw3PC))/sectionarea; %Fraction of 
the section with positive PC staining 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
     
%This step takes the intersection of the CD31 image and the pericyte 
image. 
%Those pericytes that overlap ECs are considered recruited. 
%Those pericytes that have 50% of their area overlapping with ECs are 
%considered fully recruited. 
    intersection=bwx3&bw3PC; 
    labelPC=labelmatrix(ccPC); 
    count=0; 
    areacount=0; 
    bw3PC_2=zeros(size(bw3PC)); 
    bw3PC_3=zeros(size(bw3PC)); 
    PCarea=zeros(1,ccPC.NumObjects); 
    for i=1:ccPC.NumObjects 
        for j=1:m3 
            for l=1:n3 
                if labelPC(j,l)==i && intersection(j,l)==1 
                    count=count+1; 
                end 
                if labelPC(j,l)==i 
                    areacount=areacount+1; 
                end 
            end 
        end 
        if count>0 
            bw3PC_2(labelPC==i)=1; 
            PCarea(i)=count/areacount; 
        end 
        if count/areacount>0.5 
            bw3PC_3(labelPC==i)=1; 
        end 
        count=0; 
        areacount=0; 
    end 
    ccint=bwconncomp(bw3PC_2,8); 
    fractionrecruitedPCs=ccint.NumObjects/ccPC.NumObjects; %Fraction of 
perictyes that have been recruited. 
    ccint2=bwconncomp(bw3PC_3,8); 
    fracfullyrecruitedPCs=ccint2.NumObjects/ccPC.NumObjects; %Fraction 
of perictyes that have been fully recruited. 
  
%This step thresholds the DAPI image and counts the nuclei 
    rect=[0 0 n1/2-1 m1/2-1]; 
    IcropDAPI=imcrop(I,rect); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelDAPI = graythresh(IcropDAPI); 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    fractionofsectionwithDAPI=sum(sum(bw3DAPI))/sectionarea; %Fraction 
of the section with positive DAPI staining 
250 
 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
  
%The data is collected into the result matrix and output to an excel 
file. 
    result(k-initial+1,1)=k; 
    result(k-initial+1,2)=sectionarea; 
    result(k-initial+1,3)=totalCD31; 
    result(k-initial+1,4)=fractionofsectionwithCD31; 
    result(k-initial+1,5)=numlumens; 
    result(k-initial+1,6)=numlumensper; 
    result(k-initial+1,7)=avglumenarea; 
    result(k-initial+1,8)=totlumenarea; 
    result(k-initial+1,9)=numberofstructures; 
    result(k-initial+1,10)=fractionnumlumen; 
    result(k-initial+1,11)=lumenareapercentavgper; 
    result(k-initial+1,12)=lumenareapercent; 
    result(k-initial+1,13)=lengthlumenized; 
    result(k-initial+1,14)=numPC; 
    result(k-initial+1,15)=fractionofsectionwithPC; 
    result(k-initial+1,16)=fractionrecruitedPCs; 
    result(k-initial+1,17)=fracfullyrecruitedPCs; 
    result(k-initial+1,18)=mean(PCarea(PCarea~=0)); %Area Fraction of 
recruited PC overlapping with structure 
    result(k-initial+1,19)=numDAPI; 
    result(k-initial+1,20)=fractionofsectionwithDAPI; 
    result(k-initial+1,21)=AI; 
    result(k-initial+1,22)=ecc; 
    result(k-initial+1,23)=mal; 
    k 
end 
  
xlswrite('Result.xlsx',result); 
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B.2 CD31manual.m 
%This script analyzes images of sections of gels containing ECs and 
pericytes  
%stained for CD31. It outputs data on endothelial structures, lumens, 
and  
%pericyte recruitment. 
  
%This file is written for images taken on the LHI confocal, which 
outputs 
%images that contain each channel separately along with a merged image. 
  
%Prior to running the code, run the file ECMstart. This adds search 
paths 
%so you will be able to run this code while in the folder containing 
your 
%images. 
  
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
final=n+initial-1; 
result=zeros(n,25); 
  
fname='Image%02d.tif'; 
fname2='Image%02d_2.tif'; 
fname3='Image%02d_3.tif'; 
fname4='Image%02d_4.tif'; 
fname5='Image%02d_5.tif'; 
fname6='Image%02d_6.tif'; 
for k=initial:final 
    I=imread(sprintf(fname,k)); 
    I=rgb2gray(I); 
  
    [m1,n1]=size(I); 
    rect=[0 m1/2+1 n1/2-1 m1/2-1]; 
        %for images with red in lower left, green in top right 
%     rect=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in top right, green in top left 
    Icrop=imcrop(I,rect); 
% %%%%%use the code below if you have separate image files for each 
channel. 
% fname='Image%04d_C003.tif'; 
% fname2='Image%04d_C002.tif'; 
% for k=initial:final 
%     I=imread(sprintf(fname,k)); 
%     Icrop=rgb2gray(I); 
  
    [m2,n2]=size(Icrop); 
    sectionarea=m2*n2; 
  
%To accurately identify as many lumens as possible, multiple ways of  
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%thresholding the image are used. 
  
    I2b=imadjust(Icrop); 
    level = graythresh(I2b); 
    bwx = im2bw(I2b,level); 
     
    level = graythresh(Icrop); 
    bwy = im2bw(Icrop,level); 
     
    se=strel('disk',1); 
    bwza=imdilate(bwx,se); 
    bwz=imerode(bwza,se); 
     
    se1=strel('disk',2); 
    bwzb=imdilate(bwx,se1); 
    bww=imerode(bwzb,se1); 
       
    figure,imshow(bwzb) 
    choice=menu('Options','Subtract Region','Draw a line','Done'); 
    while choice~=3 
        switch choice 
            case 1 
                title('After zooming, press any key. Then draw a 
polygon around the area you want to remove') 
                bwzb=subtractregion(bwzb); 
                imshow(bwzb) 
            case 2 
                title('After zooming, press any key. Then click on the 
endpoints of the line you want to draw'); 
                bwzb=drawline(bwzb); 
                imshow(bwzb) 
            case 3 
                break 
        end 
        choice=menu('Options','Subtract Region','Draw a line','Done'); 
    end 
     
% The following steps fill small holes in the images (large holes are 
% lumens). 
    filledx = imfill(bwx,4,'holes'); 
    holesx = filledx & ~bwx; 
    bigholesx = bwareaopen(holesx,5); 
    smallholesx = holesx & ~bigholesx; 
    bwx2 = bwx|smallholesx; 
    bwx3 = bwareaopen(bwx2,20,8); 
    ccx = bwconncomp(bwx3,8); 
    numberofstructures=ccx.NumObjects; %number of interconnected CD31+ 
structures in the image. 
    ccxlabel=labelmatrix(ccx); 
     
    filledy = imfill(bwy,4,'holes'); 
    holesy = filledy & ~bwy; 
    bigholesy = bwareaopen(holesy,5); 
     
    filledz1 = imfill(bwza,4,'holes'); 
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    holesz1 = filledz1 & ~bwza; 
    bigholesz1a = bwareaopen(holesz1,5); 
    bigholesz1=imdilate(bigholesz1a,se); 
     
    filledz2 = imfill(bwz,4,'holes'); 
    holesz2 = filledz2 & ~bwz; 
    bigholesz2 = bwareaopen(holesz2,5); 
     
    filledz3 = imfill(bwzb,4,'holes'); 
    holesz3 = filledz3 & ~bwzb; 
    bigholesz3a = bwareaopen(holesz3,5); 
    bigholesz3=imdilate(bigholesz3a,se1); 
     
    filledz4 = imfill(bww,4,'holes'); 
    holesz4 = filledz4 & ~bww; 
    bigholesz4 = bwareaopen(holesz4,5); 
     
%This step determines the level of CD31 staining. 
    totalCD31=sum(sum(bwx3))*scale^2; %units=um^2 
    fractionofsectionwithCD31=sum(sum(bwx3))/sectionarea; %Fraction of 
the section with positive CD31 staining 
  
%This step merges all the lumens identified in the various thresholded 
%images and removes any small lumens. 
    
lumens1=bigholesx|bigholesy|bigholesz1|bigholesz2|bigholesz3|bigholesz4
; 
    lumens=bwareaopen(lumens1,5); 
  
% This step compares the mean intensity of the lumen to the mean 
intensity 
% of the area immediately surrounding the lumen. A true lumen will have 
a 
% high ratio of surrounding intensity to lumen intensity. 
    cclumen = bwconncomp(lumens,8); 
    lumenlabel=labelmatrix(cclumen); 
    lumenstat=regionprops(cclumen,Icrop,'MeanIntensity'); 
    lumenintens=[lumenstat.MeanIntensity]; 
    lumens2=lumens; 
    se2=strel('disk',3); 
    outerintens2=zeros(1,cclumen.NumObjects); 
    size1=zeros(1,cclumen.NumObjects); 
    ratio=zeros(4,cclumen.NumObjects); 
    for i=1:cclumen.NumObjects 
        single=zeros(size(lumens1)); 
        single(lumenlabel==i)=1; 
        size1(i)=sum(sum(single))/i; 
        single2=imdilate(single,se); 
        single3=imdilate(single,se2); 
        outer=single3-single2; 
        ccouter = bwconncomp(outer,8); 
        outerstat=regionprops(ccouter,Icrop,'MeanIntensity'); 
        outerintens=[outerstat.MeanIntensity]; 
        outerintens2(i)=mean(outerintens); 
        ratio(1,i)=mean(outerintens); 
        ratio(2,i)=lumenintens(i); 
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        ratio(3,i)=mean(outerintens)/lumenintens(i); 
        if mean(outerintens)/lumenintens(i)<2 %this number can be 
edited to fit the image set 
            lumens2(lumenlabel==i)=0; 
        else 
            outer2=zeros(size(outer)); 
            for j=1:(m1/2-1)*(n1/2-1) 
                if outer(j)==1 
                    outer2(j)=ccxlabel(j); 
                end 
            end 
            uniq=unique(outer2); 
            [s1,s2]=size(uniq); 
            ratio(4,i)=s1; 
%             if s1>3 
%                 lumens2(lumenlabel==i)=0; 
%             end 
        end 
        outerlabel=labelmatrix(ccouter); 
%         figure,imshow(label2rgb(outerlabel)) 
    end 
  
    figure,imshow(lumens2) 
    choice=menu('Options','Subtract Region','Done'); 
    while choice~=3 
        switch choice 
            case 1 
                title('After zooming, press any key. Then draw a 
polygon around the area you want to remove') 
                lumens2=subtractregion(lumens2); 
                imshow(lumens2) 
            case 2 
                break 
        end 
        choice=menu('Options','Subtract Region','Done'); 
    end 
       
%This step calculates properties of the true lumens (those identified 
by 
%the previous step). 
    stats=regionprops(lumens2,'Area'); 
    numlumens=length([stats.Area]); %Number of lumens in the image 
    numlumensper=numlumens/sectionarea/scale^2*1e6; %Number of lumens 
per mm^2 
    avglumenarea=mean([stats.Area])*scale^2; %units=um^2; Average area 
of a lumen 
    totlumenarea=sum([stats.Area])/sectionarea; %Lumen area as a 
fraction of the area of the sec 
  
    biglumens2=bwareaopen(lumens2,200,8); %only large lumens are used 
here because they are the most important 
    stats=regionprops(biglumens2,'Eccentricity','MajorAxisLength'); 
    ecc=mean([stats.Eccentricity]); %Eccentricity - a measure of how 
round the lumen is (scale from 0 to 1 where 0 is a circle and 1 is a 
line segment) 
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    mal=mean([stats.MajorAxisLength])*scale; % Major Axis Length - a 
measure of the lumen length 
  
%This step fills in all lumens and calculates the anisotropy index for 
each 
%structure identified. The anisotropy index is calculated based on the  
% average angle of the structures. This is meant for use with 
longitudinal  
% sections of aligned tissues. 
    filledx2=lumens2|bwx3; 
    filledx3=imfill(filledx2,'holes'); 
    stats2=regionprops(filledx3,'MajorAxisLength','Orientation'); 
    a={stats2.Orientation}; 
    p={stats2.MajorAxisLength}; 
    a2=cell2mat(a); 
    p2=cell2mat(p); 
    for i=1:length(a2) 
        if a2(i)<0 
            a2(i)=a2(i)+180; 
        end 
    end 
    avga=ones(1,length(a2)).*mean(a2); 
    AIx=p2.*abs(cos(deg2rad(a2-avga))); 
    AIy=p2.*abs(sin(deg2rad(a2-avga))); 
    AI=sum(AIx)/sum(AIy); %Anisotropy Index 
  
%This step calculates how much of the structures are lumenized. 
    ccfilled=bwconncomp(filledx3,8); 
    filledlabel=labelmatrix(ccfilled); 
    count1=0; 
    count2=0; 
    areacount1=0; 
    filledx4=zeros(size(filledx3)); 
    filledx5=zeros(size(filledx3)); 
    filledarea=zeros(1,ccfilled.NumObjects); 
    [m2,n2]=size(filledx3); 
    for i=1:ccfilled.NumObjects 
        for j=1:m2 
            for l=1:n2 
                if filledlabel(j,l)==i && biglumens2(j,l)==1 
                    count1=count1+1; 
                    count2=count2+1; 
                elseif filledlabel(j,l)==i && lumens2(j,l)==1 
                    count1=count1+1; 
                end 
                if filledlabel(j,l)==i 
                    areacount1=areacount1+1; 
                end 
            end 
        end 
        if count1>0 
            filledx4(filledlabel==i)=1; 
            filledarea(i)=count1/areacount1; 
        end 
        if count2>0 
            filledx5(filledlabel==i)=1; 
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        end 
        count1=0; 
        count2=0; 
        areacount1=0; 
    end 
    filledx4=logical(filledx4); 
    filledx5=logical(filledx5); 
    ccfilled2=bwconncomp(filledx4,8); 
    fractionnumlumen=ccfilled2.NumObjects/ccfilled.NumObjects; 
%Fraction of structures that contain lumens. 
    lumenareapercentavgper=mean(filledarea); %average percentage of 
each structure filled with lumens 
    lumenareapercent=sum(sum(lumens2))/sum(sum(filledx4)); %area 
percentage of structures that are lumens (only includes structures that 
are lumenized) 
    stats3=regionprops(filledx5,'MajorAxisLength'); 
    
lengthlumenized=sum([stats.MajorAxisLength])/sum([stats3.MajorAxisLengt
h]); %fraction of structure length covered with lumens (only includes 
lumenized structures) 
     
%This step thresholds the pericyte image. 
    rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in lower left and green in top right 
%     rectPC=[0 0 n1/2-1 m1/2-1]; 
        %for images with red in top right and green in top left 
    IcropPC=imcrop(I,rectPC); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelPC = graythresh(IcropPC); 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    ccPC = bwconncomp(bw3PC,8); 
    [m3,n3]=size(bw3PC); 
  
%This step determines the level of PCs. 
    totalPC=sum(sum(bw3PC))*scale^2; %units=um^2 
    fractionofsectionwithPC=sum(sum(bw3PC))/sectionarea; %Fraction of 
the section with positive PC staining 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
     
%This step takes the intersection of the CD31 image and the pericyte 
image. 
%Those pericytes that overlap ECs are considered recruited. 
%Those pericytes that have 50% of their area overlapping with ECs are 
%considered fully recruited. 
    intersection=bwx3&bw3PC; 
    labelPC=labelmatrix(ccPC); 
    count=0; 
    areacount=0; 
    bw3PC_2=zeros(size(bw3PC)); 
    bw3PC_3=zeros(size(bw3PC)); 
    PCarea=zeros(1,ccPC.NumObjects); 
    for i=1:ccPC.NumObjects 
        for j=1:m3 
            for l=1:n3 
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                if labelPC(j,l)==i && intersection(j,l)==1 
                    count=count+1; 
                end 
                if labelPC(j,l)==i 
                    areacount=areacount+1; 
                end 
            end 
        end 
        if count>0 
            bw3PC_2(labelPC==i)=1; 
            PCarea(i)=count/areacount; 
        end 
        if count/areacount>0.5 
            bw3PC_3(labelPC==i)=1; 
        end 
        count=0; 
        areacount=0; 
    end 
    ccint=bwconncomp(bw3PC_2,8); 
    fractionrecruitedPCs=ccint.NumObjects/ccPC.NumObjects; %Fraction of 
perictyes that have been recruited. 
    ccint2=bwconncomp(bw3PC_3,8); 
    fracfullyrecruitedPCs=ccint2.NumObjects/ccPC.NumObjects; %Fraction 
of perictyes that have been fully recruited. 
  
%This step thresholds the DAPI image and counts the nuclei 
    rect=[0 0 n1/2-1 m1/2-1]; 
    IcropDAPI=imcrop(I,rect); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelDAPI = graythresh(IcropDAPI); 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    fractionofsectionwithDAPI=sum(sum(bw3DAPI))/sectionarea; %Fraction 
of the section with positive DAPI staining 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
  
%The data is collected into the result matrix and output to an excel 
file. 
    result(k-initial+1,1)=k; 
    result(k-initial+1,2)=sectionarea; 
    result(k-initial+1,3)=totalCD31; 
    result(k-initial+1,4)=fractionofsectionwithCD31; 
    result(k-initial+1,5)=numlumens; 
    result(k-initial+1,6)=numlumensper; 
    result(k-initial+1,7)=avglumenarea; 
    result(k-initial+1,8)=totlumenarea; 
    result(k-initial+1,9)=numberofstructures; 
    result(k-initial+1,10)=fractionnumlumen; 
    result(k-initial+1,11)=lumenareapercentavgper; 
    result(k-initial+1,12)=lumenareapercent; 
    result(k-initial+1,13)=lengthlumenized; 
    result(k-initial+1,14)=numPC; 
    result(k-initial+1,15)=fractionofsectionwithPC; 
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    result(k-initial+1,16)=fractionrecruitedPCs; 
    result(k-initial+1,17)=fracfullyrecruitedPCs; 
    result(k-initial+1,18)=mean(PCarea(PCarea~=0)); %Area Fraction of 
recruited PC overlapping with structure 
    result(k-initial+1,19)=numDAPI; 
    result(k-initial+1,20)=fractionofsectionwithDAPI; 
    result(k-initial+1,21)=AI; 
    result(k-initial+1,22)=ecc; 
    result(k-initial+1,23)=mal; 
    k 
  
imwrite(lumens2,sprintf(fname2,k)) 
close all 
end 
  
xlswrite('Result.xlsx',result); 
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B.3 CD31frombw.m 
%This script analyzes images of sections of gels containing ECs and 
pericytes  
%stained for CD31. It outputs data on endothelial structures, lumens, 
and  
%pericyte recruitment. 
  
%This file is written for images taken on the LHI confocal, which 
outputs 
%images that contain each channel separately along with a merged image. 
  
%Prior to running the code, run the file ECM start. This adds search 
paths 
%so you will be able to run this code while in the folder containing 
your 
%images. 
  
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
final=n+initial-1; 
result=zeros(n,28); 
  
fname='Image%02d.tif'; 
fname2='Image%02d_2.tif'; 
for k=initial:final 
if exist(sprintf(fname2,k),'file')==0 
    continue 
end 
    I=imread(sprintf(fname,k)); 
    I=rgb2gray(I); 
    [m1,n1]=size(I); 
    rect=[0 m1/2+1 n1/2-1 m1/2-1]; 
        %for images with red in lower left, green in top right 
%     rect=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in top right, green in top left 
    Icrop=imcrop(I,rect); 
     
    [m2,n2]=size(Icrop); 
    sectionarea=m2*n2; 
     
    I2b=imadjust(Icrop); 
    level = graythresh(I2b); 
    bwx = im2bw(I2b,level); 
    filledx = imfill(bwx,4,'holes'); 
    holesx = filledx & ~bwx; 
    bigholesx = bwareaopen(holesx,5); 
    smallholesx = holesx & ~bigholesx; 
    bwx2 = bwx|smallholesx; 
    bwx3 = bwareaopen(bwx2,20,8); 
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    lumens=imread(sprintf(fname2,k)); 
    lumensclass=isa(lumens,'logical'); 
    if lumensclass==1 
        lumens2=lumens; 
    else 
        level=graythresh(lumens); 
        lumens2=im2bw(lumens,level); 
    end 
     
%This step calculates properties of the true lumens (those identified 
by 
%the previous step). 
    stats=regionprops(lumens2,'Area'); 
    numlumens=length([stats.Area]); %Number of lumens in the image 
    numlumensper=numlumens/sectionarea/scale^2*1e6; %Number of lumens 
per mm^2 
    avglumenarea=mean([stats.Area])*scale^2; %units=um^2; Average area 
of a lumen 
    totlumenarea=sum([stats.Area])/sectionarea; %Lumen area as a 
fraction of the area of the sec 
  
    biglumens2=bwareaopen(lumens2,200,8); %only large lumens are used 
here because they are the most important 
    stats=regionprops(biglumens2,'Eccentricity','MajorAxisLength'); 
    ecc=mean([stats.Eccentricity]); %Eccentricity - a measure of how 
round the lumen is (scale from 0 to 1 where 0 is a circle and 1 is a 
line segment) 
    mal=mean([stats.MajorAxisLength])*scale; % Major Axis Length - a 
measure of the lumen length 
  
    count3=0; 
    count4=0; 
    count5=0; 
    MAL=[stats.MajorAxisLength]; 
    for i=1:length(MAL) 
        if MAL(i)*scale>200 
            count3=count3+1; 
            count4=count4+1; 
            count5=count5+1; 
        elseif MAL(i)*scale>150 
            count3=count3+1; 
            count4=count4+1; 
        elseif MAL(i)*scale>100 
            count3=count3+1; 
        end 
    end 
           
%This step fills in all lumens and calculates the anisotropy index for 
each 
%structure identified. The anisotropy index is calculated based on the  
% average angle of the structures. This is meant for use with 
longitudinal  
% sections of aligned tissues. 
    filledx2=lumens2|bwx3; 
    filledx3=imfill(filledx2,'holes'); 
    stats2=regionprops(filledx3,'MajorAxisLength','Orientation'); 
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    a={stats2.Orientation}; 
    p={stats2.MajorAxisLength}; 
    a2=cell2mat(a); 
    p2=cell2mat(p); 
    for i=1:length(a2) 
        if a2(i)<0 
            a2(i)=a2(i)+180; 
        end 
    end 
    avga=ones(1,length(a2)).*mean(a2); 
    AIx=p2.*abs(cos(deg2rad(a2-avga))); 
    AIy=p2.*abs(sin(deg2rad(a2-avga))); 
    AI=sum(AIx)/sum(AIy); %Anisotropy Index 
  
%This step calculates how much of the structures are lumenized. 
    ccfilled=bwconncomp(filledx3,8); 
    filledlabel=labelmatrix(ccfilled); 
    count1=0; 
    count2=0; 
    areacount1=0; 
    filledx4=zeros(size(filledx3)); 
    filledx5=zeros(size(filledx3)); 
    filledarea=zeros(1,ccfilled.NumObjects); 
    [m2,n2]=size(filledx3); 
    for i=1:ccfilled.NumObjects 
        for j=1:m2 
            for l=1:n2 
                if filledlabel(j,l)==i && biglumens2(j,l)==1 
                    count1=count1+1; 
                    count2=count2+1; 
                elseif filledlabel(j,l)==i && lumens2(j,l)==1 
                    count1=count1+1; 
                end 
                if filledlabel(j,l)==i 
                    areacount1=areacount1+1; 
                end 
            end 
        end 
        if count1>0 
            filledx4(filledlabel==i)=1; 
            filledarea(i)=count1/areacount1; 
        end 
        if count2>0 
            filledx5(filledlabel==i)=1; 
        end 
        count1=0; 
        count2=0; 
        areacount1=0; 
    end 
    filledx4=logical(filledx4); 
    filledx5=logical(filledx5); 
    ccfilled2=bwconncomp(filledx4,8); 
    fractionnumlumen=ccfilled2.NumObjects/ccfilled.NumObjects; 
%Fraction of structures that contain lumens. 
    lumenareapercentavgper=mean(filledarea); %average percentage of 
each structure filled with lumens 
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    lumenareapercent=sum(sum(lumens2))/sum(sum(filledx4)); %area 
percentage of structures that are lumens (only includes structures that 
are lumenized) 
    stats3=regionprops(filledx5,'MajorAxisLength'); 
    
lengthlumenized=sum([stats.MajorAxisLength])/sum([stats3.MajorAxisLengt
h]); %fraction of structure length covered with lumens (only includes 
lumenized structures) 
     
%The data is collected into the result matrix and output to an excel 
file. 
    result(k-initial+1,1)=k; 
    result(k-initial+1,2)=sectionarea; 
    result(k-initial+1,5)=numlumens; 
    result(k-initial+1,6)=numlumensper; 
    result(k-initial+1,7)=avglumenarea; 
    result(k-initial+1,8)=totlumenarea; 
    result(k-initial+1,10)=fractionnumlumen; 
    result(k-initial+1,11)=lumenareapercentavgper; 
    result(k-initial+1,12)=lumenareapercent; 
    result(k-initial+1,13)=lengthlumenized; 
    result(k-initial+1,21)=AI; 
    result(k-initial+1,22)=ecc; 
    result(k-initial+1,23)=mal; 
    k 
end 
  
xlswrite('Result.xlsx',result); 
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B.4 BasementMembrane.m 
%This file is written for images taken on the LHI confocal, which 
outputs 
%images that contain each channel separately along with a merged image. 
  
%Prior to running the code, run the file ECM start. This adds search 
paths 
%so you will be able to run this code while in the folder containing 
your 
%images. 
  
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
inputlevel=input('What threshold would you like to use? '); 
level=inputlevel/255; 
final=n+initial-1; 
result=zeros(n,5); 
  
fname='Image%02d.tif'; 
fname2='Image%02d_2.tif'; 
for i=initial:final 
    I=imread(sprintf(fname,i)); 
    I=rgb2gray(I); 
  
    [m1,n1]=size(I); 
    rect=[0 m1/2+1 n1/2-1 m1/2-1]; 
        %for images with red in lower left, green in top right 
%     rect=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in top right, green in top left 
    Icrop=imcrop(I,rect); 
% %%%%%use the code below if you have separate image files for each 
channel. 
% fname='Image%04d_C003.tif'; 
% fname2='Image%04d_C002.tif'; 
% for k=initial:final 
%     I=imread(sprintf(fname,k)); 
%     Icrop=rgb2gray(I); 
  
    [m2,n2]=size(Icrop); 
    sectionarea=m2*n2; %Area of the image 
         
    imsum=sum(sum(Icrop))/sectionarea/scale^2*1e6; 
    BWim=im2bw(Icrop,level); 
    cc=bwconncomp(BWim,8); 
    numabove=cc.NumObjects; 
     
    stats=regionprops(BWim,Icrop,'MeanIntensity'); 
    avgabove=mean([stats.MeanIntensity]); 
     
    %This step thresholds the PC image and counts the cells 
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    rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
    IcropPC=imcrop(I,rectPC); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelPC = graythresh(IcropPC); 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    ccPC = bwconncomp(bw3PC,8); 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
     
    %This step thresholds the DAPI image and counts the nuclei 
    rectDAPI=[0 0 n1/2-1 m1/2-1]; 
    IcropDAPI=imcrop(I,rectDAPI); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelDAPI = graythresh(IcropDAPI); 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
       
    imsumperDAPI=imsum/numDAPI; 
    avgaboveperDAPI=avgabove/numDAPI; 
     
    result(i-initial+1,1)=i; 
    result(i-initial+1,2)=sectionarea; 
    result(i-initial+1,3)=imsum; 
    result(i-initial+1,4)=numabove; 
    result(i-initial+1,5)=numPC; 
    result(i-initial+1,6)=avgabove; 
    result(i-initial+1,7)=numDAPI; 
    result(i-initial+1,8)=imsumperDAPI; 
    result(i-initial+1,9)=avgaboveperDAPI; 
end 
close 
  
xlswrite('Result.xlsx',result); 
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B.5 ephrin.m 
%This file is written for images taken on the LHI confocal, which 
outputs 
%images that contain each channel separately along with a merged image. 
  
%Prior to running the code, run the file ECM start. This adds search 
paths 
%so you will be able to run this code while in the folder containing 
your 
%images. 
  
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
inputlevel=input('What threshold would you like to use? '); 
level=inputlevel/255; 
final=n+initial-1; 
result=zeros(n,20); 
  
fname='Image%03d.tif'; 
fname2='Image%03d_2.tif'; 
for i=initial:final 
    I=imread(sprintf(fname,i)); 
    I=rgb2gray(I); 
  
    [m1,n1]=size(I); 
    rect=[0 m1/2+1 n1/2-1 m1/2-1]; 
        %for images with red in lower left, green in top right 
%     rect=[n1/2+1 0 n1/2-1 m1/2-1]; 
        %for images with red in top right, green in top left 
    Icrop=imcrop(I,rect); 
% %%%%%use the code below if you have separate image files for each 
channel. 
% fname='Image%04d_C003.tif'; 
% fname2='Image%04d_C002.tif'; 
% for k=initial:final 
%     I=imread(sprintf(fname,k)); 
%     Icrop=rgb2gray(I); 
  
    [m2,n2]=size(Icrop); 
    sectionarea=m2*n2; %Area of the image 
         
    imsum=sum(sum(Icrop))/sectionarea/scale^2*1e6; 
    BWim=im2bw(Icrop,level); 
    cc=bwconncomp(BWim,8); 
    numabove=cc.NumObjects; 
     
    stats=regionprops(BWim,Icrop,'MeanIntensity'); 
    avgabove=mean([stats.MeanIntensity]); 
     
    %This step thresholds the DAPI image and counts the nuclei 
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    rectDAPI=[0 0 n1/2-1 m1/2-1]; 
    IcropDAPI=imcrop(I,rectDAPI); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelDAPI = graythresh(IcropDAPI); 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
       
    imsumperDAPI=imsum/numDAPI; 
    avgaboveperDAPI=avgabove/numDAPI; 
     
    %This step thresholds the PC image and counts the cells 
    rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
    IcropPC=imcrop(I,rectPC); 
%     rectPC=imread(sprintf(fname2,k)); 
%     IcropPC=rgb2gray(rectPC); 
    levelPC = graythresh(IcropPC)*4; 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    intPC=bw3PC&bw3DAPI; 
    ccPC = bwconncomp(intPC,8); 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
     
    ephPC=Icrop.*(uint8(bw3PC)); 
    imsumPC=sum(sum(ephPC))/sectionarea/scale^2*1e6; 
    BWimPC=im2bw(ephPC,level); 
    ccPC=bwconncomp(BWimPC,8); 
    numabovePC=ccPC.NumObjects; 
     
    statsPC=regionprops(BWimPC,Icrop,'MeanIntensity'); 
    avgabovePC=mean([statsPC.MeanIntensity]); 
    imsumPCperPC=imsumPC/numPC; 
    avgabovePCperPC=avgabovePC/numPC; 
     
    numEC=numDAPI-numPC; 
     
    ephEC=Icrop.*(uint8(~bw3PC)); 
    imsumEC=sum(sum(ephEC))/sectionarea/scale^2*1e6; 
    BWimEC=im2bw(ephEC,level); 
    ccEC=bwconncomp(BWimEC,8); 
    numaboveEC=ccEC.NumObjects; 
     
    statsEC=regionprops(BWimEC,Icrop,'MeanIntensity'); 
    avgaboveEC=mean([statsEC.MeanIntensity]); 
    imsumECperEC=imsumEC/numEC; 
    avgaboveECperEC=avgaboveEC/numEC; 
     
    result(i-initial+1,1)=i 
    result(i-initial+1,2)=sectionarea; 
    result(i-initial+1,3)=imsum; 
    result(i-initial+1,4)=numabove; 
    result(i-initial+1,5)=avgabove; 
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    result(i-initial+1,6)=numDAPI; 
    result(i-initial+1,7)=imsumperDAPI; 
    result(i-initial+1,8)=avgaboveperDAPI; 
    result(i-initial+1,9)=imsumPC; 
    result(i-initial+1,10)=numabovePC; 
    result(i-initial+1,11)=avgabovePC; 
    result(i-initial+1,12)=numPC; 
    result(i-initial+1,13)=imsumPCperPC; 
    result(i-initial+1,14)=avgabovePCperPC; 
    result(i-initial+1,15)=imsumEC; 
    result(i-initial+1,16)=numaboveEC; 
    result(i-initial+1,17)=avgaboveEC; 
    result(i-initial+1,18)=numEC; 
    result(i-initial+1,19)=imsumECperEC; 
    result(i-initial+1,20)=avgaboveECperEC; 
end 
close 
  
xlswrite('Result.xlsx',result); 
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B.6 QuantifyingGrowthofVessels.m 
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
final=n+initial-1; 
result=zeros(n,17); 
  
fname='MD-Experiment-%04d_c3.tif'; 
fname2='MD-Experiment-%04d_c4.tif'; 
fname3='MD-Experiment-%04d_c5.tif'; 
for k=initial:final 
%CONVERTING IMAGE TO A BLACK AND WHITE IMAGE 
I=imread(sprintf(fname,k)); 
I=rgb2gray(I);  %converts image into a grayscale image 
Icrop=I; 
[m1,n1]=size(Icrop); 
sectionarea=m1*n1; 
se=strel('disk',5); %used to dilate image 
se2=strel('disk',2); %used to dilate image 
I2a=imdilate(Icrop,se); %dilates the original grayscale image 
I2=imerode(I2a,se2); %erodes the dilated image  
I3 = imadjust(I2);   %Increases the contrast of the image  
level = graythresh(I3)*.9;   %automatically determines threshold for 
creating binary image  
% % lowering the threshold level slightly ensures that all structures 
are included; the automatic thresholding consistently excludes some 
structures 
bw = im2bw(I3,level);  %converts grayscale image to binary image (using 
determined threshold)   
bw2 = bwareaopen(bw,50,8);   %removes any continuous structure smaller 
than 300 pixels in area 
bwx2=bwareaopen(bw2,500,8); 
cc = bwconncomp(bwx2,8);   %function bwconncomp finds all connected 
components from binary image (8=connectivity parameter) 
NUMBEROFCONTINUOUSSTRUCTURES=cc.NumObjects/sectionarea/scale^2*1e6;   
%gives the number of distinct objects from the previous command <--I 
think this is the best determination of the total # of structures 
labeled = labelmatrix(cc);   %labelmatrix allows you to vizualize 
connected components 
whos labeled; %identifies the  labeled structures 
RGB_label = label2rgb(labeled, @spring, 'c', 'shuffle'); %arbitrarily 
assigns a color to each structure 
CD31=sum(sum(bw2))/sectionarea*scale^2*1e6; %total area CD31 per mm2 
  
  
%LOCATING STRUCTURES 
bw3=bwmorph(bw2,'fill',Inf); %fills in any holes in the structures 
resulting from the thresholding process 
bw4=bwmorph(bw3,'thin',Inf);%thins objects to lines 
bw5=bw4; %creates a copy of the original image bw4 
juncs=findjunctions(bw4); %finds junctions from the thinned image (bw4) 
269 
 
juncs2=imdilate(juncs,se2); %dilates the junction points found by 
'juncs' 
  
for i=1:m1 
    for j=1:n1 
        if bw4(i,j)==1 && juncs2(i,j)==1 
        bw4(i,j)=0; 
        end 
    end 
end 
%for each matching point in image 'bw4' (thinned image) and 'juncs2' 
(dilated junction points), this deletes that point in 'bw4'-->separates 
structures 
  
bw4b=bwareaopen(bw4,20); %removes any structures from image 'bw4' that 
are less than 20 pixels in length (purpose is to remove small segments 
that aren't actually structures) 
cc2=bwconncomp(bw4b,8); 
NUMBEROFSEGMENTS=cc2.NumObjects/sectionarea/scale^2*1e6; %this is the 
number of individual segments (NOT continuous structures) 
bw6=bw5-bw4b; %this image is the original thinned image (bw5) minus the 
structures that we want to include (bw4b)-->results in an image of the 
segments we DON'T want to include 
bw7a=bw5-bw6; %this is the structures we want to include in the image 
(w/ junctions) 
bw7b=bwmorph(bw7a,'thin',Inf); %removes any segments thicker than 1 
pixel resulting from including "juncs2" 
bw7=bwareaopen(bw7b,20); 
% figure, imshow(bw7); 
juncs3=juncs-juncs; %just a black image 
  
endpoint=findendpoints(bw7); 
endpoint2=imdilate(endpoint,se2); 
for i=1:m1 
   for j=1:n1 
        if endpoint2(i,j)==1 && juncs2(i,j)==1 
            juncs3(i,j)=1; 
       end 
    end 
end     
%this determines which of the original junctions are actually junctions 
in the final image (which junction points are in the final image bw7) 
  
  
  
%CALCULATING PARAMETERS OF INTEREST 
cc3=bwconncomp(juncs3,8); 
NUMBEROFJUNCTIONS=cc3.NumObjects/sectionarea/scale^2*1e6; 
bw8 = bwconncomp(bw7,8);   %function bwconncomp finds all connected 
components from binary image (8=connectivity parameter) 
stats=regionprops(bw8,'orientation','Area'); %gives stats for each 
identified structure 
TOTALVESSELLENGTH=sum(sum(bw7))/sectionarea/scale^2*1e6; %total vessel 
length is just the area of the thinned image bw7 
AVERAGEVESSELLENGTHcontinuousstructures=TOTALVESSELLENGTH/NUMBEROFCONTI
NUOUSSTRUCTURES; %this is the average length of CONTINUOUS structures 
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AVERAGEVESSELLENGTHsegments=TOTALVESSELLENGTH/NUMBEROFSEGMENTS; %this 
is the average length of the small segments 
AVERAGEDIAMETER=sum(sum(bw3))/sum(sum(bw7)); %this is the total area 
divided by total vessel length 
a={stats.Orientation}; 
p={stats.Area}; 
a2=cell2mat(a); 
p2=cell2mat(p); 
for i=1:length(a2) 
    if a2(i)<0 
        a2(i)=a2(i)+180; 
    end 
end 
avga=ones(1,length(a2)).*mean(a2); 
AIx=p2.*abs(cos(deg2rad(a2-avga))); 
AIy=p2.*abs(sin(deg2rad(a2-avga))); 
AI=sum(AIx)/sum(AIy); %Anisotropy Index 
  
%overlay structures on original image 
bw10=imdilate(bw7,se2); 
Ia=imadjust(Icrop); 
for i=1:m1; 
    for j=1:n1; 
        if bw10(i,j)==1; 
            Ia(i,j)=0; 
        end; 
    end; 
end; 
  
%This step thresholds the pericyte image. 
%     rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
%         %for images with red in lower left and green in top right 
% %     rectPC=[0 0 n1/2-1 m1/2-1]; 
%         %for images with red in top right and green in top left 
%     IcropPC=imcrop(I,rectPC); 
    rectPC=imread(sprintf(fname2,k)); 
    IcropPC=rgb2gray(rectPC); 
    levelPC = graythresh(IcropPC)*2; 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    ccPC = bwconncomp(bw3PC,8); 
    [m3,n3]=size(bw3PC); 
  
%This step determines the level of PCs. 
    totalPC=sum(sum(bw3PC))*scale^2; %units=um^2 
    fractionofsectionwithPC=sum(sum(bw3PC))/sectionarea; %Fraction of 
the section with positive PC staining 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
  
%This step takes the intersection of the CD31 image and the pericyte 
image. 
%Those pericytes that overlap ECs are considered recruited. 
%Those pericytes that have 50% of their area overlapping with ECs are 
%considered fully recruited. 
    intersection=bw2&bw3PC; 
    labelPC=labelmatrix(ccPC); 
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    count=0; 
    areacount=0; 
    bw3PC_2=zeros(size(bw3PC)); 
    bw3PC_3=zeros(size(bw3PC)); 
    PCarea=zeros(1,ccPC.NumObjects); 
    for i=1:ccPC.NumObjects 
        for j=1:m3 
            for l=1:n3 
                if labelPC(j,l)==i && intersection(j,l)==1 
                    count=count+1; 
                end 
                if labelPC(j,l)==i 
                    areacount=areacount+1; 
                end 
            end 
        end 
        if count>0 
            bw3PC_2(labelPC==i)=1; 
            PCarea(i)=count/areacount; 
        end 
        if count/areacount>0.5 
            bw3PC_3(labelPC==i)=1; 
        end 
%         count 
%         areacount 
        count=0; 
        areacount=0; 
    end 
    ccint=bwconncomp(bw3PC_2,8); 
    fractionrecruitedPCs=ccint.NumObjects/ccPC.NumObjects; %Fraction of 
perictyes that have been recruited. 
    ccint2=bwconncomp(bw3PC_3,8); 
    fracfullyrecruitedPCs=ccint2.NumObjects/ccPC.NumObjects; %Fraction 
of perictyes that have been fully recruited. 
  
%This step thresholds the DAPI image and counts the nuclei 
%     rect=[0 0 n1/2-1 m1/2-1]; 
%     IcropDAPI=imcrop(I,rect); 
    rectDAPI=imread(sprintf(fname3,k)); 
    IcropDAPI=rgb2gray(rectDAPI); 
    levelDAPI = graythresh(IcropDAPI)*2; 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    fractionofsectionwithDAPI=sum(sum(bw3DAPI))/sectionarea; %Fraction 
of the section with positive DAPI staining 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
  
figure,imshow(bwx2) 
figure,imshow(Ia) 
     
result(k-initial+1,1)=k; 
result(k-initial+1,2)=sectionarea; 
result(k-initial+1,3)=NUMBEROFCONTINUOUSSTRUCTURES; 
result(k-initial+1,4)=NUMBEROFSEGMENTS; 
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result(k-initial+1,5)=NUMBEROFJUNCTIONS; 
result(k-initial+1,6)=TOTALVESSELLENGTH*scale; 
result(k-initial+1,7)=AVERAGEVESSELLENGTHcontinuousstructures*scale; 
result(k-initial+1,8)=AVERAGEVESSELLENGTHsegments*scale; 
result(k-initial+1,9)=AVERAGEDIAMETER*scale; 
result(k-initial+1,10)=AI; 
result(k-initial+1,11)=fractionofsectionwithPC; 
result(k-initial+1,12)=numPC; 
result(k-initial+1,13)=fractionrecruitedPCs; 
result(k-initial+1,14)=fracfullyrecruitedPCs; 
result(k-initial+1,15)=fractionofsectionwithDAPI; 
result(k-initial+1,16)=numDAPI; 
result(k-initial+1,17)=CD31; 
k 
end 
  
xlswrite('Results.xlsx',result); 
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B.7 CropQuantifyingGrowthofVessels.m 
clear all 
  
n=input('How many images would you like to analyze? '); 
initial=input('What is the number of the first image? '); 
scale=input('What is the scale of the image? 1 pixel = __ um '); 
final=n+initial-1; 
result=zeros(n,17); 
  
fname='MD-Experiment-%04d_c3.tif'; 
fname2='MD-Experiment-%04d_c4.tif'; 
fname3='MD-Experiment-%04d_c5.tif'; 
for k=initial:final 
%CONVERTING IMAGE TO A BLACK AND WHITE IMAGE 
I=imread(sprintf(fname,k)); 
I=rgb2gray(I);  %converts image into a grayscale image 
imshow(imadjust(I)) 
takemeout=roipoly; 
takemeout=double(takemeout); 
Icrop=I; 
[m1,n1]=size(Icrop); 
sectionarea=sum(sum(takemeout)); 
se=strel('disk',5); %used to dilate image 
se2=strel('disk',2); %used to dilate image 
I2a=imdilate(Icrop,se); %dilates the original grayscale image 
I2=imerode(I2a,se2); %erodes the dilated image  
I3 = imadjust(I2);   %Increases the contrast of the image  
level = graythresh(I3)*.9;   %automatically determines threshold for 
creating binary image  
% % lowering the threshold level slightly ensures that all structures 
are included; the automatic thresholding consistently excludes some 
structures 
bw = im2bw(I3,level);  %converts grayscale image to binary image (using 
determined threshold)   
bw2 = bwareaopen(bw,50,8);   %removes any continuous structure smaller 
than 300 pixels in area 
bw2=croptopoly(bw2,takemeout); 
I4 = imadjust(Icrop);   %Increases the contrast of the image  
levelx = graythresh(I4)*1.4;   %automatically determines threshold for 
creating binary image  
bwx2=bwareaopen(bw2,500,8); 
cc=bwconncomp(bwx2,8); %function bwconncomp finds all connected 
components from binary image (8=connectivity parameter) 
NUMBEROFCONTINUOUSSTRUCTURES=cc.NumObjects/sectionarea/scale^2*1e6;   
%gives the number of distinct objects from the previous command <--I 
think this is the best determination of the total # of structures 
labeled = labelmatrix(cc);   %labelmatrix allows you to vizualize 
connected components 
whos labeled; %identifies the  labeled structures 
RGB_label = label2rgb(labeled, @spring, 'c', 'shuffle'); %arbitrarily 
assigns a color to each structure 
CD31=sum(sum(bw2))/sectionarea*scale^2*1e6; %total area CD31 per mm2 
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%LOCATING STRUCTURES 
bw3=bwmorph(bw2,'fill',Inf); %fills in any holes in the structures 
resulting from the thresholding process 
bw4=bwmorph(bw3,'thin',Inf);%thins objects to lines 
bw5=bw4; %creates a copy of the original image bw4 
juncs=findjunctions(bw4); %finds junctions from the thinned image (bw4) 
juncs2=imdilate(juncs,se2); %dilates the junction points found by 
'juncs' 
  
for i=1:m1 
    for j=1:n1 
        if bw4(i,j)==1 && juncs2(i,j)==1 
        bw4(i,j)=0; 
        end 
    end 
end 
%for each matching point in image 'bw4' (thinned image) and 'juncs2' 
(dilated junction points), this deletes that point in 'bw4'-->separates 
structures 
  
bw4b=bwareaopen(bw4,20); %removes any structures from image 'bw4' that 
are less than 20 pixels in length (purpose is to remove small segments 
that aren't actually structures) 
cc2=bwconncomp(bw4b,8); 
NUMBEROFSEGMENTS=cc2.NumObjects/sectionarea/scale^2*1e6; %this is the 
number of individual segments (NOT continuous structures) 
bw6=bw5-bw4b; %this image is the original thinned image (bw5) minus the 
structures that we want to include (bw4b)-->results in an image of the 
segments we DON'T want to include 
bw7a=bw5-bw6; %this is the structures we want to include in the image 
(w/ junctions) 
bw7b=bwmorph(bw7a,'thin',Inf); %removes any segments thicker than 1 
pixel resulting from including "juncs2" 
bw7=bwareaopen(bw7b,20); 
% figure, imshow(bw7); 
juncs3=juncs-juncs; %just a black image 
  
endpoint=findendpoints(bw7); 
endpoint2=imdilate(endpoint,se2); 
for i=1:m1 
   for j=1:n1 
        if endpoint2(i,j)==1 && juncs2(i,j)==1 
            juncs3(i,j)=1; 
       end 
    end 
end     
%this determines which of the original junctions are actually junctions 
in the final image (which junction points are in the final image bw7) 
  
  
  
%CALCULATING PARAMETERS OF INTEREST 
cc3=bwconncomp(juncs3,8); 
NUMBEROFJUNCTIONS=cc3.NumObjects/sectionarea/scale^2*1e6; 
bw8 = bwconncomp(bw7,8);   %function bwconncomp finds all connected 
components from binary image (8=connectivity parameter) 
275 
 
stats=regionprops(bw8,'orientation','Area'); %gives stats for each 
identified structure 
TOTALVESSELLENGTH=sum(sum(bw7))/sectionarea/scale^2*1e6; %total vessel 
length is just the area of the thinned image bw7 
AVERAGEVESSELLENGTHcontinuousstructures=TOTALVESSELLENGTH/NUMBEROFCONTI
NUOUSSTRUCTURES; %this is the average length of CONTINUOUS structures 
AVERAGEVESSELLENGTHsegments=TOTALVESSELLENGTH/NUMBEROFSEGMENTS; %this 
is the average length of the small segments 
AVERAGEDIAMETER=sum(sum(bw3))/sum(sum(bw7)); %this is the total area 
divided by total vessel length 
a={stats.Orientation}; 
p={stats.Area}; 
a2=cell2mat(a); 
p2=cell2mat(p); 
for i=1:length(a2) 
    if a2(i)<0 
        a2(i)=a2(i)+180; 
    end 
end 
avga=ones(1,length(a2)).*mean(a2); 
AIx=p2.*abs(cos(deg2rad(a2-avga))); 
AIy=p2.*abs(sin(deg2rad(a2-avga))); 
AI=sum(AIx)/sum(AIy); %Anisotropy Index 
  
%overlay structures on original image 
bw10=imdilate(bw7,se2); 
Ia=imadjust(Icrop); 
for i=1:m1; 
    for j=1:n1; 
        if bw10(i,j)==1; 
            Ia(i,j)=0; 
        end; 
    end; 
end; 
  
%This step thresholds the pericyte image. 
%     rectPC=[n1/2+1 0 n1/2-1 m1/2-1]; 
%         %for images with red in lower left and green in top right 
% %     rectPC=[0 0 n1/2-1 m1/2-1]; 
%         %for images with red in top right and green in top left 
%     IcropPC=imcrop(I,rectPC); 
    rectPC=imread(sprintf(fname2,k)); 
    IPC=rgb2gray(rectPC); 
    IcropPC=IPC; 
    levelPC = graythresh(IcropPC)*2; 
    bwPC = im2bw(IcropPC,levelPC); 
    bw3PC = bwareaopen(bwPC,10,8); 
    bw3PC=croptopoly(bw3PC,takemeout); 
    ccPC = bwconncomp(bw3PC,8); 
    [m3,n3]=size(bw3PC); 
  
%This step determines the level of PCs. 
    totalPC=sum(sum(bw3PC))*scale^2; %units=um^2 
    fractionofsectionwithPC=sum(sum(bw3PC))/sectionarea; %Fraction of 
the section with positive PC staining 
    numPC=ccPC.NumObjects/sectionarea/scale^2*1e6; %number PC per mm^2 
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%     intersection=bwx3&bw3PC; 
%     intersection2=bwareaopen(intersection,5); 
%     ccint=bwconncomp(intersection2,8); 
%     fractionrecruitedPCs=ccint.NumObjects/ccPC.NumObjects; 
  
%This step takes the intersection of the CD31 image and the pericyte 
image. 
%Those pericytes that overlap ECs are considered recruited. 
%Those pericytes that have 50% of their area overlapping with ECs are 
%considered fully recruited. 
    intersection=bw2&bw3PC; 
    labelPC=labelmatrix(ccPC); 
    count=0; 
    areacount=0; 
    bw3PC_2=zeros(size(bw3PC)); 
    bw3PC_3=zeros(size(bw3PC)); 
    PCarea=zeros(1,ccPC.NumObjects); 
    for i=1:ccPC.NumObjects 
        for j=1:m3 
            for l=1:n3 
                if labelPC(j,l)==i && intersection(j,l)==1 
                    count=count+1; 
                end 
                if labelPC(j,l)==i 
                    areacount=areacount+1; 
                end 
            end 
        end 
        if count>0 
            bw3PC_2(labelPC==i)=1; 
            PCarea(i)=count/areacount; 
        end 
        if count/areacount>0.5 
            bw3PC_3(labelPC==i)=1; 
        end 
%         count 
%         areacount 
        count=0; 
        areacount=0; 
    end 
    ccint=bwconncomp(bw3PC_2,8); 
    fractionrecruitedPCs=ccint.NumObjects/ccPC.NumObjects; %Fraction of 
perictyes that have been recruited. 
    ccint2=bwconncomp(bw3PC_3,8); 
    fracfullyrecruitedPCs=ccint2.NumObjects/ccPC.NumObjects; %Fraction 
of perictyes that have been fully recruited. 
  
%This step thresholds the DAPI image and counts the nuclei 
%     rect=[0 0 n1/2-1 m1/2-1]; 
%     IcropDAPI=imcrop(I,rect); 
    rectDAPI=imread(sprintf(fname3,k)); 
    IDAPI=rgb2gray(rectDAPI); 
    IcropDAPI=IDAPI; 
    levelDAPI = graythresh(IcropDAPI)*2; 
    bwDAPI = im2bw(IcropDAPI,levelDAPI); 
277 
 
    bw3DAPI = bwareaopen(bwDAPI,10,8); 
    bw3DAPI=croptopoly(bw3DAPI,takemeout); 
    ccDAPI = bwconncomp(bw3DAPI,8); 
    fractionofsectionwithDAPI=sum(sum(bw3DAPI))/sectionarea; %Fraction 
of the section with positive DAPI staining 
    numDAPI=ccDAPI.NumObjects/sectionarea/scale^2*1e6; %number nuclei 
per mm^2 
  
figure,imshow(bwx2) 
figure,imshow(Ia) 
     
result(k-initial+1,1)=k; 
result(k-initial+1,2)=sectionarea; 
result(k-initial+1,3)=NUMBEROFCONTINUOUSSTRUCTURES; 
result(k-initial+1,4)=NUMBEROFSEGMENTS; 
result(k-initial+1,5)=NUMBEROFJUNCTIONS; 
result(k-initial+1,6)=TOTALVESSELLENGTH*scale; 
result(k-initial+1,7)=AVERAGEVESSELLENGTHcontinuousstructures*scale; 
result(k-initial+1,8)=AVERAGEVESSELLENGTHsegments*scale; 
result(k-initial+1,9)=AVERAGEDIAMETER*scale; 
result(k-initial+1,10)=AI; 
result(k-initial+1,11)=fractionofsectionwithPC; 
result(k-initial+1,12)=numPC; 
result(k-initial+1,13)=fractionrecruitedPCs; 
result(k-initial+1,14)=fracfullyrecruitedPCs; 
result(k-initial+1,15)=fractionofsectionwithDAPI; 
result(k-initial+1,16)=numDAPI; 
result(k-initial+1,17)=CD31; 
k 
end 
  
xlswrite('Results.xlsx',result); 
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B.8 opticaldensity.m 
clear all 
  
fname=input('Enter root for polarizer/analyzer file (ex: ''cala''): '); 
  
sep = ''; 
fnp = [fname sep modind(0,5) '.tif']; 
I=imread(fnp,'TIFF'); 
imshow(I) 
  
bkg=roipoly; 
close 
  
intens=zeros(1,20); 
for i=1:20 
    fnp2=[fname sep modind(i-1,5) '.tif']; 
    I2=imread(fnp2,'TIFF'); 
    stats=regionprops(bkg,I2,'MeanIntensity'); 
    intens(i)=[stats.MeanIntensity]; 
end 
  
for i=1:20; 
    if intens(i)==max(intens) 
        maxintim=i-1; 
    end 
end 
  
fnp3 = [fname sep modind(maxintim,5) '.tif']; 
I3=imread(fnp3); 
imshow(I3) 
[x1,y1]=ginput(2); 
dist=abs(y1(1)-y1(2)); 
  
num=input('How many regions would you like to analyze? '); 
  
reg=zeros(size(I3)); 
for i=1:num 
    [ar1,x2,y2]=roipoly(I3); 
    reg=reg+ar1; 
    y3=y2+ones(size(y2))*dist; 
    y4=y2-ones(size(y2))*dist; 
    ar2=roipoly(I3,x2,y3); 
    ar3=roipoly(I3,x2,y4); 
    reg=reg+ar1+ar2+ar3; 
end 
reg=im2bw(reg); 
cc=bwconncomp(reg); 
  
stats2=regionprops(cc,I3,'MeanIntensity'); 
intens2=[stats2.MeanIntensity]; 
intens3=zeros(2,1); 
intens4=zeros(2,1); 
intens5=zeros(num,1); 
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intens3(1)=intens2(1); 
intens3(2)=intens2(3); 
nor=zeros(num,1); 
nor(1)=1; 
intens5(1)=intens2(2); 
for i=2:num 
    intens4(1)=intens2(i*3-2); 
    intens4(2)=intens2(i*3); 
    nor(i)=mean(intens3)/mean(intens4); 
    intens5(i)=intens2(i*3-1); 
end 
  
result=intens5.*nor; 
  
xlswrite('Result.xlsx',result); 
close 
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B.9 ECMstart.m 
dirbase='C:\Krissy\UMN\Matlab\ECM Image Analysis'; 
imgpath='C:\Krissy\UMN\Results'; 
  
dir0=[dirbase '\BasementMembrane']; 
dir1=[dirbase '\CollagenI']; 
dir2=[dirbase '\CD31']; 
dir3=[dirbase '\3DRecon']; 
  
disp(['Adding search path ' dirbase]);addpath(dirbase); 
disp(['Adding search path ' dir0]);addpath(dir0); 
disp(['Adding search path ' dir1]);addpath(dir1); 
disp(['Adding search path ' dir2]);addpath(dir2); 
disp(['Adding search path ' dir2]);addpath(dir3); 
disp(['Changing directory to  ' imgpath]);eval(['cd ' imgpath]); 
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B.10 WMstart.m 
dirbase='C:\Krissy\UMN\Matlab\Whole Mount Stain Analysis'; 
imgpath='C:\Krissy\UMN\Results'; 
  
disp(['Adding search path ' dirbase]);addpath(dirbase); 
disp(['Changing directory to  ' imgpath]);eval(['cd ' imgpath]); 
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B.11 kmrpmstart.m 
%userrpmstart.m 
% This startup script sets personal  
% paths and variables for the user's  
% rpm settings. 
  
% Modify the statements below to point  
% to your personal matlab directory and  
% to your images subdirectory. 
dirbase='C:\Krissy\UMN\rpmscripts'; 
imgpath='C:\Krissy\UMN\Results'; 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Don't modify the statements below. 
dir0=[dirbase '\RPMScripts']; 
dir1=[dir0 '\rpm']; 
dir2=[dir0 '\rpmsupport']; 
dir2a=[dir2 '\Basic']; 
dir3a=[dirbase '\High speed']; 
disp(['Adding search path ' dirbase]);addpath(dirbase); 
disp(['Adding search path ' dir0]);addpath(dir0); 
disp(['Adding search path ' dir1]);addpath(dir1); 
disp(['Adding search path ' dir2]);addpath(dir2); 
disp(['Adding search path ' dir2a]);addpath(dir2a); 
disp(['Adding search path ' dir3a]);addpath(dir3a); 
disp(['Changing directory to  ' imgpath]);eval(['cd ' imgpath]); 
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B.12 drawline.m 
function I=drawline(I) 
  
        zoom on 
        pause; 
        [x,y]=ginput(2); 
        if abs(x(2)-x(1))>abs(y(2)-y(1)) 
            m=(y(2)-y(1))/(x(2)-x(1)); 
            b=y(1)-m*x(1); 
            if x(1)<x(2) 
                t=[x(1):1:x(2)]; 
                t=round(t); 
                s=round(m.*t+b); 
            else 
                t=[x(2):1:x(1)]; 
                t=round(t); 
                s=round(m.*t+b); 
            end 
        else 
            m=(x(2)-x(1))/(y(2)-y(1)); 
            b=x(1)-m*y(1); 
            if y(1)<y(2) 
                s=[y(1):1:y(2)]; 
                s=round(s); 
                t=round(m.*s+b); 
            else 
                s=[y(2):1:y(1)]; 
                s=round(s); 
                t=round(m.*s+b); 
            end 
        end 
  
        for i=1:length(s) 
            I(s(i),t(i),1)=255; 
        end 
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B.13 subtractregion.m 
function I=subtractregion(I) 
  
zoom on 
pause; 
takemeout=roipoly; 
takemeout=double(takemeout); 
indices=find(takemeout==1); 
I(indices)=0; 
I=double(I); 
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B.14 overlay.m 
function y=overlay(I,red,green,blue) 
  
R = I; 
G = I; 
B = I; 
R(red~=0) = 255; 
G(red~=0) = 0; 
B(red~=0) = 0; 
R(green~=0)=0; 
G(green~=0)=255; 
B(green~=0)=0; 
R(blue~=0)=0; 
G(blue~=0)=0; 
B(blue~=0)=255; 
  
y = cat(3,R,G,B); 
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B.15 croptopoly.m 
function I=croptopoly(I,takemeout) 
  
indices=find(takemeout==0); 
I(indices)=0; 
I=double(I); 
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B.16 findendpoints.m 
function y=findendpoints(x) 
  
lut= 
   [0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 1 1 1 1 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]; 
  
 y=applylut(x,lut); 
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B.17 findjunctions.m 
function y=findjunctions(x) 
  
lut= 
   [0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 1 0 0 1 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 1 1 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 1 1 1 0 1 1 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 1 1 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 1 0 1 1 1 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 1 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 1 1 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 ... 
    0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0]; 
  
 y=applylut(x,lut); 
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Appendix C. Model Code 
clear all 
  
delx=.0005; %cm = 5 um distance between nodes 
perm=9.92e-11; %cm^2 tissue permeability 
mu=.0089; %P viscosity 
u=1333.22; %(g/s^2/cm)/mmHg = unit multiplier 
kx=perm/mu*u; %2.67e-6; %10^-5/60; %cm^2/(s*mmHg) x direction 
ky=perm/mu*u; %2.67e-6; %10^-5/60; %cm^2/(s*mmHg) y direction 
Dx=1/delx; %Darcy's Law component x direction 
Dy=1/delx; %Darcy's Law component y direction 
Dx2=kx/delx; %Darcy's Law component x direction 
Dy2=ky/delx; %Darcy's Law component y direction 
P=pi/8/mu/delx^3*u; %Poiseuille Flow component(mass balance) - mult by 
r^4, divide by tubule length 
P2=1/8/mu*u; %Poiseuille Flow component(mom. balance) - mult by r^2, 
divide by tubule length 
gelwidth=41; %number of node points per construct width 
gellength=51; %number of node points per construct length 
gelsize=gelwidth*gellength; 
vxinlet=1.33e-4; %cm/s average x velocity at inlet 
poutlet=0; %mmHg pressure at outlet 
pinlet=vxinlet*delx*gellength/kx+poutlet; %pressure at inlet 
vxcomp=gelsize; 
vycomp=2*gelsize; 
result=zeros(6,21); 
  
%Tubule Characteristics 
rmean=.0003; %cm = 3 um radius 
rstdev=.0000125; %cm = 0.125 um 
lmean=.01; %cm = 100 um length 
lstdev=.001; %cm = 10 um 
amean=0; %angle 
astdev=pi/9*2; 
n=100; %number of tubules 
bi=22; %number of bifurcations (must be <= n/3) 
  
for aa=1:1 
%Matrix T: endpoints matrix notation(4),endpoints vector notation(2), 
    %radius(1),ideal length(1),angle(1),actual length(1) 
T=zeros(n,10); 
T(:,7)=rmean+rstdev.*randn(n,1); 
T(1:(bi*3),8)=lmean/2+(lstdev/2).*randn(bi*3,1); 
T((bi*3+1):n,8)=lmean+lstdev.*randn(n-(bi*3),1); 
T(:,9)=amean+astdev.*randn(n,1); 
for i=1:bi*3 
    while T(i,7)<0 
        T(i,7)=rmean+rstdev.*randn(1,1); 
    end 
    while T(i,9)>pi/2||T(i,9)<-pi/2 
        T(i,9)=amean+astdev*randn(1,1); 
    end 
    while T(i,8)<sqrt(2)*delx 
        T(i,8)=lmean/2+(lstdev/2).*randn(1,1); 
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    end 
end 
for i=bi*3+1:n 
    while T(i,7)<0 
        T(i,7)=rmean+rstdev.*randn(1,1); 
    end 
    while T(i,9)>pi/2||T(i,9)<-pi/2 
        T(i,9)=amean+astdev*randn(1,1); 
    end 
    while T(i,8)<sqrt(2)*delx 
        T(i,8)=lmean+lstdev.*randn(1,1); 
    end 
end 
  
B=zeros(bi,2); %Bifurcation nodes 
B(:,1)=ceil(rand*(gelwidth-3))+1; 
B(:,2)=ceil(rand*(gellength-2))+1; 
for i=1:bi 
    for j=i:bi 
        if B(i,1)==B(j,1)&&B(i,2)==B(j,2) 
            B(j,1)=ceil(rand*(gelwidth-2))+1; 
            B(j,2)=ceil(rand*(gellength-2))+1; 
        end 
    end 
end  
for i=1:bi 
    %First bi rows are tubules leading up to bifurcations 
    T(i,1)=B(i,1)-round(sin(T(i,9))*T(i,8)/delx); 
    T(i,2)=B(i,2)-round(cos(T(i,9))*T(i,8)/delx); 
    T(i,3)=B(i,1); 
    T(i,4)=B(i,2); 
    %Second bi rows are tubules leading away from bifurcations 
    T(i+bi,1)=B(i,1); 
    T(i+bi,2)=B(i,2); 
    T(i+bi,3)=T(i+bi,1)+round(sin(T(i+bi,9))*T(i+bi,8)/delx); 
    T(i+bi,4)=T(i+bi,2)+round(cos(T(i+bi,9))*T(i+bi,8)/delx); 
    %Third bi rows are other tubules leading away from bifurcations 
    T(i+2*bi,1)=B(i,1); 
    T(i+2*bi,2)=B(i,2); 
    T(i+2*bi,3)=T(i+2*bi,1)+round(sin(T(i+2*bi,9))*T(i+2*bi,8)/delx); 
    T(i+2*bi,4)=T(i+2*bi,2)+round(cos(T(i+2*bi,9))*T(i+2*bi,8)/delx); 
end 
  
%Rest of T = single tubules 
for i=3*bi+1:n 
% for i=1:n 
    T(i,1)=ceil(rand*(gelwidth-3))+1; 
    T(i,2)=ceil(rand*(gellength-2))+1; 
    T(i,3)=T(i,1)+round(sin(T(i,9))*T(i,8)/delx); 
    T(i,4)=T(i,2)+round(cos(T(i,9))*T(i,8)/delx); 
end 
for i=1:n 
    T(i,5)=gellength*(T(i,1)-1)+T(i,2); 
    T(i,6)=gellength*(T(i,3)-1)+T(i,4); 
    T(i,10)=sqrt((T(i,1)-T(i,3))^2+(T(i,2)-T(i,4))^2)*delx; 
end 
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% Make sure all tubules are within the gel 
for i=1:bi 
    while T(i,1)>gelwidth-2||T(i,1)<2||T(i,2)>gellength-
1||T(i,2)<2||... 
            T(i,3)>gelwidth-2||T(i,3)<2||T(i,4)>gellength-
1||T(i,4)<1||... 
            T(i+bi,1)>gelwidth-2||T(i+bi,1)<2||T(i+bi,2)>gellength-
1||T(i+bi,2)<2||... 
            T(i+bi,3)>gelwidth-2||T(i+bi,3)<2||T(i+bi,4)>gellength-
1||T(i+bi,4)<2||... 
            T(i+2*bi,1)>gelwidth-
2||T(i+2*bi,1)<2||T(i+2*bi,2)>gellength-1||... 
            T(i+2*bi,2)<2||T(i+2*bi,3)>gelwidth-2||T(i+2*bi,3)<2||... 
            T(i+2*bi,4)>gellength-1||T(i+2*bi,4)<2 
        B(i,1)=ceil(rand*(gelwidth-3))+1; 
        B(i,2)=ceil(rand*(gellength-2))+1; 
            T(i,1)=B(i,1)-round(sin(T(i,9))*T(i,8)/delx); 
            T(i,2)=B(i,2)-round(cos(T(i,9))*T(i,8)/delx); 
            T(i,3)=B(i,1); 
            T(i,4)=B(i,2); 
            T(i+bi,1)=B(i,1); 
            T(i+bi,2)=B(i,2); 
            T(i+bi,3)=T(i+bi,1)+round(sin(T(i+bi,9))*T(i+bi,8)/delx); 
            T(i+bi,4)=T(i+bi,2)+round(cos(T(i+bi,9))*T(i+bi,8)/delx); 
            T(i+2*bi,1)=B(i,1); 
            T(i+2*bi,2)=B(i,2); 
            
T(i+2*bi,3)=T(i+2*bi,1)+round(sin(T(i+2*bi,9))*T(i+2*bi,8)/delx); 
            
T(i+2*bi,4)=T(i+2*bi,2)+round(cos(T(i+2*bi,9))*T(i+2*bi,8)/delx); 
        T(i,5)=gellength*(T(i,1)-1)+T(i,2); 
        T(i,6)=gellength*(T(i,3)-1)+T(i,4); 
        T(i,10)=sqrt((T(i,1)-T(i,3))^2+(T(i,2)-T(i,4))^2)*delx; 
        T(i+bi,5)=gellength*(T(i+bi,1)-1)+T(i+bi,2); 
        T(i+bi,6)=gellength*(T(i+bi,3)-1)+T(i+bi,4); 
        T(i+bi,10)=sqrt((T(i+bi,1)-T(i+bi,3))^2+(T(i+bi,2)-
T(i+bi,4))^2)*delx; 
        T(i+2*bi,5)=gellength*(T(i+2*bi,1)-1)+T(i+2*bi,2); 
        T(i+2*bi,6)=gellength*(T(i+2*bi,3)-1)+T(i+2*bi,4); 
        T(i+2*bi,10)=sqrt((T(i+2*bi,1)-T(i+2*bi,3))^2+... 
            (T(i+2*bi,2)-T(i+2*bi,4))^2)*delx; 
    end 
    if T(i+bi,3)==T(i+2*bi,3)&&T(i+bi,4)==T(i+2*bi,4) 
        r=round(rand*2); 
        if r==1 
            T(i+2*bi,3)=T(i+2*bi,3)+1; 
        else 
            T(i+2*bi,3)=T(i+2*bi,3)-1; 
        end 
    end 
end 
for i=3*bi+1:n 
% for i=1:n 
    while T(i,1)>gelwidth-2||T(i,1)<2||T(i,2)>gellength-
1||T(i,2)<2||... 
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            T(i,3)>gelwidth-2||T(i,3)<2||T(i,4)>gellength-
1||T(i,4)<2||T(i,10)==0 
        T(i,1)=ceil(rand*(gelwidth-3))+1; 
        T(i,2)=ceil(rand*(gellength-2))+1; 
        T(i,3)=T(i,1)+round(sin(T(i,9))*T(i,8)/delx); 
        T(i,4)=T(i,2)+round(cos(T(i,9))*T(i,8)/delx); 
        T(i,5)=gellength*(T(i,1)-1)+T(i,2); 
        T(i,6)=gellength*(T(i,3)-1)+T(i,4); 
        T(i,10)=sqrt((T(i,1)-T(i,3))^2+(T(i,2)-T(i,4))^2)*delx; 
    end 
end 
  
%Darcy's Law Base 
A=sparse(zeros(3*gelsize)); 
%middle 
for i=1+gellength:(gelwidth-1)*gellength 
    if rem(i,gellength)==2 
        for k=i:i+gellength-3 
            %mass balance 
            A(k,k+1+vxcomp)=Dx; 
            A(k,k+vxcomp)=-Dx; 
            A(k,k+gellength+vycomp)=Dy; 
            A(k,k+vycomp)=-Dy; 
            %x-momentum balance 
            A(k+vxcomp,k+vxcomp)=1; 
            A(k+vxcomp,k-1)=-Dx2; 
            A(k+vxcomp,k)=Dx2; 
            %y-momentum balance 
            A(k+vycomp,k+vycomp)=1; 
            A(k+vycomp,k-gellength)=-Dy2; 
            A(k+vycomp,k)=Dy2; 
        end 
    end 
end 
  
%top 
for i=2:gellength-1 
    %mass balance 
    A(i,i+1+vxcomp)=Dx; 
    A(i,i+vxcomp)=-Dx; 
    A(i,i+vycomp)=-Dy; 
    A(i,i+gellength+vycomp)=Dy; 
    %x-momentum balance 
    A(i+vxcomp,i+vxcomp)=1; 
    A(i+vxcomp,i-1)=-Dx2; 
    A(i+vxcomp,i)=Dx2; 
    %y-momentum balance 
    A(i+vycomp,i+vycomp)=1; 
end 
%bottom 
for i=(gelwidth-1)*gellength+2:gelsize-1 
    %mass balance 
    A(i,i+1+vxcomp)=Dx; 
    A(i,i+vxcomp)=-Dx; 
    A(i,i-gellength+vycomp)=-Dy; 
    A(i,i+vycomp)=Dy; 
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    %x-momentum balance 
    A(i+vxcomp,i+vxcomp)=1; 
    A(i+vxcomp,i-1)=-Dx2; 
    A(i+vxcomp,i)=Dx2; 
    %y-momentum balance 
    A(i+vycomp,i+vycomp)=1; 
end 
  
%inlet&outlet 
for i=gellength+1:gelsize-gellength 
    if rem(i,gellength)==0 
        %mass balance 
        A(i,i)=1; 
        %x-momentum balance 
        A(i+vxcomp,i+vxcomp)=1; 
        A(i+vxcomp,i-1)=-Dx2; 
        A(i+vxcomp,i)=Dx2; 
        %y-momentum balance 
        A(i+vycomp,i+vycomp)=1; 
        A(i+vycomp,i-gellength)=-Dy2; 
        A(i+vycomp,i)=Dy2; 
    elseif rem(i,gellength)==1 
        %mass balance 
        A(i,i+vxcomp)=-Dx; 
        A(i,i+1+vxcomp)=Dx; 
        A(i,i+gellength+vycomp)=Dy; 
        A(i,i+vycomp)=-Dy; 
        %x-momentum balance 
        A(i+vxcomp,i+vxcomp)=1; 
        %y-momentum balance 
        A(i+vycomp,i+vycomp)=1; 
    end 
end 
  
%corners 
    %mass balance 
A(1,1+vxcomp)=-Dx; 
A(1,2+vxcomp)=Dx; 
A(1,1+vycomp)=-Dy; 
A(1,1+gellength+vycomp)=Dy; 
  
A(gellength,gellength)=1; 
  
A(gelsize-gellength+1,gelsize-gellength+1+vxcomp)=-Dx; 
A(gelsize-gellength+1,gelsize-gellength+2+vxcomp)=Dx; 
A(gelsize-gellength+1,gelsize-gellength+1+vycomp)=Dy; 
A(gelsize-gellength+1,gelsize-gellength*2+1+vycomp)=-Dy; 
  
A(gelsize,gelsize)=1; 
  
    %x-momentum 
A(1+vxcomp,1+vxcomp)=1; 
  
A(gellength+vxcomp,gellength+vxcomp)=1; 
A(gellength+vxcomp,gellength)=Dx2; 
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A(gellength+vxcomp,gellength-1)=-Dx2; 
  
A(gelsize-gellength+1+vxcomp,gelsize-gellength+1+vxcomp)=1; 
  
A(gelsize+vxcomp,gelsize+vxcomp)=1; 
A(gelsize+vxcomp,gelsize)=Dx2; 
A(gelsize+vxcomp,gelsize-1)=-Dx2; 
  
    %y-momentum 
A(1+vycomp,1+vycomp)=1; 
  
A(gellength+vycomp,gellength+vycomp)=1; 
  
A(gelsize-gellength+1+vycomp,gelsize-gellength+1+vycomp)=1; 
  
A(gelsize+vycomp,gelsize+vycomp)=1; 
  
%Add Tubule Flow 
for i=1:bi 
%%inlet of bifurcation 
    %mass balance 
    A(T(i,5),T(i,5))=A(T(i,5),T(i,5))+... 
        P*T(i,7)^4/T(i,10)*(1-T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i,5),T(i+bi,6))=A(T(i,5),T(i+bi,6))-... 
        P*T(i,7)^4/T(i,10)*T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i,5),T(i+2*bi,6))=A(T(i,5),T(i+2*bi,6))-... 
        P*T(i,7)^4/T(i,10)*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %x-momentum balance 
    A(T(i,5)+vxcomp,T(i,5))=A(T(i,5)+vxcomp,T(i,5))-... 
        P2*T(i,7)^2/T(i,10)*cos(T(i,9))*(1-T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i,5)+vxcomp,T(i+bi,6))=A(T(i,5)+vxcomp,T(i+bi,6))+... 
        P2*T(i,7)^2/T(i,10)*cos(T(i,9))*T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i,5)+vxcomp,T(i+2*bi,6))=A(T(i,5)+vxcomp,T(i+2*bi,6))+... 
        P2*T(i,7)^2/T(i,10)*cos(T(i,9))*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %y-momentum balance 
    A(T(i,5)+vycomp,T(i,5))=A(T(i,5)+vycomp,T(i,5))-... 
        P2*T(i,7)^2/T(i,10)*sin(T(i,9))*(1-T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i,5)+vycomp,T(i+bi,6))=A(T(i,5)+vycomp,T(i+bi,6))+... 
        P2*T(i,7)^2/T(i,10)*sin(T(i,9))*T(i+bi,7)^4/T(i+bi,10)/... 
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(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i,5)+vycomp,T(i+2*bi,6))=A(T(i,5)+vycomp,T(i+2*bi,6))+... 
        P2*T(i,7)^2/T(i,10)*sin(T(i,9))*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
  
%%outlet 1 of bifurcation     
    %mass balance 
    A(T(i+bi,6),T(i+bi,6))=A(T(i+bi,6),T(i+bi,6))+... 
        P*T(i+bi,7)^4/T(i+bi,10)*(1-T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+bi,6),T(i,5))=A(T(i+bi,6),T(i,5))-... 
        P*T(i+bi,7)^4/T(i+bi,10)*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+bi,6),T(i+2*bi,6))=A(T(i+bi,6),T(i+2*bi,6))-... 
        P*T(i+bi,7)^4/T(i+bi,10)*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %x-momentum balance 
    A(T(i+bi,6)+vxcomp,T(i+bi,6))=A(T(i+bi,6)+vxcomp,T(i+bi,6))-... 
        P2*T(i+bi,7)^2/T(i+bi,10)*cos(T(i+bi,9))*(1-
T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+bi,6)+vxcomp,T(i,5))=A(T(i+bi,6)+vxcomp,T(i,5))+... 
        P2*T(i+bi,7)^2/T(i+bi,10)*cos(T(i+bi,9))*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+bi,6)+vxcomp,T(i+2*bi,6))=A(T(i+bi,6)+vxcomp,T(i+2*bi,6))+... 
        
P2*T(i+bi,7)^2/T(i+bi,10)*cos(T(i+bi,9))*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %y-momentum balance 
    A(T(i+bi,6)+vycomp,T(i+bi,6))=A(T(i+bi,6)+vycomp,T(i+bi,6))-... 
        P2*T(i+bi,7)^2/T(i+bi,10)*sin(T(i+bi,9))*(1-
T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+bi,6)+vycomp,T(i,5))=A(T(i+bi,6)+vycomp,T(i,5))+... 
        P2*T(i+bi,7)^2/T(i+bi,10)*sin(T(i+bi,9))*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+bi,6)+vycomp,T(i+2*bi,6))=A(T(i+bi,6)+vycomp,T(i+2*bi,6))+... 
        
P2*T(i+bi,7)^2/T(i+bi,10)*sin(T(i+bi,9))*T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
  
%%outlet 2 of bifurcation 
    %mass balance 
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    A(T(i+2*bi,6),T(i+2*bi,6))=A(T(i+2*bi,6),T(i+2*bi,6))+... 
        P*T(i+2*bi,7)^4/T(i+2*bi,10)*(1-T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+2*bi,6),T(i,5))=A(T(i+2*bi,6),T(i,5))-... 
        P*T(i+2*bi,7)^4/T(i+2*bi,10)*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+2*bi,6),T(i+bi,6))=A(T(i+2*bi,6),T(i+bi,6))-... 
        P*T(i+2*bi,7)^4/T(i+2*bi,10)*T(i+bi,7)^4/T(i+bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %x-momentum balance 
    
A(T(i+2*bi,6)+vxcomp,T(i+2*bi,6))=A(T(i+2*bi,6)+vxcomp,T(i+2*bi,6))-... 
        P2*T(i+2*bi,7)^2/T(i+2*bi,10)*cos(T(i+2*bi,9))*(1-
T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+2*bi,6)+vxcomp,T(i,5))=A(T(i+2*bi,6)+vxcomp,T(i,5))+... 
        
P2*T(i+2*bi,7)^2/T(i+2*bi,10)*cos(T(i+2*bi,9))*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+2*bi,6)+vxcomp,T(i+bi,6))=A(T(i+2*bi,6)+vxcomp,T(i+bi,6))+... 
        
P2*T(i+2*bi,7)^2/T(i+2*bi,10)*cos(T(i+2*bi,9))*T(i+bi,7)^4/T(i+bi,10)/.
.. 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
     
    %y-momentum balance 
    
A(T(i+2*bi,6)+vycomp,T(i+2*bi,6))=A(T(i+2*bi,6)+vycomp,T(i+2*bi,6))-... 
        P2*T(i+2*bi,7)^2/T(i+2*bi,10)*sin(T(i+2*bi,9))*(1-
T(i+2*bi,7)^4/T(i+2*bi,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10))); 
    A(T(i+2*bi,6)+vycomp,T(i,5))=A(T(i+2*bi,6)+vycomp,T(i,5))+... 
        
P2*T(i+2*bi,7)^2/T(i+2*bi,10)*sin(T(i+2*bi,9))*T(i,7)^4/T(i,10)/... 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
    A(T(i+2*bi,6)+vycomp,T(i+bi,6))=A(T(i+2*bi,6)+vycomp,T(i+bi,6))+... 
        
P2*T(i+2*bi,7)^2/T(i+2*bi,10)*sin(T(i+2*bi,9))*T(i+bi,7)^4/T(i+bi,10)/.
.. 
        
(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,10)); 
end 
  
for i=3*bi+1:n 
% for i=1:n 
    %mass balance 
    A(T(i,5),T(i,5))=A(T(i,5),T(i,5))+P*T(i,7)^4/T(i,10); 
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    A(T(i,5),T(i,6))=A(T(i,5),T(i,6))-P*T(i,7)^4/T(i,10); 
    A(T(i,6),T(i,5))=A(T(i,6),T(i,5))-P*T(i,7)^4/T(i,10); 
    A(T(i,6),T(i,6))=A(T(i,6),T(i,6))+P*T(i,7)^4/T(i,10); 
     
    %x-momentum balance 
    A(T(i,5)+vxcomp,T(i,5))=A(T(i,5)+vxcomp,T(i,5))-
P2*T(i,7)^2/T(i,10)*cos(T(i,9)); 
    
A(T(i,5)+vxcomp,T(i,6))=A(T(i,5)+vxcomp,T(i,6))+P2*T(i,7)^2/T(i,10)*cos
(T(i,9)); 
    
A(T(i,6)+vxcomp,T(i,5))=A(T(i,6)+vxcomp,T(i,5))+P2*T(i,7)^2/T(i,10)*cos
(T(i,9)); 
    A(T(i,6)+vxcomp,T(i,6))=A(T(i,6)+vxcomp,T(i,6))-
P2*T(i,7)^2/T(i,10)*cos(T(i,9)); 
     
    %y-momentum balance 
    A(T(i,5)+vycomp,T(i,5))=A(T(i,5)+vycomp,T(i,5))-
P2*T(i,7)^2/T(i,10)*sin(T(i,9)); 
    
A(T(i,5)+vycomp,T(i,6))=A(T(i,5)+vycomp,T(i,6))+P2*T(i,7)^2/T(i,10)*sin
(T(i,9)); 
    
A(T(i,6)+vycomp,T(i,5))=A(T(i,6)+vycomp,T(i,5))+P2*T(i,7)^2/T(i,10)*sin
(T(i,9)); 
    A(T(i,6)+vycomp,T(i,6))=A(T(i,6)+vycomp,T(i,6))-
P2*T(i,7)^2/T(i,10)*sin(T(i,9)); 
end 
  
%set BC (inlet vx, inlet vy(=0); outlet P) 
C=zeros(3*gelsize,1); 
for i=1:gelwidth 
    C((i-1)*gellength+1+vxcomp,1)=vxinlet; 
    C(i*gellength,1)=poutlet; 
end 
p=A\C; 
  
pmap=zeros(gelwidth,gellength); 
vxmap=zeros(gelwidth,gellength); 
vymap=zeros(gelwidth,gellength); 
for i=1:gelsize 
    q=floor((i-1)/gellength)+1; 
    r=rem((i-1),gellength)+1; 
    pmap(q,r)=p(i); 
    vxmap(q,r)=p(i+vxcomp); 
    vymap(q,r)=p(i+vycomp); 
end 
[mpmap,npmap]=size(pmap); 
  
pmap2=zeros(5*size(pmap)); 
vxmap2=zeros(5*size(vxmap)); 
vymap2=zeros(5*size(vymap)); 
for i=1:mpmap 
    for j=1:npmap 
        for k=1:5 
            for l=1:5 
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                pmap2(i*5-k+1,j*5-l+1)=pmap(i,j); 
                vxmap2(i*5-k+1,j*5-l+1)=vxmap(i,j); 
                vymap2(i*5-k+1,j*5-l+1)=vymap(i,j); 
            end 
        end 
    end 
end 
  
vt=zeros(n,1); 
Qt=zeros(n,1); 
for i=1:bi 
    
pbifur=(T(i,7)^4/T(i,10)+T(i+bi,7)^4/T(i+bi,10)+T(i+2*bi,7)^4/T(i+2*bi,
10)); 
    vt(i)=P2*T(i,7)^2/T(i,10)*... 
        ((1-T(i,7)^4/T(i,10)/pbifur)*p(T(i,5))-... 
        T(i+bi,7)^4/T(i+bi,10)/pbifur*p(T(i+bi,6))-... 
        T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur*p(T(i+2*bi,6)));         
    Qt(i)=P*T(i,7)^4/T(i,10)*... 
        ((1-T(i,7)^4/T(i,10)/pbifur)*p(T(i,5))-... 
        T(i+bi,7)^4/T(i+bi,10)/pbifur*p(T(i+bi,6))-... 
        T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur*p(T(i+2*bi,6)))*delx^3;  
  
    vt(i+bi)=P2*T(i+bi,7)^2/T(i+bi,10)*... 
        ((-1+T(i+bi,7)^4/T(i+bi,10)/pbifur)*p(T(i+bi,6))+... 
        T(i,7)^4/T(i,10)/pbifur*p(T(i,5))+... 
        T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur*p(T(i+2*bi,6))); 
    Qt(i+bi)=P*T(i+bi,7)^4/T(i+bi,10)*... 
        ((-1+T(i+bi,7)^4/T(i+bi,10)/pbifur)*p(T(i+bi,6))+... 
        T(i,7)^4/T(i,10)/pbifur*p(T(i,5))+... 
        T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur*p(T(i+2*bi,6)))*delx^3; 
  
    vt(i+2*bi)=P2*T(i+2*bi,7)^2/T(i+2*bi,10)*... 
        ((-1+T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur)*p(T(i+2*bi,6))+... 
        T(i,7)^4/T(i,10)/pbifur*p(T(i,5))+... 
        T(i+bi,7)^4/T(i+bi,10)/pbifur*p(T(i+bi,6))); 
    Qt(i+2*bi)=P*T(i+2*bi,7)^4/T(i+2*bi,10)*... 
        ((-1+T(i+2*bi,7)^4/T(i+2*bi,10)/pbifur)*p(T(i+2*bi,6))+... 
        T(i,7)^4/T(i,10)/pbifur*p(T(i,5))+... 
        T(i+bi,7)^4/T(i+bi,10)/pbifur*p(T(i+bi,6)))*delx^3; 
end 
for i=3*bi+1:n 
% for i=1:n 
    vt(i)=P2*T(i,7)^2/T(i,10)*(p(T(i,5))-p(T(i,6))); 
    Qt(i)=P*T(i,7)^4/T(i,10)*(p(T(i,5))-p(T(i,6)))*delx^3; 
end 
binaryt=ones(n,1)*255; 
  
x1=T(:,1)*5-ones(n,1)*2; 
y1=T(:,2)*5-ones(n,1)*2; 
x2=T(:,3)*5-ones(n,1)*2; 
y2=T(:,4)*5-ones(n,1)*2; 
tmap=drawlines(x1,y1,x2,y2,pmap2,vt); 
tmap2=drawlines(x1,y1,x2,y2,pmap2,Qt); 
tmap3=drawlines(x1,y1,x2,y2,pmap2,binaryt); 
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maxvx=max(max(vxmap2))+max(max(vxmap2))/10; 
for i=1:5*mpmap 
    for j=1:5*npmap 
        if tmap(i,j)~=0 
            pmap2(i,j)=max(max(pmap))+max(max(pmap))/10; 
            vxmap2(i,j)=maxvx+maxvx/10; 
            vymap2(i,j)=maxvx+maxvx/10; 
        end 
    end 
end 
  
aix=0;aiy=0; 
for i=1:n 
    aix=aix+abs(T(i,4)-T(i,2)); 
    aiy=aiy+abs(T(i,3)-T(i,1)); 
    ai=aix/aiy; 
end 
  
flowgel=zeros(gelwidth-2,1); 
sumflowgel1=zeros(gellength-2,1); 
sumflowgel2=zeros(gellength-2,1); 
sumflowtubes=zeros(gellength-2,1); 
percentflowthrutubes1=zeros(gellength-2,1); 
percentflowthrutubes2=zeros(gellength-2,1); 
for i=gellength/3+1:gellength/3*2 
    for j=2:gelwidth-2 
        flowgel(j)=sqrt(vxmap2(j*5,i*5)^2+vymap2(j*5,i*5)^2); 
    end 
    flowtubes=zeros(n,1); 
    lumenarea=zeros(n,1); 
    for l=1:n 
        if T(l,2)<=i && T(l,4)>=i 
            flowtubes(l)=vt(l)*T(l,7)^2*pi; 
            lumenarea(l)=T(l,7)^2*pi; 
        end 
    end 
    sumflowgel1(i)=sum(flowgel)*(((gelwidth-3)*delx)^2-sum(lumenarea)); 
    sumflowgel2(i)=sum(flowgel)*(((gelwidth-3)*delx)^2); 
    sumflowtubes(i)=sum(flowtubes); 
    
percentflowthrutubes1(i)=sumflowtubes(i)/(sumflowgel1(i)+sumflowtubes(i
)); 
    
percentflowthrutubes2(i)=sumflowtubes(i)/(sumflowgel2(i)+sumflowtubes(i
)); 
end 
avgpercent1=mean(percentflowthrutubes1); 
avgpercent2=mean(percentflowthrutubes2); 
  
figure,image(pmap2,'CDataMapping','scaled') 
caxis([0,max(max(pmap2))*1.1]) 
colormap(jet) 
colorbar 
min(min(pmap2)) 
max(max(pmap2)) 
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figure, image(vxmap2,'CDataMapping','scaled') 
caxis([min(min(vxmap)),max(max(vxmap))+max(max(vxmap))/10]) 
colormap(jet) 
colorbar 
  
figure, image(vymap2,'CDataMapping','scaled') 
caxis([min(min(vxmap)),max(max(vxmap))+max(max(vxmap))/10]) 
caxis([-1e-3,1e-3]) 
colormap(jet) 
colorbar 
  
figure, image(tmap,'CDataMapping','scaled') 
caxis([0,max(max(tmap))]) 
colormap(jet) 
colorbar 
  
Qmap=zeros(size(vxmap2)); 
for i=1:5*mpmap 
    for j=1:5*npmap 
        if tmap2(i,j)~=0 
            Qmap(i,j)=tmap2(i,j); 
        else 
            
Qmap(i,j)=sqrt((vxmap2(i,j)*delx^2)^2+(vymap2(i,j)*delx^2)^2); 
        end 
    end 
end 
  
figure, image(Qmap,'CDataMapping','scaled') 
caxis([0,1e-8])%1e-10]) 
colormap(jet) 
colorbar 
  
figure, imshow(~tmap3) 
hold on 
x5=zeros(gellength,1); 
y5=zeros(gelwidth,1); 
for i=1:gellength 
    x5(i)=i*5-2; 
end 
for i=1:gelwidth 
    y5(i)=i*5-2; 
end 
vtx=zeros(gelwidth,gellength); 
vty=zeros(gelwidth,gellength); 
for i=1:bi 
    vtx(T(i,1),T(i,2))=vt(i)*cos(T(i,9)); 
    vty(T(i,1),T(i,2))=vt(i)*sin(T(i,9)); 
end 
for i=bi+1:bi*3 
    vtx(T(i,3),T(i,4))=vt(i)*cos(T(i,9)); 
    vty(T(i,3),T(i,4))=vt(i)*sin(T(i,9)); 
end 
for i=bi*3+1:n 
% for i=1:n 
    vtx(T(i,1),T(i,2))=vt(i)*cos(T(i,9)); 
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    vty(T(i,1),T(i,2))=vt(i)*sin(T(i,9)); 
    vtx(T(i,3),T(i,4))=vt(i)*cos(T(i,9)); 
    vty(T(i,3),T(i,4))=vt(i)*sin(T(i,9)); 
end 
quiver(x5,y5,vtx*15000,vty*15000,0); 
quiver(x5,y5,vxmap*15000,vymap*15000,0); 
% hold off 
  
result(aa,1)=delx; 
result(aa,2)=perm; 
result(aa,3)=mu; 
result(aa,4)=gelwidth; 
result(aa,5)=gellength; 
result(aa,6)=vxinlet; 
result(aa,7)=poutlet; 
result(aa,8)=rmean; %avg tube radius 
result(aa,9)=rstdev; 
result(aa,10)=lmean; %avg tube length 
result(aa,11)=lstdev; 
result(aa,12)=amean; %avg tube angle 
result(aa,13)=astdev; 
result(aa,14)=vxinlet*((gelwidth-1)*delx)^2; %Q tissue inlet defined 
result(aa,15)=mean(Qt); %Q tube 
result(aa,16)=mean(vt); %v tube 
result(aa,17)=mean(pmap(:,1)); %P tissue inlet 
result(aa,18)=vxinlet*(gellength-1)*delx/result(aa,17)*mu/u; %effective 
k 
result(aa,19)=ai; %anisotropy index 
result(aa,20)=mean(vxmap(:,gellength))*((gelwidth-1)*delx)^2; %Q tissue 
outlet 
result(aa,21)=mean(sum(tmap3)/255)/((gelwidth-1)*delx*10)^2; 
%numberlumens/mm^2 
end 
  
xlswrite('result.xls',result); 
 
